Clinical outcomes of conservative and surgical treatments in functional urology by Noordhoff, T.C. (Toscane)
CLINICAL OUTCOM
ES OF CONSERVATIVE AND SURGICAL TREATM
ENTS IN FUNCTIONAL UROLOGY 
To
scan
e C
. N
o
o
rd
h
o
ff
CLINICAL OUTCOMES
of CONSERVATIVE
and SURGICAL
TREATMENTS in
FUNCTIONAL
UROLOGY
Toscane C. Noordhoff
UITNODIGING
Voor het bijwonen van de openbare 
verdediging van het proefschrift
CLINICAL OUTCOMES
of CONSERVATIVE
and SURGICAL
TREATMENTS in
FUNCTIONAL
UROLOGY
Toscane C. Noordhoff
Woensdag 19 juni 2019
om 13.30 uur
Prof. Andries Queridozaal
Onderwijscentrum
Erasmus MC
Dr. Molewaterplein 50
3015 GE Rotterdam
Aansluitend aan de plechtigheid 
vindt een receptie plaats waar 
u van harte welkom bent. 
Paranimfen
Boudewijn Schuitmaker
Suzan van der Wiel
promotietoscane@gmail.com
16447-noordhof-cover.indd   1 22/04/2019   22:13
Toscane C. Noordhoff
CLINICAL OUTCOMES
of CONSERVATIVE
and SURGICAL
TREATMENTS in
FUNCTIONAL
UROLOGY
Toscane C. Noordhoff
COLOPHON
The work presented in this thesis was conducted at the Department of Urology,
Erasmus MC Rotterdam, The Netherlands.
ISBN: 978-94-93108-02-8
Cover design and lay-out:  Design Your Thesis, www.designyourthesis.com
Printing:  Ridderprint B.V., www.ridderprint.nl
Photographs:  Tom Schoumakers
Copyright © 2019 TC Noordhoff, Rotterdam, The Netherlands. 
All rights reserved. No part of this thesis may be reproduced, stored in a retrieval system, 
or transmitted, in any form or by any means, electronic, mechanical, photocopying, 
recording or otherwise, without written permission from the author or the copyright 
owning journals for articles published or accepted. 
Financial support for this dissertation was kindly provided by:
• Axonics Modulation Technologies, Inc.
• Stichting Urologisch Wetenschappelijk Onderzoek (SUWO)
• Stichting Wetenschappelijk Onderzoek Prostaatkanker (SWOP)
CLINICAL OUTCOMES OF CONSERVATIVE AND SURGICAL 
TREATMENTS IN FUNCTIONAL UROLOGY
Klinische uitkomsten van conservatieve en chirurgische behandelingen 
binnen de functionele urologie
Proefschrift
ter verkrijging van de graad van doctor 
aan de Erasmus Universiteit Rotterdam
op gezag van de rector magnificus
Prof. dr. R.C.M.E. Engels 
en volgens besluit van het College voor Promoties.
De openbare verdediging zal plaatsvinden op
woensdag 19 juni 2019 om 13.30 uur
door
Toscane Claudia Noordhoff
geboren te Lisse
PROMOTIECOMMISSIE
Promotor: Prof. dr. C.H. Bangma
Overige leden: Prof. dr. G.M. Ribbers
 Prof. dr. L.M.O. de Kort
 Prof. dr. R.Q. Hintzen
Copromotoren: Dr. B.F.M. Blok 
 Dr. J.R. Scheepe

CONTENTS
Chapter 1:  General introduction 11
Part I: Evidence based outcome in functional urology
Chapter 2: Surgical management of anatomic bladder outlet 
obstruction in males with neurogenic bladder dysfunction: a 
systematic review
27
Part II: Outcomes of surgical treatment in functional urology
Chapter 3: Long-term follow-up of bladder outlet procedures in children 
with neurogenic urinary incontinence
55
Chapter 4: Outcome and complications of adjustable continence 
therapy (ProACTTM) after radical prostatectomy: 10 years’ 
experience in 143 patients
71
Chapter 5: Outcome and complications of adjustable continence 
therapy (ProACTTM) in the treatment of urinary incontinence 
after transurethral resection of the prostate: a multicenter 
study
89
Part III: Patient reported outcome measures in functional urology
Chapter 6: The Multiple Sclerosis Intimacy and Sexuality Questionnaire 
(MSISQ-15): validation of the Dutch version in patients with 
multiple sclerosis and spinal cord injury
109
Chapter 7: Urotherapy in children with dysfunctional voiding and the 
responsiveness of two condition-specific questionnaires
127
Part IV: General discussion and summary
Chapter 8: General discussion 145
Chapter 9: Summary & Samenvatting 163
Part V: Appendices
List of abbreviations 181
List of publications 183
Author affiliations 185
About the author 187
Dankwoord 189
Erasmus MC PhD portfolio 193

CHAPTER 1
General introduction

13
General introduction
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FUNCTIONAL UROLOGY
The field of functional urology deals with functional disorders of the lower urinary tract 
(LUT), which consists of the urinary bladder and its sphincters, and the pelvic floor. The 
main function of the LUT is storage and voiding of urine.1 The activity of the urinary 
bladder and bladder outlet is determined by a complex set of peripheral autonomic and 
somatic nerves controlled through intact neural pathways in the spinal cord and brain.2 
Normally, during the urine storage phase the external urethral sphincter is contracted 
and the detrusor is relaxed. At the initiation of the voiding phase, voluntarily initiated 
continuous detrusor contractions occur after the external urethral sphincter opens to 
allow the bladder to be emptied at a normal pressure.1,3 
Regarding the pelvic floor, function is important in both urinary and fecal continence, 
sexual function and support to the pelvic organs. The pelvic floor consists of muscles, 
bone attachments, and fascial components.4 Fecal continence is achieved by a complex 
interactive coherence between muscle groups of the pelvic floor and sphincter 
complex, rectal compliance, consistency of stool, and cognitive function.5 During 
normal defecation, a contraction of the rectum and perineal muscles simultaneously 
with a relaxation of the anal sphincter results in stool evacuation.6 For normal sexual 
function desire, arousal, and orgasm are important.4,7 In female sexual function, the 
pelvic floor has a critical role in addition to maintain bladder and bowel continence, 
and pelvic support. The exact role in male is unclear, although it appears to have some 
influence on sexual function.7 
Clinical evaluation of LUT and/or pelvic floor dysfunction is based on the following four 
domains: urinary, anorectal, sexual dysfunction, and pelvic organ prolapse. Patients 
may experience symptoms in more than one domain.3,8,9 Selected common symptoms 
of each domain are described below:
Urinary symptoms - LUT symptoms can be related to the storage phase, voiding phase 
or post voiding phase. Examples of symptoms during storage phase are: frequency, 
nocturia, urgency, and involuntary leakage of urine. Urinary incontinence can be 
divided into: stress-, urge-, and mixed urinary incontinence. Involuntary leakage from 
the urethra synchronous with effort, or coughing, or sneezing is defined as stress 
urinary incontinence. Urge urinary incontinence is involuntary leakage from urethra 
accompanied with the sensation of a sudden desire to void difficult to defer. Mixed 
urinary incontinence is associated with both stress and urge urinary incontinence. 
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During the voiding phase, symptoms of hesitancy, weak or intermittent stream, or 
straining can occur. Feeling of incomplete emptying and post micturition dribble are 
examples of symptoms experienced immediately after micturition.1,3
Anorectal symptoms - Disorders of anorectal function include defecation disorders, 
fecal incontinence, and proctalgia syndromes.6,10 A defecation disorder is characterized 
by difficulty in evacuating stool from the rectum resulting in chronic or recurring 
symptoms. The cause of a defecation disorder can be functional or structural or 
coexisting anorectal disturbance.10 Fecal incontinence is associated with symptoms 
of involuntary loss of flatus, liquid, or solid stool.5,10 The etiologies can have congenital 
causes (spinal cord defects and anorectal malformations), acquired causes (obstetrical 
injury or anorectal surgery), and nonstructural causes (e.g. infectious colitis, side effects 
of medication).5 Patients with proctalgia syndromes experience rectal pain.10 
Sexual dysfunction - The cause of sexual dysfunction could be any experienced 
problem or symptom influencing normal sexual function. In women, symptoms of 
sexual dysfunction may occur together with other pelvic floor symptoms such as 
urinary incontinence, fecal incontinence, or pelvic organ prolapse. Low sexual desire 
and arousal, infrequent orgasm, and dyspareunia are associated with pelvic floor 
symptoms.4 The two most prevalent male sexual dysfunctions are erectile dysfunction 
and premature ejaculation.11 
Pelvic organ prolapse - Laxity or weakness of the pelvic floor muscles and ligaments 
can result in a prolapse with or without symptoms. Possible symptoms include the 
sensation of prolapse, low back pain, the need to digitally replace the prolapse in order 
to defecate or void, or problems with sexual intercourse. In women, an uro-genital 
prolapse can occur when one or more structures (the anterior vaginal wall, the posterior 
vagina wall, and the apex of the vagina) have descended.1,3 Rectal prolapse may present 
with symptoms such as anal protrusion, rectal pain, fecal incontinence or constipation.6 
PATIENT POPULATIONS
Gender, age, and the presence of a neurological condition may influence the relevance, 
severity and bother of symptoms, as well as the management of LUT and pelvic floor 
dysfunctions. A health care professional can gain much information from the way in 
which a patient enters the consultation room. For example, the walking pattern or 
the need of any assistance (manual/electric wheelchair, walking device) may reveal a 
neurogenic role in the origin of the complaints.
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Within the field of functional urology, it is important to distinguish the neuro-urological 
patients from the non-neuro-urological patients. Neurological conditions can cause 
urological symptoms due to any disturbance of the neural pathways that coordinate 
the LUT. It is mainly the extent and location of the neurological lesion that determine 
the severity and nature of the urological symptoms. Both adults and pediatric neuro-
urological patients, are at risk for functional disturbance of the urinary tract with 
possible irreversible deterioration of the lower and upper urinary tract on the long 
term.12 The origin of a neurogenic bladder dysfunction can be congenital, like spina 
bifida, or acquired, like traumatic spinal cord injury.
In children without a neurological condition, urinary continence (normal storage 
and emptying of the bladder) is expected around the age of four. Children with LUT 
conditions in the absence of congenital anatomical or neurologic abnormalities may 
present with urinary symptoms due to malfunction of the storage phase, the voiding 
phase, or both.13 The International Children’s Continence Society (ICCS) grouped 
all these functional bladder problems under the term day-time LUT conditions. 
Often comorbidities are encountered concomitantly with LUT conditions, such as 
constipation, fecal incontinence, urinary tract infections, nocturnal enuresis and 
psychiatric disorders.13-15
MANAGEMENT
Symptoms of LUT and pelvic floor disorders can have a negative impact on the quality 
of life of men, women and children. In the evaluation of symptoms of LUT and pelvic 
floor dysfunction, assessment of patient history and physical examination are essential. 
If relevant, additional investigations can be done, such as bladder and bowel diaries, 
urinalysis, urodynamics, measurement of post void residual urine, ultrasound, and 
lab test of renal function.3,4,10-13 Conservative treatment could be the first step in the 
treatment of LUT and pelvic floor disorders, including lifestyle modifications, urotherapy, 
pelvic floor therapy or psychological therapy. Besides non-pharmacological therapy, 
a variety of pharmacological treatments can be given in combination with other 
conservative treatment. If conservative treatment is unsuccessful or suspected to be 
unsuccessful, a surgical intervention could be considered. Various surgical treatments 
are available ranging from minimally invasive to complex reconstructions. For example, 
for the male stress urinary incontinence various surgical treatment options are available 
like injection of urethral bulking agents, adjustable continence balloons, male sling, or 
artificial urinary sphincter.16 In general, the aim of each treatment modality is to reduce 
the symptoms of LUT and pelvic floor disorders using a stepwise approach in consensus 
with the patient’s perception of the bothersomeness of the symptoms. 
16
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LUT and pelvic floor disorders may present in neuro-urological patients in various ways. 
The main challenging urological goals in the management of neuro-urological patients, 
both adults and children, are to preserve the lower and upper urinary tract function, to 
maintain or achieve urinary continence, and to improve the quality of life.12,17 In case of 
neurogenic urinary incontinence, conservative treatments such as clean intermittent 
catheterization and anticholinergic medications could be considered. If conservative 
therapy fails, a surgical option to increase the bladder outlet resistance could be 
discussed, such as bladder neck sling, bladder neck reconstruction, artificial, and injection 
of bulking agents.18-22 These bladder outlet procedures can be combined with bladder 
augmentation to improve bladder capacity and/or continent catheterizable urinary 
channel for catheterization.18-20,22 In general, recognizing the neuro-urological origin 
and problem is important in determining personalized treatment goals. Guidelines for 
the management of neuro-urological adults and children are available.12,17,19
OUTCOME MEASURES: TRADITIONAL AND PATIENT REPORTED
The International Continence Society (ICS) defined five domains to describe outcome in 
patients with LUT dysfunction: the patient’s observations, quantification of symptoms, 
the clinician’s observations (anatomic and functional), quality of life, and socioeconomic 
measures. To evaluate the effect of an intervention an assessment before and after 
the intervention is mandatory. The chosen outcome measure determines the effect 
of an intervention, which may vary between or within the domains. Therefore, a 
multidimensional approach is preferred, in particular because of the possible patient-
physician discrepancy.23,24 Traditional outcome measures, such as bladder and bowel 
diaries, pad tests, measurement of post void residual urine volume, assess the presence 
of symptoms, but do not assess the impact on quality of life or symptom bother from 
the patient’s perceptive. When evaluating  treatments of LUT and pelvic floor disorders, 
traditional outcome measures may give insight in quantitative changes of symptom 
presence. The outcomes may be converted into a symptom reduction rate when 
treatment is evaluated. For example, treatment outcome is defined by the ICCS as no 
response (<50% reduction of LUT symptoms), partial response (50% to 99% reduction 
of LUT symptoms), and complete response (100% reduction of LUT symptoms).13 
Conversely, LUT symptoms and impact on quality of life may not be equally assessed by 
patient and physician.25,26 A physician’s perception of symptom bother and idea of cure 
can be in discrepant from the patient’s perception. This is why it is important to collect 
patient reported outcomes besides traditional outcomes. 
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Nowadays, various patient reported outcome measures (PROMs), usually in the form 
of validated standardized self-administered questionnaires, are available to capture 
patients’ perspectives of health, disease, and effect of intervention. Subjective 
perceptions can be objectivized as quantifiable measure. The challenge is to choose 
the appropriate condition-specific or generic questionnaire available in the preferred 
language. Besides, most questionnaires are not comparable with each other and their 
quality varies. In order to achieve more insight into the quality of a questionnaire, 
measurement properties such as validity and reliability can be determined.27 
Several PROMs are available in Dutch and validated to evaluate the domains of dysfunction 
of the LUT and pelvic floor in non-neurogenic patients. The use of a validated and 
appropriate questionnaire is recommended by the guideline on Urinary Incontinence 
of the European Urology Association when standardized assessment is required.28 The 
Urogenital Distress Inventory (UDI-6) and Incontinence Impact Questionnaire (IIQ-7) are 
validated questionnaires in Dutch to assess symptom distress of urinary incontinence 
and its impact on daily life in both men and women.29  The fecal incontinence the Fecal 
Incontinence Quality of Life (FIQL) and the Fecal Incontinence Severity Index (FISI) 
can be used to evaluate bowel complaints and fecal incontinence.30 The pelvic organ 
prolapse domain can be evaluated with the Pelvic Floor Distress Inventory (PFDI-20) and 
the Pelvic Floor Impact Questionnaire (PFIQ-7).31 To assess sexual function in men, the 
International Index of Erectile Function short form (IIEF-5)32 is available and for women 
the Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire(PISQ-12)33. The 
Dutch Vancouver Symptom Score for Dysfunctional Elimination Syndrome VSSDES is 
a validated questionnaire to assess symptoms of bladder and bowel dysfunction in 
children.34 To assess the impact of urinary incontinence on children’s quality of life the 
Dutch Pediatric urinary incontinence Quality of life (PinQ) questionnaires can be used.35 
According to the International Children’s Continence Society, both questionnaires are 
appropriate and useful tools.13 
The guideline on Neuro-urology of the European Urology Association states that 
assessment of quality of life is essential in the overall management of neuro-urological 
patients.12 In neuro-urological patients it is important to use condition-specific PROMs 
specially designed for this population. Compared to the non-neurogenic population, 
symptom bother may differ and additional symptoms may be present due to the 
neurological condition. The Dutch SF-Qualiveen is a validated short questionnaire to 
measure the urinary-specific quality of life in patients with a neurological condition.36,37 
Validated Dutch questionnaires to evaluate sexual function and anorectal symptoms in 
neuro-urological patients are still missing.
18
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The routine use of PROMs in oncology have resulted in better communication between 
patient and physician, greater patient satisfaction, detection of unrecognized problems, 
and improvement in monitoring of treatment response.38 The combination of traditional 
and patient reported outcomes could possibly give more insights in the evaluation of 
symptoms within functional urology.
FOCUS OF OUR RESEARCH GROUP
Our research group has been devoted to research in the field of functional disorders 
of the urogenital tract in men, women and children. The focus of our clinical research 
line is testing the psychometric measurement properties of PROMs and evaluating 
traditional and patient reported outcomes of treatments within this field. The main goal 
is to optimize care in individuals by building bridges between patients, physician, and 
researcher. This research line is continued in this thesis. 
AIMS OF THIS THESIS
This thesis aims to evaluate effectiveness of conservative and surgical treatment in 
functional urology, reflected by traditional and patient reported outcome measures. A 
distinction is made between neurogenic and non-neurogenic patients. The effectiveness 
of conservative therapy in non-neurogenic children, two surgical interventions in 
children with a neurogenic condition and one surgical intervention in two different 
groups of non-neurogenic men are evaluated. To establish an optimal practice, the 
outcomes of different surgical interventions in a neurogenic population are assessed. 
Additionally, focus is placed on providing validated Dutch versions of PROMs that 
evaluate sexual function in neurogenic adults and urinary and anorectal symptoms in 
non-neurogenic children. 
OUTLINE OF THIS THESIS 
Part I. Evidence based outcome in functional urology
In the first part of this thesis, chapter 2, the focus is to identify an effective treatment 
option according to evidence based medicine. Different surgical therapies for the 
treatment of anatomic bladder outlet obstruction in males with neurogenic bladder 
dysfunction are systematically reviewed.
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Part II. Outcome of surgical treatment in functional urology
In this part the outcomes of different surgical treatments to manage urinary incontinence 
are described. The long-term results of bladder outlet procedures such as bladder neck 
sling and bladder neck reconstruction in children with neurogenic urinary incontinence 
are evaluated in chapter 3. Chapters 4 and 5 focus on outcomes, complications and 
re-interventions of minimally invasive continence therapy named ProACTTM in non-
neurogenic men with stress-urinary incontinence after radical prostatectomy and 
transurethral resection of the prostate. The patients’ overall response to the intervention 
is assessed with the Patient Global Impression of Improvement scale.
Part III. Patient reported outcome measures in functional urology
Different internationally accepted PROMs were translated into Dutch and their 
measurement properties were evaluated. The Multiple Sclerosis Intimacy and Sexuality 
Questionnaire (MSISQ-15) evaluates symptoms of sexual dysfunction in multiple sclerosis 
patients. In chapter 6 the translation and validation process of the Dutch MSISQ-15 in 
patients with neurological disease such as multiple sclerosis and spinal cord injury is 
described. Chapter 7 evaluates the responsiveness of the Dutch Vancouver Symptom 
Score for Dysfunctional Elimination Syndrome (VSSDES) and the Dutch Pediatric urinary 
incontinence Quality of life score (PinQ) used in children with dysfunctional voiding. 
The VSSDES evaluates symptoms of bladder and bowel dysfunction. The effect of 
bladder dysfunction on the quality of life is measured with the PinQ. Besides, chapter 7 
describes the outcome of extended urotherapy for children with dysfunctional voiding.
Part IV. General discussion and summary
In chapter 8 the added value of a therapy’s effectiveness reflected by traditional and 
patient reported outcome measures is discussed in view of the results of this thesis 
and present literature. The implications for clinical practice and research, challenges in 
future research and future perspective are discussed.
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ABSTRACT
Context: Surgical treatment of anatomic bladder outlet obstruction (BOO) may be 
indicated in males with neurogenic bladder dysfunction. A bothersome complication 
after surgery is urinary incontinence.
Objective: To identify the optimal practice in the surgical treatment of anatomic BOO 
in males with neurogenic bladder dysfunction, due to multiple sclerosis, Parkinson 
disease, spinal cord injury (SCI), spina bifida, or cerebrovascular accident (CVA).
Evidence acquisition: A systematic review was conducted according to the Preferred 
Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement. 
Medline, Embase, Cochrane controlled trial databases, Web of Science, and Google 
Scholar were searched for publications until January 2017. 
Evidence synthesis: A total of 930 abstracts were screened. Eight studies were 
included. The types of anatomic BOO discussed were benign prostate obstruction, 
urethral stricture, and bladder neck sclerosis. The identified surgical treatments were 
transurethral resection of the prostate (TURP) in patients with Parkinson, CVA or SCI, 
endoscopic treatment of urethral stricture by laser ablation or urethrotomy (mainly in 
SCI patients), and bladder neck resection (BNR) in SCI patients. The outcome of TURP 
may be highly variable, and includes persistent or de novo urinary incontinence, 
regained normal micturition control, and urinary continence. Good results were seen 
in BNR and endoscopic urethrotomy studies. Laser ablation and cold knife urethrotomy 
resulted in restarting intermittent catheterization or adequate voiding. Overall, a high 
risk of bias was found.
Conclusions: This systematic review provides an overview of the current literature on 
the outcome of several surgical approaches of different types of anatomic BOO in males 
with neurogenic bladder dysfunction. Identifying the optimal practice was impossible 
due to limited availability of high-quality studies. 
Patient summary: The outcome of several surgical approaches in males with 
neurogenic bladder dysfunction with benign prostate obstruction, urethral stricture or 
bladder neck sclerosis is overviewed. The optimal practice could not be identified.
29
Surgical management of anatomic BOO in males with NBD
2
1. INTRODUCTION
Symptoms of lower urinary tract (LUT) dysfunction in patients with neurological disease 
have an effect on the quality of life.1 The type of the neurological disease and the location 
of the lesion determine the pattern of the neurogenic bladder dysfunction, which can 
be shown in various urological symptoms.1,2 Symptoms in the absence of infection or 
obvious pathology other than possible causes of outlet obstruction are suggestive for 
bladder outlet obstruction (BOO).3 Detrusor-sphincter dyssynergia is the most common 
form of BOO in people with a neurogenic bladder dysfunction.4 However, BOO can also 
have an anatomic cause, such as benign prostatic hyperplasia (BPH) or urethral stricture. 
Surgical management of anatomic BOO may result in urinary incontinence (UI). Owing 
to the effects of neurological pathology on the LUT function, the surgical outcome in 
the treatment of anatomic BOO is expected to differ from that in the non-neurogenic 
population.
A feared complication in patients treated with intermittent catheterization (IC) is 
a urethral stricture due to repeated urethral trauma. IC is the gold standard for the 
management of neurogenic LUT dysfunction.2,5 Benign prostatic obstruction due to 
BPH is a relatively common disease in older men. Fifty percent of the male population 
between 51 and 60 yr of age has LUT symptoms (LUTS) due to BPH.6 Since male patients 
with a neurogenic bladder dysfunction can have an age of >50 yr and be at a risk of 
urethral strictures, treatment for BPH or urethral stricture could be necessary. Surgical 
interventions for anatomical BOO are transurethral resection of the prostate (TURP), 
open prostatectomy, bladder neck resection (BNR), endoscopic urethrotomy, and 
urethroplasty.
This systematic review focused on the surgical management of an anatomic BOO in 
males with a neurogenic bladder dysfunction due to multiple sclerosis (MS), Parkinson 
disease, spinal cord injury (SCI), spina bifida, or stroke/cerebrovascular accident (CVA) in 
order to identify optimal practice.
2. EVIDENCE ACQUISITION
2.1 Study registration
This systematic review was conducted according to the Cochrane Handbook for 
Systematic Reviews of Interventions7 and the Preferred Reporting Items for Systematic 
Reviews and Meta-analyses (PRISMA) statement8. The study protocol was registered on 
PROSPERO (CRD42017055229; https://www.crd.york.ac.uk/PROSPERO).
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2.2 Literature search
The citation sources Web of Science and Google Scholar and the Medline, Embase, 
and Cochrane controlled trial databases were searched for all relevant publications 
until January 2017. No date restrictions were applied. Duplicates were removed. The 
reference list of the relevant reviews was searched for relevant articles. The complete 
search string is shown in the Supplementary material.
2.3 Eligibility criteria 
All publications on surgical treatment of anatomic BOO caused by BPH, urethral 
stricture, or bladder neck sclerosis in male patients aged >18 yr and neurogenic bladder 
dysfunction due to MS, Parkinson disease, SCI, spina bifida, or stroke/CVA were eligible 
for full-text retrieval. The different types of interventions were TURP, open prostatectomy, 
endoscopic urethrotomy, urethroplasty, BNR, or any other surgical treatment for 
anatomic BOO. This review did not address surgical treatment of functional BOO due 
to neurogenic bladder dysfunction. Cancer was an exclusion criterion. Case reports 
with <10 adult neuro-urological (NU) patients, non-English text articles, conference 
abstracts, and reviews were excluded. The study population of all studies had to treat 
>90% adult NU patients, or the results for adult NU patients were separately reported. 
2.4 Selection of studies
Two reviewers (T.N. and J.G.) independently screened the titles and abstracts in 
Endnote (EndNote X7; Thomson Reuters, Philadelphia, PA, USA). The full text of all 
potentially eligible publications was independently screened by the same reviewers 
using a standardized screening form. A third reviewer (B.B.) resolved any disagreements 
between the two reviewers.
2.5 Data extraction 
The predefined data were independently extracted from the included full-text 
publications by two reviewers (J.G. and T.N.) using a standardized form. Any 
disagreements were resolved by the third reviewer (B.B.). General characteristics of the 
studies and study populations included the type of study, country, number of patients, 
age, neurological disease, type of anatomic BOO, type of intervention, and type of 
outcome measures.
2.6 Outcome measures
The measures of the outcome of the intervention were divided in primary and secondary 
outcomes.
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Primary outcomes: 
1. Degree of UI (pad use)
2. Results of invasive and non-invasive urodynamic measurements
Secondary outcomes: 
1. Quality of life 
2. Adverse effects after treatment
3. Surgical outcome measures 
4. Renal function
5. Socioeconomic measures
6. Other outcomes: non-prespecified outcome important when performing the 
review
2.7 Subgroup analyses
The predefined subgroups were type of anatomic BOO, type of intervention, and 
underlying NU pathology.  
2.8 Risk of bias assessment 
The Cochrane Risk of bias Assessment Tool7 together with an assessment of the 
main confounders following recommendations of the Cochrane handbook for 
nonrandomized comparative studies9 were used to perform a risk of bias analysis for 
included nonrandomized comparative studies. We developed a list of main confounders. 
The identified confounders were age, underlying NU pathology, previous treatments for 
anatomic BOO, and previous surgeries of the LUT. During data extraction, the identified 
confounders were analyzed in the studies. Confounding bias was classified as “high” if 
the confounder was unadjusted during analysis, imbalanced between the groups, or 
not considered or described. To determine the risk of bias for noncomparative studies, 
the availability of a priori protocol, selective outcome reporting (reporting bias), and 
incomplete data outcome (attrition bias) was assessed. Review Manager (RevMan) 
version 5.3 (The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, 
2014) was used to compute the risk of bias figure.
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3. EVIDENCE SYNTHESIS
3.1 Search results
The PRISMA flow diagram in Figure 1 shows the results of literature search and study 
selection. The initial literature search resulted in 930 abstracts. After reviewing 84 full-
text articles, eight studies were included.10-17
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in
g	
Records	identified	through	
database	searching	
(n	=	1033)	
In
cl
ud
ed
	
El
ig
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ty
	
Id
en
ti
fic
at
io
n	
Additional	records	identified	
through	citation	sources	
(n	=	333)	
Records	after	duplicates	removed	
(n	=	930)	
Records	screened	
(n	=	930)	
Records	excluded	
(n	=	846)	
Full-text	articles	assessed	
for	eligibility	
(n	=	84)	
Full-text	articles	excluded		
(n	=	76)	
Reasons:	
-	Functional	BOO	(n	=	14)	
-	No	intervention	(n	=	5)	
-	No	adult	NU	patients	(n	=	21)	
-	Review	(n	=	20)	
-	<	10	NU	patients	or	not	
separately	reported	(n	=	13)	
-	Full-text	not	available	(n	=	3)		
Included	studies	
(n	=	8)	
FIGURE 1. The literature search and study selection. BOO = bladder outlet obstruction; NU = 
neuro-urological; PRISMA = Preferred Reporting Items for Systematic Reviews and Meta-analyses.
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3.2 Characteristics of included studies
3.2.1 Design of studies
Table 1 shows the descriptives of the included studies. They were all retrospective and 
published between 1972 and 2017. The design of two studies was comparative, and the 
other six studies were single-arm studies. A total of 333 NU patients with an anatomic 
BOO were included in the studies, and 251 of them underwent a surgical treatment for 
anatomic BOO. All study participants were included consecutively. 
3.2.2 Underlying neurological disease
Of the 333 included patients, the neurogenic bladder dysfunction was due to SCI in 
201 men11,12,14,16, Parkinson disease in 73 men10,17, CVA in 53 men13,15, spina bifida in four 
men12, and MS in two men12.
3.3 Identified treatment
The interventions reported in the included studies were TURP, endoscopic urethrotomy, 
BNR, urethroplasty, and meatotomy. One single treatment was applied in six studies. 
More than one treatment modality was applied in two studies. However, in these 
studies urethroplasty and meatotomy were performed in <10 cases, and the results will 
therefore not be discussed here.11,16 Most of the studies reported the results of a surgical 
treatment in one hospital. One study reported the results of eight institutions.13 In the 
studies of Perkash14 and Roth et al10, one surgeon performed the interventions. The 
number of surgeons in the other studies was unclear. 
3.3.1 Transurethral resection of the prostate
In five studies, results of TURP in men with BPH were described. 
Roth et al10 reported the outcome in 23 patients with Parkinson disease. All patients had 
refractory LUTS despite alpha blockers for ≥2 mo. The median age was 73 yr, and the 
median time since Parkinson disease was diagnosed 3 yr at the moment of TURP.
Han et al13 evaluated which factors were associated with continued use of LUTS/BPH 
medication after TURP in 372 patients, including 31 with CVA.
Elsaesser and Stoephasius16 described 46 SCI patients with anatomic BOO. This was due 
to BPH in 21 patients, who underwent a TURP. The time between the SCI and the TURP 
varied from 4 mo to 15 yr.
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Moisey and Rees15 described the results of a TURP in 22 men with a history of CVA, 
including two who also had Parkinson disease. Age ranged from 58 to 93 yr.
Staskin et al17 performed a TURP in 36 Parkinson patients. Comparing this group with 14 
unobstructed patients, risk factors for post-TURP incontinence were considered.
3.3.2 Endoscopic treatment of urethral strictures 
Endoscopic treatment of urethra strictures was reported in three studies. The underlying 
neurological disease was SCI in almost all men.
In the study of Cornejo-Dávila et al11, an endoscopic internal urethrotomy was performed 
in 12 SCI patients who mentioned any difficulty in IC and had a urethroscopically 
confirmed bulbar urethral stricture of ≤10 mm. A single cut at 12 o’clock with a 
conventional straight blade was performed. Two weeks after the procedure, the 16-Fr 
silicone Foley catheter was removed and IC with the same intervals was resumed.
Krebs et al12 identified 105 men who used IC for bladder evacuation and had urethral 
strictures. This group included 99 SCI patients, four patients with spina bifida, and two 
patients with MS. An endoscopic internal urethrotomy was performed if there were 
intractable difficulties with IC with an increased risk of urinary retention as a result 
of impaired catheter passage through the urethra and a confirmed urethral stricture 
by a retrograde uretrography. This was the case in 38 men, in whom the underlying 
neurological disease was not further specified. A cold knife incised the stricture at 12 
o’clock. If there was no bleeding, the catheter was removed after 24 hours.
Perkash14 performed endoscopic neodymium:YAG contact laser urethrotomy in 42 SCI 
patients with strictures approximately 1-4 cm (<2 cm in 39 patients). The stricture was 
identified through a 23F cystoscope, and a guide wire was passed through the stricture. 
A contact laser chisel probe, 2.5 or 3.5 mm, screwed at the end of a semirigid fiber was 
used for endoscopic laser ablation. To achieve complete ablation, the fibrous tissue was 
vaporized circumferentially. The catheter was removed the next day.
3.3.3 Bladder neck resection 
Fourteen BNRs in SCI patients were described in the study of Elsaesser and Stoephasius16. 
When an optically prominent obstruction in the bladder neck was revealed by a 
cystoscopy, the sclerotic ring was resected between 3 and 9 o’clock or full circle.16
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3.4 RESULTS ON OUTCOME
The outcome measures are summarized in Table 2. None of the studies measured the 
pad use to obtain an estimate of UI severity, and none of the studies reported on renal 
function. We added two non-prespecified outcome measures: “recurrence of anatomic 
BOO” and “definition of success of intervention used by the study”. 
3.4.1 Primary outcome of TURP 
Two Parkinson patients with overflow UI became dry, and UI persisted in the cases with 
urge UI.17 Most of the patients (5/6) with abnormal sphincter control in preoperative 
urodynamic study became incontinent after TURP. Just one out of 24 patients who had 
normal sphincter control became incontinent.17 De novo UI after TURP was reported 
in patients with Parkinson17 in contrast to the study of Roth et al10. In this study, UI was 
resolved or improved or persisted after TURP, and de novo UI was not seen.10 
Moisey and Rees15 observed a regained normal micturition control in 16 (73%) out of 22 
CVA patients. Han et al13 (CVA patients) and Elsaesser and Stoephasius16 (SCI patients) did 
not report the outcome on continence.13,16 The latter authors considered the outcome 
of TURP good or improved in 16 out of 21 patients, with a postvoided residues of <100 
or <200 ml, respectively.16 No urodynamic data for CVA patients were provided.13,15
3.4.2 Primary outcome of endoscopic treatment of urethral strictures
UI was not observed in the three studies.11,12,14 Cornejo-Dávila et al11 and Krebs et al12 
mentioned that IC was restarted in all patients after endoscopic urethrotomy. The study 
population of Krebs et al12 needed one to five procedures. The possibility of adequate 
voiding after laser ablation was seen in 39 of 42 patients (93%). The pre- or postoperative 
way of bladder empting (IC or spontaneous voiding) was not reported.14
3.4.3 Primary outcome of BNR 
A postvoid residue of <100 ml could be obtained in 11/14 SCI patients after one or more 
procedures, while the procedure failed completely in three patients.16
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3.5 SUBGROUP ANALYSES
A subgroup analyses was not possible to perform or contributive. The studies included 
a small number of patients with different types of anatomic BOO, intervention, and 
underlying NU pathology. 
3.6 Risk of bias assessment
The risk of bias assessed by the Cochrane Risk of bias Assessment Tool and confounding 
factors was classified high for the two comparative studies. The included studies were 
assessed as having a high or unclear risk of bias (Figure 2). 
FIGURE 2. Risk of bias summary. 
+ = low risk of bias; ? = unclear risk of bias; - = high risk of bias; BOO = bladder outlet obstruction; NU = neuro-urological.
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3.7 DISCUSSION
3.7.1 Principal findings
To our knowledge, this is the first review with the focus on surgical management of 
anatomic BOO in NU patients. The identified surgical treatments were TURP in patients 
with Parkinson, CVA or SCI, endoscopic treatment of urethral stricture by laser ablation or 
urethrotomy (mainly in SCI patients), and BNR in SCI patients. The results of TURP in the 
different types of NU patients varied. De novo UI after TURP in Parkinson patients ranged 
from 0% to 20%.10,17 Bladder function had improved after TURP in 76% of SCI patients, 
defined as postvoiding residue <200 mL.16 In CVA patients, poorer results on bladder 
function were seen in case of more severe neurological impairment.15 Additionally, CVA 
appeared to be a risk factor of persistent voiding dysfunction and continued medical 
therapy after TURP.13 Good results were seen in BNR and endoscopic urethrotomy studies 
in SCI patients. Both laser ablation and cold knife urethrotomy resulted in restarting IC 
or adequate voiding. However, studies with a follow up of >1 yr showed that one or 
more reinterventions due to recurrence were sometimes necessary.12,14 
3.7.2 Interpretations of findings
First of all, our interpretations are based on a limited number of included studies with 
a low level of evidence. The surgical outcome of TURP in NU patients may be highly 
variable and includes persistent or de novo UI, regained normal micturition control, and 
urinary continence. A urodynamic study could have a predictive value. Staskin et al17 
described an association between postoperative continence and the degree of voluntary 
sphincter control in Parkinson patients. In NU patients, an invasive urodynamic study is 
necessary to determine the exact type of neurogenic LUT dysfunction, recommended 
by the European Association of Urology guidelines.2,5 A recent systematic review and 
meta-analysis reported a significant association between preoperative urodynamically 
proven BOO and better surgical outcome after TURP.18 However, this was not specified 
for NU patients. If a urodynamic study is of value in non-NU patients it will definitely be 
important for NU patients in order to distinguish a functional BOO from an anatomic 
BOO.
IC is part of regular treatment of NU patients who cannot effectively empty their 
bladders. It may however cause a urethral stricture, which in turn may necessitate a 
surgical intervention. The presentation and management of a urethral stricture is less 
uncertain in comparison with BPH in NU patients. The presence of a urethral stricture 
should be assessed when inability or difficulty with IC occurs. Repeated urethral 
dilation or endoscopic urethrotomy or urethroplasty are possible initial treatments, 
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especially for short bulbar strictures, according to the American Urological Association 
guidelines.19 Repeated urethral dilatation and endoscopic urethrotomy (cold knife or 
laser incision) have similar outcomes. Better outcome but higher morbidity is seen 
in urethroplasty.19 Nonetheless, in patients who are not candidates for urethroplasty, 
endoscopic urethrotomy should be followed by at least 4 mo of IC to maintain urethral 
patency and reduce the recurrence rate.19 Most of the NU patients already perform IC. 
Endoscopic reinterventions in the included studies were all successful.12,14 The American 
Urological Association guideline recommends a urethroplasty when a urethral stricture 
treated with urethrotomy recurs.19 This recommendation is based on a retrospective 
study without NU patients, which showed an association between repeat transurethral 
manipulation of urethral strictures and increased complexity of the stricture, 
complicating definitive urethroplasty.20 To our knowledge, no study discussing the 
results of urethroplasty after a recurrent urethral stricture of an endoscopic treatment 
in NU patients is available. In contrast to non-NU patients, even though the risk of 
strictures remains, IC is necessary in the management of neurogenic LUT dysfunction 
and will be continued either after urethrotomy or urethroplasty.
Good results of BNR were seen in 11/14 SCI patients with a cystoscopically observed 
sclerotic ring.16 In two men, successful outcome was obtained only after a transurethral 
external sphincterotomy after two failed BNRs. This may indicate that a cystoscopy 
insufficiently discriminates between anatomic and functional BOO. 
3.7.3 Implication for research and clinical practice
The available data, presented here, are insufficient to determine the optimal practice 
in the surgical treatment of anatomic BOO in NU patients. A urodynamic study should 
not lack in the work-up of BOO in NU patients. In patients with inability or difficulty 
with IC, the presence of a urethral stricture should first be assessed. Implications of the 
neurological bladder dysfunction on the surgical outcome of anatomic BOO cannot 
be determined in our review. Future studies should compare different surgical and 
medical therapies of benign prostatic obstruction in NU patients and focus on possible 
predictors of the outcome, especially concerning UI. In addition, optimal treatment of 
urethral strictures has yet to be determined.
3.7.4 Strengths and limitations
Our study gives an overview of the current literature on the surgical treatment of 
anatomic BOO in NU patients. Despite the use of strict guidelines when conducting 
this systematic review, several limitations should be addressed. First, all included 
studies were retrospective and had poor scientific quality. Second, the limited number 
45
Surgical management of anatomic BOO in males with NBD
2
of included studies, and the small number and heterogeneity of the patients between 
and in the studies made a subgroup analysis impossible. None of the studies compared 
interventions in the management of the same type of anatomic BOO. Finally, different 
terminology and parameters of outcome were used. A recently published systematic 
review found a considerable heterogeneity in outcome parameters to report of surgical 
interventions in NU patients.21 To improve the quality of studies and draw meaningful 
conclusions, standardized terminology and definitions of outcome in accordance with 
the International Continence Society should be used.3,22  
4. CONCLUSIONS
The eight included studies, with relatively poor scientific quality, demonstrated outcomes 
of various surgical approaches in different types of anatomic BOO and in heterogeneous 
NU study populations. Therefore, identifying the optimal practice in surgical treatment 
of these NU patients was not possible in this review with limited availability of eligible 
studies. However, our study provides an overview of the current literature on the 
surgical treatments. Future studies in NU patients with anatomic BOO should focus on 
the outcome of the surgical intervention for continence and preoperative noninvasive 
and invasive urodynamic measurements. Furthermore, standardized terminologies and 
definitions of outcomes should be used.
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SUPPLEMENTARY MATERIAL: SEARCH STRATEGY
Embase.com
(‘neurogenic bladder’/exp OR ((‘bladder disease’/exp OR ‘nocturia’/de OR ‘micturition 
disorder’/de OR ‘urinary hesitancy’/de OR ‘urine incontinence’/exp OR ‘urine retention’/
de OR prostatism/de OR ‘impaired bladder emptying’/de OR ‘postvoid residual urine 
volume’/de OR ‘lower urinary tract symptom’/exp) AND (‘neurologic disease’/de OR 
‘Parkinson disease’/de OR ‘multiple sclerosis’/de OR ‘spinal dysraphism’/exp OR ‘spinal 
cord disease’/exp OR ‘cerebrovascular accident’/exp OR ‘brain infarction’/exp OR ‘brain 
ischemia’/exp)) OR (((neuroge* OR neurolog* OR neuropath* OR spastic*) NEAR/6 
(bladder* OR vesical* OR urogenit*)) OR nlutd OR nlutds OR ((neurogen* OR neurologic* 
OR parkinson* OR (multiple NEAR/3 sclerosis) OR (spina* NEAR/3 ( dysraphis* OR bifida 
OR disease OR injur*)) OR stroke OR cva OR (cerebrovascula* NEAR/3 (accident* OR 
event*)) OR ((brain OR cerebral*) NEAR/3 (infarct* OR ischem* OR ischaem*))) AND 
(nocturia OR post-void* OR postvoid* OR (micturition NEAR/3 disorder*) OR hesitanc 
OR incontinence OR retention OR prostatism OR (impaired NEAR/3 empty*) OR LUTS 
OR LUTD OR LUTDs OR ((dysfunction* OR symptom* OR deficien* OR overactiv* OR 
underactiv* OR hyperactiv* OR hypoactiv* OR hypoton* OR hyperton*) NEAR/6 (lower-
urinar*-tract* OR detrusor* OR urethra* OR bladder* OR void*))))):ab,ti) AND (‘bladder 
obstruction’/exp OR ‘urethra obstruction’/de OR ‘obstructive uropathy’/de OR ‘bladder 
neck stenosis’/de OR ‘urethra stenosis’/de OR ‘urinary tract obstruction’/de OR ‘prostate 
hypertrophy’/de OR (((vesical* OR bladder* OR urethr* OR prostat* OR infravesical* 
OR bph OR urinary-tract* OR uropath*) NEAR/6 (obstruct* OR stenos*)) OR (obstruct* 
NEAR/6 flow NEAR/6 urin*) OR (prostat* NEAR/3  (hypertroph* OR hyperplas*))):ab,ti) 
AND (‘surgery’/de OR ‘surgical technique’/de OR ‘urologic surgery’/exp OR ‘surgery’:lnk 
OR (surger* OR resect* OR incision* OR prostatectom* OR urethrotom* OR urethroplast* 
OR reconstruct* OR replace* OR turp OR bni OR diversion* OR conduit* OR strictur*):ab,ti) 
NOT (child/exp NOT adult/exp) NOT (female/exp NOT male/exp) NOT ([Conference 
Abstract]/lim OR [Letter]/lim OR [Note]/lim OR [Editorial]/lim) AND [english]/lim
Medline Ovid
(“Urinary Bladder, Neurogenic”/ OR ((exp “Urinary Bladder Diseases”/ OR exp 
“Lower Urinary Tract Symptoms”/ OR exp “Urination Disorders”/ OR exp “Urological 
Manifestations”/ ) AND (exp “Nervous System Diseases”/ OR exp “Parkinson Disease”/ 
OR “Multiple Sclerosis”/ OR exp “Spinal Dysraphism”/ OR exp “Spinal Cord Diseases”/ 
OR exp “Stroke”/)) OR (((neuroge* OR neurolog* OR neuropath* OR spastic*) ADJ6 
(bladder* OR vesical* OR urogenit*)) OR nlutd OR nlutds OR ((neurogen* OR neurologic* 
OR parkinson* OR (multiple ADJ3 sclerosis) OR (spina* ADJ3 ( dysraphis* OR bifida OR 
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disease OR injur*)) OR stroke OR cva OR (cerebrovascula* ADJ3 (accident* OR event*)) 
OR ((brain OR cerebral*) ADJ3 (infarct* OR ischem* OR ischaem*))) AND (nocturia OR 
post-void* OR postvoid* OR (micturition ADJ3 disorder*) OR hesitanc OR incontinence 
OR retention OR prostatism OR (impaired ADJ3 empty*) OR LUTS OR LUTD OR LUTDs OR 
((dysfunction* OR symptom* OR deficien* OR overactiv* OR underactiv* OR hyperactiv* 
OR hypoactiv* OR hypoton* OR hyperton*) ADJ6 (lower-urinar*-tract* OR detrusor* 
OR urethra* OR bladder* OR void*))))).ab,ti,kf.) AND (exp “Urethral Obstruction”/ 
OR “Prostatic Hyperplasia”/ OR (((vesical* OR bladder* OR urethr* OR prostat* OR 
infravesical* OR bph OR urinary-tract* OR uropath*) ADJ6 (obstruct* OR stenos*)) OR 
(obstruct* ADJ6 flow ADJ6 urin*) OR (prostat* ADJ3  (hypertroph* OR hyperplas*))).
ab,ti,kf.) AND (“Surgical Procedures, Operative”/ OR exp “Urologic Surgical Procedures”/ 
OR “surgery”.xs. OR (surger* OR resect* OR incision* OR prostatectom* OR urethrotom* 
OR urethroplast* OR reconstruct* OR replace* OR turp OR bni OR diversion* OR conduit* 
OR strictur*).ab,ti,kf.) NOT (child/ NOT adult/) NOT (female/ NOT male/) NOT (letter OR 
news OR comment OR editorial OR congresses OR abstracts).pt. AND english.la.
Cochrane CENTRAL
((((neuroge* OR neurolog* OR neuropath* OR spastic*) NEAR/6 (bladder* OR vesical* 
OR urogenit*)) OR nlutd OR nlutds OR ((neurogen* OR neurologic* OR parkinson* OR 
(multiple NEAR/3 sclerosis) OR (spina* NEAR/3 ( dysraphis* OR bifida OR disease OR 
injur*)) OR stroke OR cva OR (cerebrovascula* NEAR/3 (accident* OR event*)) OR ((brain 
OR cerebral*) NEAR/3 (infarct* OR ischem* OR ischaem*))) AND (nocturia OR post-
void* OR postvoid* OR (micturition NEAR/3 disorder*) OR hesitanc OR incontinence OR 
retention OR prostatism OR (impaired NEAR/3 empty*) OR LUTS OR LUTD OR LUTDs OR 
((dysfunction* OR symptom* OR deficien* OR overactiv* OR underactiv* OR hyperactiv* 
OR hypoactiv* OR hypoton* OR hyperton*) NEAR/6 (lower-urinar*-tract* OR detrusor* 
OR urethra* OR bladder* OR void*))))):ab,ti) AND ((((vesical* OR bladder* OR urethr* OR 
prostat* OR infravesical* OR bph OR urinary-tract* OR uropath*) NEAR/6 (obstruct* OR 
stenos*)) OR (obstruct* NEAR/6 flow NEAR/6 urin*) OR (prostat* NEAR/3  (hypertroph* 
OR hyperplas*))):ab,ti) AND ((surger* OR resect* OR incision* OR prostatectom* OR 
urethrotom* OR urethroplast* OR reconstruct* OR replace* OR turp OR bni OR diversion* 
OR conduit* OR strictur*):ab,ti) 
Web of science
TS=(((((neuroge* OR neurolog* OR neuropath* OR spastic*) NEAR/5 (bladder* OR 
vesical* OR urogenit*)) OR nlutd OR nlutds OR ((neurogen* OR neurologic* OR 
parkinson* OR (multiple NEAR/2 sclerosis) OR (spina* NEAR/2 ( dysraphis* OR bifida 
OR disease OR injur*)) OR stroke OR cva OR (cerebrovascula* NEAR/2 (accident* OR 
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event*)) OR ((brain OR cerebral*) NEAR/2 (infarct* OR ischem* OR ischaem*))) AND 
(nocturia OR post-void* OR postvoid* OR (micturition NEAR/2 disorder*) OR hesitanc 
OR incontinence OR retention OR prostatism OR (impaired NEAR/2 empty*) OR LUTS 
OR LUTD OR LUTDs OR ((dysfunction* OR symptom* OR deficien* OR overactiv* OR 
underactiv* OR hyperactiv* OR hypoactiv* OR hypoton* OR hyperton*) NEAR/5 (lower-
urinar*-tract* OR detrusor* OR urethra* OR bladder* OR void*)))))) AND ((((vesical* OR 
bladder* OR urethr* OR prostat* OR infravesical* OR bph OR urinary-tract* OR uropath*) 
NEAR/5 (obstruct* OR stenos*)) OR (obstruct* NEAR/5 flow NEAR/5 urin*) OR (prostat* 
NEAR/2  (hypertroph* OR hyperplas*)))) AND ((surger* OR resect* OR incision* OR 
prostatectom* OR urethrotom* OR urethroplast* OR reconstruct* OR replace* OR turp 
OR bni OR diversion* OR conduit* OR strictur*))) AND DT=(article) AND LA=(english)
Google scholar
“neurogenic|neurologic|neuropathic|spastic bladder”|nlutd|nlutds obstruction|stenosis 
surgery|resection|incision|prostatectomy|urethrotomy|urethroplasty|reconstruction|re
placement|stricture
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SUMMARY
Introduction: Achieving continence in children with neurogenic sphincteric 
incompetence is a challenge. Awareness of the long-term outcome in this young patient 
population is important. In the past 25 years, the study institution has built experience in 
bladder outlet procedures such as bladder neck sling and bladder neck reconstructions.
Objective: The objective of this study was to evaluate the long-term outcome on 
continence and re-intervention rate of bladder outlet procedures in children with 
neurogenic urinary incontinence in the study institution.
Design: All children who underwent a bladder neck procedure between 1992 and 2017 
at the study institution were retrospectively reviewed. Continence at the end of follow-
up was the primary endpoint, defined as ‘dry’ when there was an interval of a minimum 
of 4 h without urinary leakage. Non-parametric tests were used for statistical analysis.  
Results: During this 25-year period, a total of 60 children underwent a bladder outlet 
procedure, either a bladder neck sling (n = 43) or a bladder neck reconstruction (n = 17). 
The median age at surgery was 11.6 years (interquartile [IQR] 7.8-13.9). Concomitant 
surgery consisted of bladder augmentation in 80% and continent catheterizable urinary 
channel in 97% of children. Dry rate within 1 year was 38%. After a median follow-up 
of 10.4 years (IQR 6.5-15.5), 77% of all children were dry. Twenty-five children (42%) 
needed one or more re-interventions, including redo of the bladder outlet procedure, 
other type of outlet procedure, bulking agents, bladder augmentation, and bladder 
neck closure. 
Discussion: This study confirms that achieving continence is a challenge. The inconsistent 
use of the definition of urinary continence creates confusion in the literature and makes 
comparison of outcome with other studies difficult. Openness of (long-term) results in 
achieving urinary continence is important and helpful for future patients. 
Conclusion: On the long term, the majority of children with neurogenic urinary 
incontinence were dry after a bladder outlet procedure, but a considerable number 
of patients had a re-intervention. The initial outcome on continence was slightly 
disappointing. Reporting long-term results is essential and helpful for patient counseling. 
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1. INTRODUCTION
The main challenging urological goals in children with neurogenic bladder dysfunction 
are to preserve the upper urinary tract function and to achieve urinary continence.1-3 
Management should focus on ensuring bladder emptying, attaining safe bladder 
storage pressure and capacity, and adequate sphincteric outlet resistances.1-3 A 
urodynamic evaluation is necessary to characterize the cause of urinary incontinence.4-6 
Surgical therapy could be considered when non-surgical therapy such as anticholinergic 
medications and intermittent catheterization fails. The appropriate surgical management 
must be determined individually for each child based on urodynamic findings.1,2,4-6 
The etiology of urinary incontinence secondary to neurogenic sphincteric deficiency 
includes myelomeningocele (MMC), sacral agenesis, acquired spinal cord tumor, 
iatrogenic injury, and trauma.5 Surgical options that have been developed to increase 
bladder outlet resistance in the treatment of neurogenic sphincteric incompetence are 
bladder neck sling, bladder neck reconstruction, artificial urinary sphincter (AUS), and 
injection of bulking agents.1,2,4-6 These bladder outlet procedures can be combined with 
bladder augmentation to improve bladder capacity and/or continent catheterizable 
urinary channel for catheterization.1,2,4,5 Unfortunately, reports on long-term results are 
scarce. 
In the past 25 years, the study institution has built experience in bladder outlet 
procedures such as bladder neck sling and bladder neck reconstructions. Based on 
clinical experience, continence on the long term can be achieved with both bladder neck 
reconstruction and bladder neck sling, but a re-intervention for persistent incontinence 
is not exceptional. This study aimed to evaluate the long-term outcome on continence 
of bladder outlet procedures in children with neurogenic urinary incontinence at the 
study institution. Furthermore, the re-intervention rate and complication rate were 
evaluated. 
2. MATERIAL AND METHODS
2.1 Study population
Children (age <18 years) with neurogenic urinary incontinence secondary to sphincteric 
deficiency who underwent a bladder outlet procedure (bladder neck reconstruction 
or bladder neck sling) between 1992 and 2017 at the study institution were eligible 
for inclusion. Children with a postoperative follow-up of less than 1 year were 
excluded. The principles of Helsinki Declaration were followed in lieu of formal ethics 
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committee approval. The etiologies of neurogenic urinary incontinence were MMC, 
VACTERL-associated (vertebral defects, anorectal malformations, cardiac defects, 
tracheoesophageal fistula, renal anomalies, and limb abnormalities) cause, and 
sacrococcygeal teratoma. The individual patients’ medical charts were retrospectively 
reviewed. Primary outcome was the postoperative continence rate at the last outpatient 
visit. Urinary continence was defined as ‘dry’ when there was a patient-reported interval 
of a minimum of 4 hours without urinary leakage between voiding or intermittent 
catheterizations. Secondary outcomes were continence within 1-year postoperative, re-
interventions, and complications.   
2.2 Surgical procedure
The purpose of the bladder outlet procedure was to increase the bladder outlet resistance. 
The bladder outlet procedure was often combined with the creation of a continent 
catheterizable urinary channel, most commonly an appendicovesicostomy. All patients 
were analyzed pre-operatively with urodynamic study and cystoscopy. Pre-operatively, 
a low-pressure urinary reservoir with sufficient capacity, using anticholinergics, was 
aimed for. In this practice, it is of standard care to start with anticholinergics and 
intermittent catheterization in children with MMC immediately after birth. A bladder 
outlet procedure was combined with bladder augmentation if a low compliant and/or a 
small capacity bladder insufficiently responsive to anticholinergics or botulinum toxin A 
was seen on urodynamic study interpreted by the urologists and urodynamic physician. 
In general, in the study institution a bladder compliance reported of <15 mL/cmH2O on 
urodynamic study was defined as low compliant, and a bladder capacity of <50% of the 
expected bladder capacity calculated with the formula ([age {years} + 1] x 30 mL) was 
defined as low capacity.
Before the bladder outlet procedure, the anatomy of the bladder outlet was evaluated 
by cystoscopy at the time of the surgery. In this study, bladder outlet procedures were 
divided in two types: bladder neck reconstruction and bladder neck sling. The choice of 
technique depended on the preference of the surgeon. A bladder neck reconstruction 
was performed using one of the three techniques described by Jones et al7, Pippi Salle8, 
or Dees9. The results of those techniques were chosen to be merged because they all 
increase the bladder outlet resistance by lengthening and narrowing the urethra with 
tubularization of the trigone. The bladder neck sling procedure was based on coaptation, 
elevation, and narrowing of the urethra by suspension of the bladder neck  by placing 
an autologous rectus fascial strip around the bladder neck and fixing the ends to the 
pubic symphysis.10 
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2.3 Follow-up
All patients had an outpatient visit within 1 year postoperatively combined with a 
urodynamic study. Depending of the underlying disease, the outpatient visits varied 
in interval at the urologist or pediatrician. During follow-up visits, all patients were 
asked about (in)continence, and patient-reported dry interval was noted. If severe 
incontinence was reported, a urodynamic study was conducted, and when indicated, 
a re-intervention was planned. All patients underwent a renal ultrasound investigation. 
The time interval between bladder outlet procedure and re-intervention of the 
bladder neck was determined. In case of usage of bulking agents, two types were 
used: dextranomer/hyaluronic acid copolymer or polydimethylsiloxane. Complications 
>30 days postoperatively were categorized into bladder stones, problems with 
catheterization of the continent catheterizable urinary channel, or other complications. 
The duration of follow-up was defined as the time from the date of surgery to the date 
of the last outpatient visit.
2.4 Statistical analysis
Information about urinary leakage, frequency of intermittent catheterization, 
demographic data, and data on medical history were retrospectively collected from 
patients’ medical charts. Descriptive statistics are presented as median (interquartile 
range [IQR]), frequency, and percentiles. The chi-squared test and the Mann-Whitney 
U test were used to analyze categorical and continuous variables, respectively. The 
occurrence of a re-intervention over time is distributed in a Kaplan-Meier curve. A two-
sided P-value of <0.05 was considered significant. Statistical analyses were performed 
using SPSS, version 24.0 (IBM Corp., Armonk, NY). 
3. RESULTS
3.1 Study population
A total of 60 patients underwent bladder outlet procedures from 1992 to 2017 at a 
median age of 11.6 (IQR 7.8-13.9) years. Thirty-five (58.3%) patients were female. The 
etiology of neurogenic urinary incontinence was predominantly (91.7%) MMC. In Table 1 
the patient characteristics are shown. Forty-three (71.7%) patients underwent a bladder 
neck sling procedure and 17 (28.3%) a bladder neck reconstruction. Concomitant 
surgeries included a continent catheterizable urinary channel in 58 (96.7%) patients and 
bladder augmentation in 48 (80.0%) patients. Five patients had a urological history of 
bulking agents (before bladder neck sling n = 3 and before bladder neck reconstruction 
n = 2). 
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TABLE 1. Characteristic presented as number (%) or median (interquartile range). 
Total, n = 60 BNS, n = 43 BNR, n = 17 P-value
Gender 
- Female
- Male
35 (58.3%)
25 (41.7%)
31 (72.1%)
12 (27.9%)
4 (23.5%)
13 (76.5%)
P < 0.001a
Median age at operation, yrs (IQR) 11.6 (7.8-13.9) 11.8 (8.5-14.1) 10.4 (7.6-12.5)
P = 0.279b
Median follow up, yrs (IQR) 10.4 (6.5-15.5) 11.2 (7.5-18.2) 8.9 (6.1-15.1)
P = 0.305b
Etiology
- MMC
- VACTERL association
- Sacrococcygeal teratoma
55 (91.7%)
4 (6.7%)
1 (1.7%)
41 (95.4%)
1 (2.3%)
1 (2.3%)
14 (82.4%)
3 (17.6%)
-
P = 0.086a
Concomitant surgery:
- Continent catheterizable channel 
- Bladder augmentation 
- Ureteral reimplantation
58 (96.7%)
48 (80.0%)
5 (8.3%)
41 (95.3%)
33 (76.7%)
3 (7.0%)
17 (100%)
15 (88.2%)
2 (11.8%)
P = 0.366a 
P = 0.316a 
P = 0.545a
Bladder neck sling (BNS); bladder neck reconstruction (BNR).
a Chi-squared test
b Mann-Whitney U test
3.2 Continence outcome
Within 1 year postoperatively, 23 (38.3%) patients were dry, 15 after bladder neck sling 
and 8 after bladder neck reconstruction (P = 0.38, Table 2). 
TABLE 2. Continence outcome presented in number (%) and numbers specified for gender. 
Total BNS BNR P-value
Dry rate <1yr follow-up 23/60 (38.3%)  15/43 (34.9%) 8/17 (47.1%) P = 0.382a
Men, n = 25 5/12 6/13 P = 0.821a
Women, n = 35 10/31 2/4 P = 0.482a
Dry rate >1yr follow-up 46/60 (76.7%) 33/43 (76.7%) 13/17 (76.5%) P = 0.982a
Men, n = 25 10/12 9/13 P = 0.409a
Women, n = 35 23/31 4/4 P = 0.247a
Bladder neck sling (BNS); bladder neck reconstruction (BNR).
a Chi-squared test
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After a median follow-up of 10.4 (IQR 6.5-15.5) years, 46 (76.6%) patients were dry 
(minimum of 4-hours interval) with or without additional continence procedures. 
Thirteen (21.7%) patients were not dry (urethral leakage n = 6, leakage from urinary 
conduit n = 6, urinary leakage from both n = 1), and one (1.7%) patient, who had a 
bladder neck sling procedure, was dry with a 3-h interval. The majority of incontinent 
patients accepted the situation. The initial bladder outlet procedure of the dry patients 
was bladder neck sling in 33 of 43 patients and bladder neck reconstruction in 13 of 17 
patients (P = 0.98, Table 2). Dryness rate within 1 year and dryness rate on the long term 
did not differ between the types of bladder outlet procedure, also when specified for 
gender (Table 2).
3.3. Re-interventions
After a median follow-up of 10.4 years, 41.7% (25/60) of the study population received 
a re-intervention of the bladder neck procedure. Within this group, the median time 
between bladder outlet procedure and re-intervention was 1.0 (IQR 0.6-2.6) year. The 
Kaplan-Meier curve presents the time until re-intervention during follow-up (Figure 
1). Most re-interventions were carried out because of a bladder outlet problem, 
except in two patients. In one, a bladder augmentation was applied because of a poor 
bladder compliance. Another required a bladder augmentation (combined with redo 
of the bladder neck sling) for a de novo therapy-resistant detrusor overactivity. The 
re-interventions included redo of the bladder outlet procedure, other type of outlet 
procedure than the initial one, bulking agents, bladder augmentation, and bladder 
neck closure. The various re-interventions of the bladder neck and the outcome on 
continence are specified in Figure 2. In 58.3% (35/60) of the study population, a re-
intervention was not necessary; 31 patients were dry, and four patients considered the 
incontinence acceptable. 
3.4 Complications
After a median follow-up of 5.1 (IQR 3.7-9.2) years, 23 patients were treated for a 
bladder stone. The occurrence rate of a bladder stone was comparable between the 
types of bladder outlet procedures. All patients with bladder stones had a continent 
catheterizable urinary channel, and 20 patients had an augmented bladder. In eight 
patients the bladder stones recurred. 
After a median follow-up of 1.2 (IQR 0.8-5.4) years, the continent catheterizable urinary 
channel was surgically revised because of problems with catheterization in 15 patients, 
nine with a bladder neck sling and six with a bladder neck reconstruction. There was no 
difference between the two types of bladder outlet procedures.
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FIGURE 1. Re-intervention-free survival after bladder outlet procedure distributed in a Kaplan-
Meier curve.
Two patients had an abdominal laparotomy (32 and 40 months postoperatively, 
respectively) on suspicion of a bladder perforation. The type of bladder outlet 
procedure was different, but both underwent concomitant surgery including a bladder 
augmentation and a continent catheterizable urinary channel. 
4. DISCUSSION
Although techniques and insights have changed over the years, achieving continence 
in children with neurogenic sphincteric incompetence is still a challenge. The choice 
of a bladder outlet procedure with or without concomitant surgery such as bladder 
augmentation and continent catheterizable urinary channel is influenced by the 
patient’s needs, gender, bladder function, and the surgeon’s preference. Long-term 
outcome of these surgical procedures, especially in view of the young age of these 
patients, is important, but unfortunately, reports on this aspect are sparse. In this 
retrospective cohort study, the continence results within 1 year after a bladder neck 
sling and bladder neck reconstruction were rather disappointing (dry: 38 %). On the 
long term (median follow-up of 10.4 years), continence rate was modest to good (dry: 
77%), although re-intervention was required in 42% to achieve this result. 
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FIGURE 2. Long-term results on dryness with or without reintervention. FU, follow-up; IQR, 
interquartile range.
Comparison with other studies is difficult because of the different modifications of 
surgery techniques used, alternated concomitant surgery, small number of patients 
analyzed, varying time of follow-up (the majority short term), and different definitions 
of urinary continence. Reported continence rates after bladder neck sling procedure 
ranged from 40% to 100% and after a bladder neck reconstruction from 50% to 88%. 
However, follow-up was short in most of these studies.5 The long-term results on 
continence after bladder neck sling (77%) and bladder neck reconstruction (77%) are 
within this range. For both the types of procedure, re-intervention was necessary in 
more than 40% of cases (42% bladder neck sling and 41% bladder neck reconstruction). 
Reported re-intervention rates in other series are scarce, amounting to 3%-40% for 
bladder neck sling11-13 and 12%-83% for bladder neck reconstruction5,14. A summary of 
the literature used for this discussion is given in Table 3.
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The inconsistent use of the definition of urinary continence creates confusion in the 
literature.15 In some studies cured and improved patients are grouped together; others 
use vague terms such as ‘social continence’.14,15 Urinary continence was defined as an 
interval of a minimum of 4 h without urinary leakage between voiding or intermittent 
catheterizations. Besides outcome on continence, another important outcome is 
patient’s satisfaction. Completely dry will not automatically be proportional to a patient’s 
satisfaction. In the follow-up, it was not of standard care to use validated questionnaires 
to measure patient’s symptoms or quality of life. Hence, it was impossible to evaluate 
the outcome of surgical (re)intervention on urinary continence in relation to patient-
reported outcome and effect on the quality of life.
In this series, more bladder neck sling procedures were performed in females than in 
males. Ten of 12 males after bladder neck sling became dry at the end of follow-up. 
Contradictory outcomes on continence in males are described in the literature, ranging 
from 0% to 87%.11,12,16 One study presented favorable results on continence (87%), but 
this was only a small series of 15 boys, and urinary continence was defined as complete 
‘passive’ urinary continence.12 Injury to the periprostatic neurovascular bundle during 
the surgery could lead to impotence. Bladder neck sling procedures are not an obvious 
choice in boys due to unclear results on continence together with the risk of impotence. 
In boys, a bladder neck reconstruction is chosen to be preferred to minimize damage 
on the neurovascular bundle of the prostate. A bladder neck sling procedure could 
possibly give more damage on the posterior side of the bladder neck. Although most 
literature studies did not report on outcomes of erectile function, one study reported 
preservation of erectile function after bladder neck sling in four postpubertal males.16 
As the population in whom these interventions are performed is young, retaining sexual 
function should be a point of attention. 
Before the bladder outlet procedure and during follow-up, intravesical pressure, bladder 
capacity, and compliance should be evaluated with urodynamic studies. Sufficient 
capacity and adequate compliance are essential to achieve urinary continence and 
protect the upper urinary tract. In this study, the bladder outlet procedure was 
combined with bladder augmentation in 80% (n = 48, Table 1) due to insufficient pre-
operative response to anticholinergics or botulinum toxin A. During follow-up another 
two patients required a bladder augmentation. Considering a bladder outlet procedure 
without bladder augmentation should be based on careful patient selection. Shared 
decision-making with the patient/parents is important to ensure understanding of the 
risk of a future re-intervention and the need of committed follow-up.17 
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The injection of bulking agents and AUS are other techniques to increase the resistance 
of the bladder neck in the treatment of neurogenic sphincteric incompetence. 
According to the literature, in about one-third of cases, continence can be achieved 
with bulking agents as primary therapy.1,18-20 However, deterioration in continence is 
expected on the long term.19,20 The exact role, primary or secondary therapy, of this 
minimally invasive technique in neurogenic sphincteric incompetence seems unclear. In 
a recently published study by Faure et al, 13 (45%) children with neurogenic sphincteric 
incompetence, who were primarily treated with bladder neck reconstruction, had 
become dry with injection of bulking agents.14 Injections of bulking agents as secondary 
procedure, after bladder neck sling, resulted in two (7%) dry patients, described by 
Vocht et al.21 In this study, bulking agents resulted in continence in four patients after 
bladder neck sling (44%) and in three (75%) after bladder neck reconstruction (Figure 
2). It is worthwhile to consider the injection of bulking agents for relief of mild urinary 
continence after previous bladder outlet procedure. Of course, the patient/parents 
should be clearly counseled on the expectations.
The study institution has no experience with AUS in children. Variable continence rates 
in children with neurogenic urinary incontinence are described in the literature at 
varying time of follow-up periods. Continence rates reported by Kryger et al22, Simeoni 
et al23, and Catti et al24 were 56% (mean follow-up 15.4 years), 77% (mean follow-up 5.1 
years), and 73% (median follow-up 5.5 years), respectively. Continence results appear 
independent of age at the time of implantation.6,22 Better results were described when 
the AUS is implanted on a non-operated bladder neck.6,23 Revision rate of long-term 
experience is 0.03 revisions per patient-year.4,5 Patients in the neurogenic population 
are often wheelchair bound; therefore, it is suggested that there is a risk of perineal 
pressure which could possibly lead to complications. Some considerations should be 
made before implantation of the AUS in children. The most important are to recognize 
the general risk of infection and the possible problem of erosion and revision. Other 
aspects to evaluate are the patient’s bladder capacity and compliance, patient’s mobility, 
and previous surgery of the bladder neck. Furthermore, the need of intermittent 
catheterization is not ruled out after an AUS. 
Several limitations of this study must be mentioned. First is the retrospective single-
center design of this study and the fact that the medical files in the study institution were 
digitalized during the period 1992 - 2017. Together, this may have resulted in missing 
data, such as data retrieved from voiding charts or information about sexual function. 
Second, data of urodynamic studies were not assessed because the primary outcome 
was urinary continence and secondarily the re-interventions and complications were 
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reviewed. Finally, the heterogenicity in re-interventions and type of bladder outlet 
procedure could be a source of bias. Unfortunately, the number of patients was too 
small to investigate in detail the differences in surgical techniques. 
Despite the limitations, the strength of this study is the long-term follow-up and 
the openness of results in achieving urinary continence. Those long-term results are 
valuable for patient counseling and for creating realistic expectations in patients and 
parents of the outcome of surgical treatment. Based on these results and the number of 
patients, it is not possible to state which technique is the most preferred or to indicate 
outcome predictors. Both would be interesting for future research. Additionally, future 
studies should use patient-reported outcome measurements to evaluate the effect of 
surgery on symptoms and the quality of life. 
5. CONCLUSION
This study confirms that achieving continence is a challenge in children with urinary 
incontinence secondary to neurogenic sphincteric incompetence. The number of dry 
patients after a bladder neck sling and bladder neck reconstruction within 1 year was 
somewhat disappointing, although long-term moderate-to-good continence rates were 
noted. However, a considerable number of patients had a re-intervention. Reporting 
long-term results is essential and helpful for patient counseling.  
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ABSTRACT
Aims: To evaluate our outcomes of the adjustable continence balloons ProACT™ for the 
treatment of male stress urinary incontinence after radical prostatectomy.
Methods: Between May 2007-August 2016 the ProACT™ was implanted in 143 patients 
without a history of radiotherapy. Endpoints were patient-reported changes in pad 
counts and complications. Treatment was considered successful if no pad or just one 
“security” pad per day sufficed, and improved if daily pad use was reduced by ≥50%.
Results: Incontinence before implantation was mild in 36 (25%), moderate in 57 (40%), 
and severe in 50 (35%) patients. Complications within 30 days were classified by the 
Clavien-Dindo classification; eight (5.6%) grade I, three (2.1%) grade II, three (2.1%) 
grade IIIb, and 129 (90.2%) patients had no complication. Revision was done in 43 
(30%) patients. The IPSS quality of life item improved significantly from 5.0 (IQR 4.0-5.0) 
preoperative to 2.0 (IQR 1.0-4.0) and 1.0 (IQR 0.0-3.0) 6 and 12 months after implantation, 
respectively. After a median follow up of 56 months (range 28 to 79, n = 112), 72 (64%) 
patients were improved, including 51 (45%) patients were successful. Daily pad use 
decreased from 3.0 to 1.0 (67% reduction). The median outcome on the Patient Global 
Impression of Improvement scale was “much better”, and 97 (87%) patients perceived 
improvement.
Conclusions: The minimally invasive ProACT™ device showed a clear beneficial 
continence outcome in patients with stress urinary incontinence after radical 
prostatectomy. The majority of the patients were satisfied and perceived improvement 
≥50% on daily pad use on the long term.
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1. INTRODUCTION
Post prostatectomy urinary incontinence (PPI) is a devastating complication after a 
radical prostatectomy (RP).1 In most cases this concerns stress urinary incontinence 
(SUI) caused by intrinsic sphincter deficiency.2 The prevalence of SUI after is up to 60%, 
at varying times after the operation.3 Usually, SUI has a great negative impact on the 
patients’ quality of life.2,4 Several approved devices for the surgical treatment for male SUI 
are available. One of these is the ProACT™ device (Uromedica, Inc., MN) which consists 
of two periurethrally placed volume-adjustable balloons.1 The volume of the balloons 
can be adjusted in an outpatient setting to achieve the optimal balance between 
voiding pressure and continence.1 Successful outcome after ProACT™ implantation has 
been correlated with an increase in urethral resistance and increased maximum urethral 
closure pressure.5,6
Several studies reported a significant reduction of daily pad use and improvement 
on quality of life index scores with the use of ProACT™. Some studies showed dry or 
daily pad use improvement rates ranging from 60-92% limited to 12-24 months.1,7-9 
Long term outcomes reported in the literature are hardly available. Three studies with 
a mixed population of patients with PPI and post transurethral resection of the prostate 
incontinence with a follow up ranging from 56-58 months showed a 50-66% overall dry 
rate, defined as ”no pad or one security pad”,10,11 or a 4.5% overall dry rate, defined as 
“no pads”.12
Quality of life is an important outcome domain in the treatment of urinary incontinence.13 
Multiple-question condition-specific quality of life instruments give access to many 
components of the condition, but some are extensive and minimally suitable in the 
standard clinical setting.13-15 The Patient Global Impression of Improvement (PGI-I) scale 
is a global index that provides an overall response to an intervention.13 It is a simple, 
easy-to-use and easy to interpret tool in clinical practice and research settings.13-15 The 
PGI-I scale has been used and/or has been validated for women with SUI,13 women with 
urogenital prolapse,14 men with lower urinary tract symptoms secondary to benign 
prostatic hyperplasia,15 and patients with non-urological diseases.16
We have been using the ProACT™ device for the treatment of male SUI after RP at our 
department Urology since May 2007. The aim of this study is to evaluate our results in 
terms of success, changes in pads use, complications and patient-reported estimates of 
improvement assessed with the PGI-I scale. 
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2. PATIENTS AND METHODS
2.1 Study population
We included patients with SUI after RP who had the ProACT™ device implanted between 
May 2007 and August 2016 after conservative treatment with pelvic floor exercises for 
1 year had failed. In all patients the possibility of adjustable continence balloons, male 
sling, and artificial sphincter were discussed. Patients with an artificial urinary sphincter 
(AUS) or male sling in situ and those with a history of adjuvant radiotherapy after RP 
were excluded. Severe SUI and a history of failed and removed urinary incontinence 
devices (AUS, male sling or ProACT™) were not exclusion criteria. All included patients 
underwent a cystoscopy (to assess the presence of a stricture) and an urodynamic study.
2.2 Intervention
Initially, the ProACT™ device was implanted percutaneously with the use of a rigid 
19F cystoscope and fluoroscopy in the anterior posterior direction. After April 2014 a 
flexible cystoscope was used. The flexible cystoscope provides retrospective intravesical 
examination during implantation and the use of it may decrease the amount of 
bladder neck perforations. Furthermore, a flexible cystoscope causes less friction in the 
bladder neck than a rigid cystoscope and results in less chance of increased SUI just 
after placement of the balloons. Two separate titanium ports are placed in the scrotum 
and connected to each of the balloons, respectively, via a tube. All procedures were 
performed by the same surgeon (BB) with the patient in lithotomy position mostly 
under general anesthesia, otherwise under spinal anesthesia. Perioperative intravenous 
antibiotic prophylaxis consisting of cefazolin and metronidazole was given. In most 
cases patients were discharged from the hospital on the day of surgery after removal 
of the transurethral catheter and a successful voiding trial. If the bladder neck was 
perforated intraoperatively the balloon was still placed ipsilaterally of the perforation 
but as a rule more laterally than without a perforation. In these patients, the transurethral 
catheter was removed at day 5 or 7 and oral antibiotics were started at approximately 
the removal time. After the implantation, patients visited the outpatient clinic every 3-4 
weeks. Balloon volume was adjusted with maximal 1 mL per balloon per visit by needle 
puncture of the subcutaneous port sited in the scrotum. This was done by a specialized 
nurse or by the surgeon until continence was achieved.
2.3 Design
After obtaining approval by the local ethics committee (MEC-2017-05) all eligible 
patients were sent an information letter and a three-item questionnaire with a return 
envelope;
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1. The dichotomous question: “Would you recommend ProACT™ to someone else?” to 
be answered by yes or no.
2. The PGI-I scale: check the number that describes how your condition is now 
compared to before the ProACT™ implantation: 1. “very much better”, 2 “much 
better”, 3. “a little better”, 4. “no change”, 5. “a little worse”, 6. “much worse”, 7. “very 
much worse”.
3. The open-ended question: How many pads do you use daily?
Other relevant data were retrospectively retrieved from the individual patients’ medical 
charts. Preoperative evaluation included medical history, anamnestic pad count, 
voiding diary, American Society of Anesthesiologists (ASA) classes, and International 
Prostate Symptom Score (IPSS). The severity of urinary incontinence was classified by 
the anamnestic pad use per day and ranked as mild (1 or 2 pads), moderate (3 or 4 
pads) or severe (5 or more pads or use of condom catheter). Postoperative evaluation 
included anamnestic pad count, IPSS, and complications. Complications within 30 
days postoperative were graded using the Clavien-Dindo Classification of Surgical 
Complications.17 Failure of the intervention was defined as explantation with or without 
revision of the ProACT™ device, or as an additional surgical procedure needed because 
of persistent incontinence (eg, onabotulinumtoxin-A injected in the bladder wall, sacral 
neuromodulation, bulking agents, male sling, AUS).
Postoperative continence was assessed according to changes in pad counts. The 
outcome of the treatment was defined as “successful” when the patient was dry (no 
pad or a single “security pad” per day); as “improved” when ≥50% reduction in daily pad 
use against preoperative use was reported; and as “little/no improvement” when <50% 
reduction in daily pad use against preoperative use was obtained. The PGI-I question 
served to evaluate a patient’s perception of improvement on his condition. A lower 
score on the 7-point scale corresponds with a better condition than before ProACT™ 
implantation.
2.4 Statistical analysis
Statistical analyses were performed using SPSS version 21.0 (IBM Corp., Armonk, NY). 
A two-sided P-value <0.05 was considered statistically significant. Descriptive statistics 
are presented as percentages for qualitative variables and median and interquartile 
range (IQR) for quantitative variables. The Wilcoxon signed-rank test was used to 
compare preoperative and postoperative quantitative variables. A student-t-test was 
used to compare change in pad use and outcome on the PGI-I scale. Time to ProACT™ 
failure is distributed in a Kaplan-Meier curve. A binary multivariate logistic regression 
analysis was conducted using the backward method.  The parameters (age, BMI, pre-
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operative use of >5 pads per day, time between prostatectomy and implantation of 
ProACT™, and complications) with P < 0.05 on univariate analysis were considered in 
building the model to investigate the association between these variables and a non-
successful outcome.
3. RESULTS
A total of 143 out of 150 patients were included; the median follow up period was 
46.0 (IQR 21.0-76.0) months. Seven patients with a sling or AUS in situ were excluded. 
Patient characteristics are shown in Table 1. The median time between prostatectomy 
and ProACT™ implantation was 37.0 months (IQR 20.0 – 87.0 months). Twenty-one 
(14.7%) patients had undergone prior anti-incontinence surgery with bulking agents, 
AUS, urethral sling, urethrotomy, and/or ProACT™ in various hospitals. At the time the 
questionnaires were sent 11 patients were deceased. Overall, the median preoperative 
anamnestic pad use per day was 3.5 (IQR 2.0 – 5.0, n = 143). Urinary incontinence was 
classified as mild in 36 (25.2%), moderate in 57 (39.8%) and severe in 50 (35.0%) patients.
3.1 Continence outcome
After implantation and a median of four balloon volume adjustments daily pad 
usage had decreased significantly from a median of 3.5 (IQR 2.0-5.0) pads per day 
preoperatively to a median of 1.0 (IQR 0.0-2.0) pads per day at 6 months and 0.0 (IQR 
0.0-2.0) pads per day at 1 year (Table 2). Six months after implantation 72.9% (97/133) 
patients had ≥50% reduction in daily pad use against preoperative, including 47.4% 
(63/133) who had become dry (no pad or one security pad per day). After 1 year 50.6% 
(48/95) patients were dry (no pad or one security pad per day) of the 77.9% (74/95) 
patients whose daily pad use was reduced with ≥50%. The score on the IPSS quality 
of life item (IPSS-QOL) had improved significantly from 5.0 (IQR 4.0-5.0) preoperative 
to 2.0 (IQR 1.0-4.0) 6 months after implantation and 1.0 (IQR 0.0-3.0) 12 months after 
implantation (Table 2).
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TABLE 1. Patient characteristics of the study population presented as number (%) or median 
(interquartile range). a Unless stated otherwise.
Characteristics n = 143a
Age, years [IQR] 69.0 [66.0 – 73.0] 
Weight, kg [IQR] 83.0 [78.0 – 89.0] (n = 142)
BMI, kg/m2 [IQR] 26.1 [24.1 – 28.1] (n = 142)
Type of prostatectomy
- Retropubic radical prostatectomy
- Laparoscopic radical prostatectomy
- Robot-assisted radical prostatectomy
65 (45.5)
33 (23.0)
45 (31.5)
Previous urological surgery
- Urethrotomy
- Male sling
- AUS
- Bulking agents
- AUS and urethrotomy
- Male sling and ProACTTM in different clinic
9 (6.3)
2 (1.4)
5 (3.5)
3 (2.1)
1 (0.7)
1 (0.7)
Incontinence severity before
- mild: 1-2 pads/day
- moderate: 3-4 pads/day
- severe: 5 or more pads/day
36 (25.2)
57 (39.8)
50 (35.0)
ASA score
- I
- II
- III
27 (18.9)
95 (66.4)
21 (14.7)
Type of anesthesia
- Spinal
- General
18 (12.6)
125 (87.4)
Operating time, minutes [IQR] 69.0 [60.0 – 77.0] (n = 123)
Number of adjustments, n [IQR] 4.0 [2.0-6.0] (n = 139)
Volume left balloon, mL [IQR]
Volume right balloon, mL [IQR]
4.5 [2.5-7.0]
4.5 [2.5-7.0]
(n = 134)
Died
- reason unknown, after follow up
- malignancy
- multi organ failure
- Suicide
5
4
1
1
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3.2 Questionnaire
The questionnaires were sent to 132 patients with a response rate of 120 (90.9%). The 
median time between the implantation of ProACT™ and the questionnaire was 59.0 
(IQR 29.0 – 87.0) months. One hundred and six (88.3%) patients would recommend the 
ProACT™ to someone else, eight (6.7%) not and six (5.0%) did not answer this question. 
In eight (6.7%) patients who responded on the questionnaire, the ProACT™ has been 
removed; in three patients an AUS was implanted; in two patients a male sling was 
implanted; two patients accepted the incontinence; and one patient was on the waiting 
list for the ProACT™. One hundred and twelve (93.3%) patients had the ProACT™ in situ 
and 32 (28.6%) responders had one or more ProACT™ revisions. The daily pad use of the 
112 responders with ProACT™ in situ was significantly reduced from 3.0 (IQR 2.0-4.9) to 
1.0 (IQR 0.0-2.9) pads per day after a median follow up of 56.0 (IQR 27.5 – 79.0) months 
(P < 0.001, table 2). This corresponds with a 66.7% decrease in pad use. The median 
outcome on the PGI-I scale in the patients with the device in situ was 2.0 (IQR 1.0-2.0, n 
= 111). Ninety-seven (87.4%) patients reported improvement; 14 (12.6%) no difference 
or deterioration. The mean difference in pad use before and after the implantation 
was significantly different in those two groups (P = 0.03), namely in the group with 
improvement on the PGI-I scale mean decrease of 2.5 pad per day (mean pad use pre-
operative 3.7) and in the group with no difference or deterioration on the PGI-I scale 0.0 
pad per day (mean pad use pre-operative 5.3).
3.3 Intra-operative complications
Seventeen (11.9%) intraoperative perforations of the urethra occurred. In two cases, 
there was minimal perforation and patients received antibiotics and the transurethral 
catheter was removed the same day. The other 15 patients were treated with a 
transurethral catheter from 5 to 7 days.
3.4 Post-operative complications
In Table 3 the short-term (<30 days) post-operative complications and management are 
summarized. By the Clavien-Dindo classification, three (2.1%) complications were grade 
IIIb. Two (1.4%) patients had post-operative pain. A total of 129 (90.2%) patients had no 
complication. On the long term (>30 days), 78 (55.7%) patients had no complication. 
There were 79 (55.2%) patients without failure of the ProACT™. One or more revisions 
had been done in 43 (30.1%) patients, mostly because of an unilateral balloon defect 
(Table 4). Two patients received an AUS after one ProACT™ revision and one patient after 
two ProACT™ revisions. After balloon failure nine (6.3%) patients accepted the situation. 
An additional surgery was given to six (4.2%) patients (eg, onabotulinumtoxin-A injected 
in the bladder wall, sacral neuromodulation, bulking agents). Six (4.2%) patients with 
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failure of the ProACT™ received a different device after removing the balloons (four 
patients an AUS and two patients a male sling). The failure-free survival after ProACT™ 
implantation is shown in a Kaplan-Meier curve (Figure 1).
TABLE 3. Post-operative complications, <30 days, presented as number and graded using the 
Clavien-Dindo Classification.
n = 143 Cause Management
No complication 129
Grade I 8 7 acute urinary retention catheter for a week and prophylactic 
antibiotics around removing the catheter
1 intraoperative perforation 
and scrotal hematoma
catheter for a week and antibiotics
Grade II 3 2 scrotal hematoma and pain oral pain medication
1 infection antibiotics
Grade IIIb 3 1 urethral perforation 
and hematuria
removed under local anesthetics 
and new balloons were implanted 
2-4 months after removal1 infection and intraoperative 
perforation 
1 dislocation and pain
TABLE 4. Reasons of ProACTTM reinterventions, presented in numbers (%).
ProACT reinterventions First redo Second redo Third redo Fourth redo
Defect of the balloon(s) 22 (15.4) 8 (5.6) 1 (0.7)
Infection 5 (3.5) 1 (0.7) 1 (0.7) 1 (0.7)
Bladder neck perforation 2 (1.4) 2 (1.4) 1 (0.7)
Erosion 2 (1.4) 1 (0.7)
Persistent incontinence 8 (5.6)
Migration/dislocation 4 (2.8) 2 (1.4)
Total 43 (30.1) 13 (9.1) 3 (2.1) 2 (1.4)
After a median follow up of 56.0 months univariate logistic analysis showed, 
intraoperative perforation (OR 13.89, P = 0.012), short (OR 8.00, P = 0.001) and long 
term (OR 6.83, P < 0.001) complication, and the number of adjustments of the balloons 
(OR 1.47, P < 0.001) were significant parameters. Whereas age (P = 0.431), BMI (P = 
0.942), time between prostatectomy and implantation of ProACT™ (P = 0.889), and pre-
operative >5 reported pads per day (P = 0.183) were not significantly parameters and 
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were not considered in building the model. Multivariate logistic regression analysis 
showed short term complications (OR 8.41, P = 0.004) and the number of adjustments 
of the balloons (OR 1.46, P = 0.002) were both independently associated with a non-
successful outcome.
Months from first implantation to event or survival
120100806040200
Cu
m
 S
ur
vi
va
l
1,0
0,8
0,6
0,4
0,2
0,0
Survival Function
Censored
Survival Function
Page 1
FIGURE 1. Failure free survival after implantation of ProACT™ distributed in a Kaplan-Meier curve.
4. DISCUSSION
The aim of this study was to evaluate our results with the implantation of the ProACT™ 
device, with a focus on the patients’ perception of improvement after implantation. 
After a median follow up of 56 months, 112 patients with ProACT™ in situ reported a 
45% dry rate and a 64% improvement of continence rate. The dry rate in our study is 
within the range (4.5-66%) reported in studies with comparable follow up.10-12 Venturino 
et al12 defined dry  as “no pads” versus “no or one security pad” in our study and the 
studies of Kjaer et al10 and Rouprêt et al11. Further, the decrease in daily pad use (67%) 
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in our study is more beneficial than reported in other studies with comparable follow 
up, ranging from 34% to 65%.10-12 However, patient baseline characteristics were not 
comparable with those in other studies.10-12 Our study population were men with SUI 
after RP without a history of adjuvant radiotherapy and we did not include patients 
with SUI after a transurethral resection of the prostate. A recently performed systematic 
review comparing surgical devices for SUI after RP reported an average dry or one 
safety pad rates of 66%, 48% and 64% for AUS, male sling, and ProACT™, respectively.4 
Therefore, balloon compression devices like ProACT™ and AUS seem to have similar 
superior symptom related outcome compared to the male sling, but the AUS was 
associated with the highest complication rate.4
In our study population, revision of ProACT™ was done in 43 (30%) patients. This revision 
rate is within the range of the literature, ranging from 13% to 73%.1,10-12 A significant 
difference was found in the mean number of balloon adjustments between the failure 
and the failure-free group, 5.4 versus 3.0 adjustments, respectively. This implicates that 
more tension on the balloon wall results in a higher chance of balloon failure. Another 
hypothesis could be that patients will become more active with better continence, 
which gives potentially more traction on the scrotally placed tubes resulting in friction 
between the balloons and ramus inferior of the pubic bone.
Almost 90% of the patients were satisfied with this treatment, which can be concluded 
from the scores on the PGI-I scale and the recommendations to others. The median 
outcome on the PGI-I scale after a median follow up of 56 months was “much better” 
and 87% perceived improvement. Besides, the change in pad use after the implantation 
was significantly different between the group with improvement and the group with 
no difference or deterioration on the PGI-I scale. Experiencing improvement seems to 
be proportional to improvement on the change in pad use. The PGI-I may be a valuable 
tool to evaluate a man’s overall appraisal of his condition and his response to surgical 
treatment for SUI in clinical practice and studies. Since many patients are coming from 
regions outside the direct vicinity of our hospital, they informed themselves via relatives 
and/or internet on the possibility of the adjustable continence balloons and asked for 
referral to our hospital. Consequently, almost all patients choose to be implanted with 
these balloons initially and not with the alternative options. This could give some bias on 
the satisfaction. Another possible bias could be the time between the question and the 
operation. The patient could forget how the situation was precisely before the operation. 
The validity of the PGI-I in men with SUI has not yet been established. However, a good 
construct validity of the PGI-I has been established in women with SUI and in men with 
lower urinary tract symptoms secondary to benign prostatic condition.13,15
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In contrast to Utomo et al6 severe pre-operative urinary incontinence (>5 pads per day) 
and longer duration of PPI in the present study were not independently associated with 
non-successful treatment outcome. This discrepancy is possibly explained by our longer 
median follow up (56 vs 9 months) and larger number of patients (112 vs 49). Short term 
complication and the number of balloon adjustments were significantly associated 
with a non-successful outcome. The intraoperative perforations were included in the 
short term complications. The majority of the short term complications were due 
to an intraoperative perforation. A non-successful outcome after a intraoperative 
perforation might be the result of the more lateral position of the balloon at the site of 
the perforation and the necessity for more balloon adjustments to achieve continence. 
It might be concluded not to place the balloon at the site of perforation in the same 
surgical session but this necessitates an extra operation and results in financial damage 
due to loss of the balloon.
Limitations of our study are inherent to the retrospective design. Moreover, the 
individual learning curve of the surgeon involved might have affected the results. As 
described by Hübner and Schlarp8 the treatment outcome can be improved with the 
learning curve.
Strengths of our study are the large number of patients and the relatively long follow 
up period. In various cohort and feasibility studies the follow up period ranged from 
51 to 58 months and the number of patients from 22 to 128.10-12 The prospectively sent 
questionnaire provided patient-determined estimates of their outcome and changes in 
daily pad use, which can be considered a strength.
 The results suggest that ProACT™ is the minimal invasive first line surgical treatment 
for PPI (without stratification of severity of PPI) before opting for a more invasive 
treatment, such as male sling or AUS. The balloons can be adjusted in the outpatient 
clinic, in case of failure the device can be easily removed in the outpatient clinic and 
another treatment or revision can be considered. Further research is needed, however, 
to determine outcome predictors. A possible outcome predictor could be the anatomy 
of the bladder neck post-prostatectomy.
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5. CONCLUSION
Our results demonstrate improvement of the continence rate and satisfaction in the 
majority of patients with SUI after RP without a history of radiotherapy after implantation 
of adjustable continence balloons. The revision rate should be discussed preoperatively 
with patients. Future clinical evaluation is, however, necessary to determine outcome 
predictors.
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ABSTRACT
Aims: To evaluate the outcome of adjustable continence balloons in the treatment of 
stress urinary incontinence (SUI) after transurethral resection of the prostate (TURP).
Methods: In two tertiary centers, adjustable continence balloons were implanted in 29 
patients with post-TURP SUI between 2007 and 2018. Endpoints of this retrospective 
multicenter study were patient-reported changes in pad count and complications. Dry 
was defined as no pad or one security pad. 
Results: Preoperative urinary incontinence was mild in 7 (24%), moderate in 12 (41%), 
and severe in 10 (35%) patients. The median follow-up duration was 21 (interquartile 
range [IQR] IQR 11-43) months. Within 30 days postoperatively, a Clavien-Dindo grade 
≤II complication occurred in 24% of the patients. Reintervention rate was 24%. Six and 
12 months after implantation, the International Prostate Symptom Score (IPSS) quality-
of-life item improved significantly from 5 (IQR 5-6) preoperatively to 3 (IQR 1-4.5), and 
1 (IQR 0-3), respectively. At last visit (median 21 months after implantation), outcome 
on continence had improved in 76% of the patients, including 45% dry patients. After 
a median follow-up of 28 months (IQR 13-63, n = 23), all but one patient reported 
improvement on the Patient Global Impression of Improvement (PGI-I) scale. In detail, 
10 patients reported “very much better” condition compared to before the implantation, 
10 patients “much better”, two patients “a little better”, and one patient “no change”. 
Daily pad use decreased from three (IQR 2-5) to one (IQR 0-2) pads per day (P < 0.001). 
Conclusions: This is hitherto the first study reporting results of adjustable continence 
balloons in the treatment of post-TURP SUI. The therapy was found to be safe and 
efficient. The majority of our study population reported improvement on their condition 
and ≥50% reduction in daily pad use. 
91
Outcome of ProACT after TURP
5
1. INTRODUCTION
A transurethral resection of the prostate (TURP) is currently the standard surgical 
procedure in the treatment of a bladder outlet obstruction caused by benign prostate 
enlargement.1,2 A rare but unfortunate complication is post-TURP urinary incontinence.3 
Post-TURP urinary incontinence can be due to damage to the sphincter, pre-existing 
bladder dysfunction, or new onset bladder dysfunction.3 According to the International 
Consultation on Incontinence (ICI), the incidence of post-TURP stress urinary 
incontinence (SUI) is about 1%, irrespective of the TURP techniques used (ie, monopolar, 
bipolar, or laser).3 
Urinary incontinence after prostate surgery can significantly alter a person’s quality of 
life.4,5 In cases of male SUI secondary to sphincter deficiency, conservative treatment 
may be tried for periods up to 6 to 12 months in advance of a surgical treatment.3-5 
When conservative treatment fails, several surgical implants are available, such as 
artificial urinary sphincter, male sling, and adjustable continence balloons.3-5 The latter 
device consists of two periurethrally placed balloons (ProACTTM) whose volumes can be 
adjusted to achieve the optimal balance between voiding pressure and continence.6 
Reported long-term dry rates (no pad or one security pad) range from 45% to 66% 
with a follow up of 56 to 58 months.7-9 The majority or all patients included in these 
studies were treated for SUI after radical prostatectomy. Patients with post-TURP SUI are 
a different population in view of a different mechanism of injury. Usually, it is damage to 
the proximal part of the external striated urethral sphincter distal to the verumontanum.4 
The aim of this retrospective multicenter study was to evaluate the efficacy of adjusted 
continence balloons in patients with post-TURP SUI. Efficacy and safety were evaluated 
in terms of achieving continence, changes in pads use, complications, re-interventions 
and patient-reported estimates of improvement assessed with the Patient Global 
Impression of Improvement (PGI-I) scale. 
2. PATIENTS AND METHODS
We retrospectively evaluated data prospectively collected from all patients who had the 
ProACTTM (Uromedica, Inc., MN) device implanted as surgical treatment of post-TURP SUI 
after May 2007 in two tertiary centers: Erasmus University Medical Center in Rotterdam, 
the Netherlands and Policlinico Tor Vergata in Rome, Italy. Conservative treatment with 
pelvic floor exercises had failed in all patients. Urethrocystoscopy and urodynamic study 
were performed to rule out urethral strictures and to evaluate the bladder function. 
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Exclusion criteria were a history of radiotherapy, neurogenic bladder dysfunction, and 
a male sling or an artificial urinary sphincter (AUS) in situ. The local ethics committee 
of Erasmus University Medical Center in Rotterdam approved this study (MEC-2017-
05, MEC-2018-1287). The Comitato Etico Policlinico Tor Vergata in Rome gave a general 
permission to anonymously collect data for scientific purposes. 
Preoperative assessment included medical history, anamnestic daily pad count, voiding 
diary, and International Prostate Symptom Score (IPSS). The preoperative severity of 
urinary incontinence was determined by the anamnestic daily pad count, classified 
as mild (1-2 pads), moderate (3-4 pads), or severe (≥5 pads). In each institution, one 
experienced surgeon had implanted the adjustable continence balloons using the 
technique described by Hübner and Schlarp6. In brief, two ProACT™ balloons were 
implanted via two incisions in the perineum, at either side of the bladder neck. Most of 
the patients were under general anesthesia and some under spinal anesthesia during 
the procedure. Intravenous cefazolin and metronidazole were given perioperatively 
as antibiotic prophylaxis. After removal of the transurethral catheter and a successful 
voiding trial, patients were discharged from hospital on the day of surgery or the day 
after. Within a period of six months after the implantation, the balloon volume was 
adjusted at the outpatient clinic by needle puncture of the subcutaneous port in the 
scrotum. Postoperative assessment included anamnestic daily pad count, IPSS, and 
complications. 
All patients in Rotterdam received an information letter, a three-item questionnaire 
and a return envelope by post. In Rome, those three questions were asked during last 
scheduled outpatient visit. The three questions asked were: 
1. “Would you recommend adjustable continence balloons to someone else?” to be 
answered by yes or no.
2. Which number describes how your condition is now compared to before the 
adjustable continence balloons: 1. “very much better”, 2. “much better”, 3. “a little 
better”, 4. “no change”, 5. “a little worse”, 6. “much worse”, 7. “very much worse” (PGI-I 
scale).
3. How many pads do you use daily? 
Other relevant patient characteristics were retrospectively retrieved from the medical 
charts. Treatment outcome on continence was assessed by the change in preoperative 
and postoperative anamnestic daily pad use. The definition of “dry” was no pad or a 
single security pad per day. “Improvement” was defined as a daily pad reduction of 
≥50% compared to the preoperative situation. “Little/no improvement” was defined as 
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no or less than 50% reduction of daily pad use compared to preoperative. Perception 
of improvement on condition was assessed with the PGI-I (7-points) scale; a lower score 
corresponds with a better condition. Complications within 30 days were classified by the 
Clavien-Dindo Classification of Surgical Complications.10 Failure of the interventions was 
defined as explantation with or without revision of adjustable continence balloons, or as 
an additional surgical procedure because of persistent incontinence, or as acceptance 
of the situation with persistent incontinence.
Statistical analyses were performed using SPSS version 24.0 (IBM Corp., Armonk, NY). 
Descriptive statistics are presented as percentages for qualitative variables and median 
and interquartile range (IQR) for quantitative variables. The Wilcoxon signed-rank test 
was used to compare preoperative and postoperative quantitative variables. Pearson’s 
chi-squared test was used to compare categories. Time to adjustable continence 
balloons failure is distributed in a Kaplan-Meier curve. A two-sided P-value < 0.05 was 
considered statistically significant.
3. RESULTS
Twenty-nine out of 31 eligible patients were included; 26 patients in Rotterdam and 
five in Rome. Reason for exclusion in two patients was a non-functional male sling in 
situ, both patients were included in Rotterdam. Urinary incontinence was classified as 
mild in 7 (24.1%), moderate in 12 (41.4%), and severe in 10 (34.5%) patients. Median 
preoperative anamnestic pad use per day was 3.5 (IQR 2.3-5.3). The median time between 
TURP and balloon implantation was 2.2 (IQR 1.3-3.6) years. TURP had been performed 
because of lower urinary tract symptoms secondary to benign prostate enlargement. 
Two patients had prior anti-incontinence surgery with bulking agents. Preoperative 
assessment of the external urethral sphincter with urethrocystoscopy showed normal 
findings in 15 (51.7%) patients; three out of 15 patients had severe incontinence. The 
sphincter remained open in 14 (48.3%) patients; severe incontinence was seen in 
seven out of 14 patients. More severe incontinence was seen in patients with abnormal 
urethrocystoscopy findings (50.0% versus 20.0%, P = 0.09). Patient characteristics are 
shown in Table 1.
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TABLE 1. Patient and clinical characteristics presented as number (%) or median (interquartile 
range). 
Characteristics n = 29a
Age, years 70.5 (66.7-77.7)
Weight, kg 82.0 (75.5-94.0)
BMI, kg/m2 27.5 (24.8-30.0)
Type of TURP
- Monopolar or bipolar
- Laser
24 (82.8)
5 (17.2)
ASA score
- I
- II
- III
3 (10.3)
18 (62.1)
8 (27.6)
Type of anesthesia
- General
- Spinal
20 (69.0)
9 (31.0)
Operating time, minutes 33.0 (26.8-38.5) n = 28
Number of adjustments 5.0 (2.0-5.5)
Volume left balloon, mL 
Volume right balloon, mL 
5.0 (2.0-6.5)
5.0 (2.0-6.5)
Complications within 30 days
- No complication
- Clavien-Dindo grade I
- Clavien-Dindo grade II
22 (75.9%)
6 (20.7%)
1 (3.4%)
aUnless stated otherwise
3.1 Continence outcome
The median number of balloon volume adjustments after implantation was five (Table 
1). Six months after implantation, the median pad use per day was 1.0 (IQR 1.0-1.9); after 
1 year it was 1.0 (IQR 0.0-2.5). The IPSS quality of life score had improved significantly 
from preoperative 5.0 (IQR 5.0-6.0) to 3.0 (IQR 1.0-4.5) 6 months after implantation and 
to 1.0 (IQR 0.0-3.0) 1 year after implantation. The median time between implantation 
and last outpatient visit was 20.9 (IQR 10.5-43.4) months. The daily pad use reported 
at the last visit was 1.0 (IQR 0.0-2.0). At the last visit, 75.8% (22 of 29) of the patients 
reported ≥50% reduction in daily pad use against the preoperative, including 44.8% (13 
of 29) who had become dry. The seven patients with preoperative mild incontinence 
were all dry at last visit. In the 12 patients with preoperative moderate incontinence the 
outcome at last visit was: dry in four, improved in three, and little or no improvement 
in five patients. Two out of ten patients with preoperative severe incontinence were 
dry, six patients were improved and two patients had little or no improvement. In the 
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whole study population, one patient needed a single re-adjustment of the balloons (0.5 
mL) more than 5 years after the last adjustment. The other patients had no additional 
adjustments. Table 2 provides details on daily pad use, postoperative outcome on 
continence, and IPSS. 
3.2 Questionnaire
After a median follow up of 28.1 (IQR 12.8-62.9) months, 23 patients had completed 
the three-item questionnaire (response rate 79.0%). Two patients did not respond and 
four patients (minimal 4 months after the end of follow-up) had died at the time the 
questionnaire was sent. The reason of death was not related to the surgical procedure. 
Results are presented in Table 3. All patients would recommend adjustable continence 
balloons to someone else. Daily pad use improved significantly from 3.0 (IQR 2.0-5.0) to 
1.0 (IQR 0.0-2.0) pads per day (P < 0.001). Outcome on continence had improved in 15 
(65.2%) of the patients, including six (26.1%) dry patients. Twenty-two (95.7%) patients 
reported improvement on the PGI-I scale. In detail, the condition now compared with 
the condition before the adjustable continence balloons was reported “very much 
better” in 10 (43.5%) patients, “much better” in 10 (43.5%) patients, “a little better” in two 
(8.7%) patients, and “no change” in one (4.3%) patient.
3.3 Complications
In one patient an intraoperative complication occurred, that is, a perforation of the 
urethra during positioning of the right balloon. The balloon was still placed just lateral 
to the perforation. In contrast to the other patients, this patient was discharged from 
hospital with a transurethral catheter. Five days postoperatively, prophylactic antibiotics 
were started and the transurethral catheter was removed. At 6 months and 12 months 
postoperative, his pad use was improved from 6 pads per day preoperative to 2.5 and 
1.5 pads per day, respectively.  
Twenty-two (75.9%) patients were complication-free within 30 days postoperatively. 
The remaining seven patients had an acute urinary retention. The balloon volume 
was reduced in one patient, which resulted in a successful voiding trial. In the other 
six patients, the transurethral catheter was replaced and removed at day 5 or 7 with 
oral antibiotics started at approximately the removal time. In one of these patients, 
epididymitis was treated with oral antibiotics 3 days after removal of the transurethral 
catheter.   
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TABLE 3. The outcome on three-item questionnaire, presented as number (%) or median 
(interquartile range).  
Results of prospective follow-up
Postoperative follow-up in months 28.1 (12.8 -62.9)
Recommend balloons to someone else? 
Yes
No
23 (100)
-
PGI-I scale
1. very much better
2. much better
3. a little better
4. no change
5. a little worse
6. much worse
7. very much worse
10 (43.5)
10 (43.5)
2 (8.7)
1 (4.3)
-
- 
-
Daily pad use
Preoperative
Postoperative 
3.0 (2.0-5.0)
1.0 (0.0-2.0)
Postoperative outcome on continence
Dry
50-99% reduction in daily pad use
Little or no improvement
6 (26.1)
9 (39.1)
8 (34.8)
Failure of the intervention was seen in nine (31.0%) patients after a median follow-up of 
18.1 (IQR 8.4-21.6) months. The failure-free survival curve is presented in Figure 1. Four 
patients had unchanged urinary incontinence of whom two accepted the situation. The 
other two patients had additional surgery with bulking agents. At last visit, outcome 
on continence was improved in both patients. One or more replacements were 
performed in five patients; in two on account of malposition of the balloon and in three 
on account of a defective of the balloon. A second replacement was necessary in two 
patients because of erosion of one of the balloons through the urethra. The outcome 
on continence at last visit was in three patients little or no improvement, and in two 
patients improvement, including one dry patient. Preoperative severe incontinence was 
seen in six (66.7%) of the nine patients in whom the intervention had failed versus four 
(20.0%) of the 20 patients in whom the intervention was successful (P = 0.014).
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FIGURE 1. Failure free survival after implantation of balloons distributed in a Kaplan-Meier curve.
4. DISCUSSION
The aim of this study was to evaluate the efficacy of adjustable continence balloons 
in the treatment of post-TURP SUI. After a median follow-up of 21 months, two-thirds 
(22 of 29) of the patients reported to use fewer pads daily, and 13 of the 29 patients 
were even dry. All but one patient reported improvement on the PGI-I scale. Within 30 
days postoperatively, a Clavien-Dindo grade ≤II complication had occurred in 24% of 
the patients. 
Male postsurgical SUI can be caused by direct surgical injury to the external urethral 
sphincter or its innervation, though this may coexist with bladder dysfunction.4,5 
Post-TURP SUI is most likely the result of damage to the proximal part of the external 
urethral sphincter distal to the verumontanum.4 Several additional mechanisms of 
sphincteric injury after radical prostatectomy have been suggested, like: ischemia and 
immobilization by scar, atrophy due to incomplete recovery, direct pudendal nerve 
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injury or shortening of urethra below critical functional length.11 Regarding the different 
etiologies of male SUI, presumably this can have influence on the outcome of a surgical 
treatment. 
A recent systematic review addressed functional outcome and complications in the 
treatment of male postsurgical SUI with adjustable continence balloons.12 Eleven studies 
were included, of which six studies included as well patients with post-TURP SUI in the 
study population. In one of the excluded studies (because of a patient population of < 
20) post-TURP SUI patients were included as well. An overview of those seven studies 
with post-TURP SUI patients is given in Table 4 6-8,13-16. Nevertheless, none of these 
studies differentiated outcome after radical prostatectomy and post-TURP. Reported dry 
rates varied between 4.5% and 67% and reintervention rates varied between 14% and 
46% (Table 4). The dry rate (45%) at last outpatient visit, and reintervention rate (24%) 
found in the present study fall within the respective ranges. Additionally, the previously 
published results of adjustable continence balloons in patients with SUI postradical 
prostatectomy implanted by one of the surgeons of this study9 were added to Table 4 
to compare with the present study. Overall, results in literature are slightly similar, but 
important to note, besides the etiology, the size, and duration of follow-up of study 
populations differ. In short, studies are hard to compare because the etiology of SUI, 
history of adjuvant radiotherapy, duration of follow-up, different centers and surgeons, 
and definitions of outcome used in the literature are heterogeneous. Our study is 
hitherto the first reporting results of adjustable continence balloons in in the treatment 
of post-TURP SUI. 
The median postoperative daily pad use remains stable during follow-up (see Table 2 
and Table 3). Remarkably, we observed a decline of dry rate at the time the PGI-I scale 
was answered. The efficacy of the balloons could have been reduced. Another possible 
explanation for this decline in dry rate could be that continent patients will become 
much more active in time compared than they were preoperatively which can result in 
more “stress” and a decline in dryness. Furthermore, not all patients responded or could 
response and, therefore, the decline could also partly be explained by selection bias. 
Despite the decline of dry rate, the majority experienced improvement on PGI-I. 
If conservative treatment fails, the standard in surgical management of male SUI is 
AUS.4,17,18 However, alternatives to AUS, such as male sling and adjustable continence 
devices, are available. These devices do not require manual manipulation to void. 
Implantation of adjustable continence balloons is less invasive and has the advantages of 
adjusting the volume or removing the balloons in the outpatient setting. Besides, opting 
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for more invasive procedures is still possible after removal. The working mechanism of 
adjustable continence balloons with a successful outcome is contributed by an increase 
in urethral resistance and increased maximum urethral closure pressure.19,20 
The ICI reviewed the literature with results of AUS in the treatment of male SUI. Most 
of the studies included men with post-prostatectomy incontinence related to benign 
and malignant disease. Success rates range from 59% to 90%, defined by no or 1 pad 
per day, with a follow-up ranging from 1 to 7.7 years.3,21 To our knowledge, studies with 
results of AUS in exclusively post-TURP SUI patients are missing.   
Regarding the male sling in the treatment of post-TURP SUI, a few studies are published. 
Recently a systematic review was published which identified 23 post-TURP patients 
described in six studies who had undergone a male sling. A successful outcome was 
described in 78% of the patients with divergent definitions of success (total continence, 
<2 gram loss of urine, ≥50% pad reduction, subjective improvement in continence).22 
Another study (not included in the above review), reported results of 15 post-TURP 
patients treated with a male sling with a median follow-up of 70 months.23 Outcome 
on continence after implantation of the male sling was improved with a ≥50% pad 
reduction in 60% of the patients, including 47% dry patients.23 
It would be interesting to perform trials, preferably randomized, comparing adjustable 
continence balloons in the treatment of male SUI with other devices, such as male sling or 
AUS. To prevent mixed patient populations, future studies should differentiate between 
patients who have post-radical prostatectomy SUI and those who have post-TURP SUI. 
Besides, future research to define outcome predictors of adjustable continence balloons 
could be helpful in clinical practice.
Strengths of our study are the multicenter design and the specific study population. 
The etiology of the SUI was in all patients post-TURP SUI. These patients are a different 
population with a different mechanism of injury compared to patients with postradical 
prostatectomy SUI. Both tertiary centers have around one decade of experience in this 
type of surgery (10-15 procedures/year in Rome and 25 procedures/year in Rotterdam). 
Still, the study population was relatively small which hindered defining outcome 
predictors. Another limitation is inherent to the retrospective design of our study. For 
example, due to the retrospective design, we used the IPSS in the evaluation of the 
adjustable continence balloons. The IPSS is widely used in our clinical practice and this 
data was available. This measure focuses on lower urinary tract symptoms, the IPSS total 
score and IPSS quality of life item improved significantly after implantation. For this 
patient population a condition-specific questionnaire would be more interesting, such 
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as the Urogenital Distress Inventory (UDI-6)24, or the Incontinence Impact Questionnaire 
(IIQ-7)24, or the International Consultation on Incontinence Questionnaire (ICIQ)25. 
However, the use of these questionnaires is not widely spread and the minimal critical 
values have not been established.
5. CONCLUSION
Currently little is known about the efficacy of adjustable continence balloons in the 
treatment of post-TURP SUI. Adjustable continence balloons seem to be safe and 
efficient in the treatment of post-TURP SUI. The majority of our study population 
experienced improvement on their condition and needed fewer pads than before the 
implantation of adjustable continence balloons. Future research is needed to compare 
different devices and determine outcome predictors. 
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ABSTRACT
Aims: The Multiple Sclerosis Intimacy and Sexuality Questionnaire (MSISQ-15) evaluates 
symptoms of sexual dysfunction in patients with multiple sclerosis (MS). The objective 
of this study was to provide and validate a Dutch version of the MSISQ-15 in patients 
with neurological disease such as MS and spinal cord injury (SCI).
Methods: The linguistic validation process of the original English MSISQ-15 into Dutch 
was performed according to standardized guidelines. Sexually active patients with 
MS or spinal cord disorders, including SCI and cauda equine syndrome, who visited 
a tertiary urology center or a rehabilitation center completed the MSISQ-15, Pelvic 
Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12) in women, or 
International Index of Erectile Function (IIEF-15) in men at baseline (test) and 2 weeks 
later (retest). A reference group recruited from a general medical practice completed 
the questionnaires once. Data were analyzed for measurement properties. 
Results: Fifty-three patients with MS, 49 patients with spinal cord disorder, and 
50 references were included. Content validity was adequate. Internal consistency 
(Cronbach’s alpha >0.8) and reproducibility (intraclass correlation coefficient >0.8) of 
the MSISQ-15 were excellent. Patients’ MSISQ-15 scores were correlated with severity of 
symptoms of sexual dysfunction measured by PISQ-12 or IIEF-15 and confirmed positive 
rating for criterion validity. MSISQ-15 scores in patients were higher than in references 
(on a scale of 15-75: 38.9 ± 11.4 vs. 21.1 ± 5.4; P <0.001), indicating good construct 
validity. 
Conclusions: The Dutch MSISQ-15 is a reliable and valid measure to evaluate symptoms 
of sexual dysfunction in patients with MS or with SCI. 
111
Validation of the Dutch MSISQ-15
6
1. INTRODUCTION
Living with neurological diseases such as multiple sclerosis (MS) or spinal cord injury 
(SCI) might have significant consequences for a person’s sexual function and quality of 
life.1,2 Sexual function can be assessed with patient-reported outcome (PRO) measures, 
usually a questionnaire. This also allows evaluating change over time.3 
The Multiple Sclerosis Intimacy and Sexuality Questionnaire (MSISQ) evaluates 
symptoms of sexual dysfunction (SD) in MS patients, divided in three dimensions. 
Categorized as primary SD are symptoms as a result of neurologic changes that directly 
influence sexual function, such as impaired genital sensation, erectile dysfunction, 
orgasm dysfunction, decreased vagi nal lubrication, and loss or reduction of libido. 
Secondary SD includes symptoms that arise from MS and indirectly influence sexual 
function, such as muscle tightness, spas ticity, bladder and bowel dysfunction, pain, 
or discomfort in non-genital areas of the body. Tertiary SD refers to the psychological, 
emotional, social, and cultural aspects of MS that impact sexual function.4,5 The original 
version of the MSISQ was in English and consisted of 19 items and has been translated 
and validated in the Persian6 and Portuguese languages7. A re-evaluation in a larger 
English cohort resulted in a validated 15 item version.5 
At this moment, no validated Dutch PRO measure is available to assess SD in patients 
with a neurological disease. Although the MSISQ-15 was developed for patients with 
MS, the similarity between the SD symptoms of patients with MS and those with SCI, 
as well as the similarity in treatment, suggests that the instrument might work well in 
both populations. This study is designed to provide a validated Dutch version of the 
MSISQ-15 in patients with neurological diseases. 
2. MATERIALS AND METHODS
This prospective validation study was approved by the Institutional Ethics Committee 
(MEC-2016-370) and conducted at a tertiary urology center and at a rehabilitation 
center. 
2.1. Study populations and study design
2.1.1 Patient group
Adults with MS or SCI or cauda equina syndrome were eligible for inclusion if they spoke 
Dutch fluently. Exclusion criteria consisted of dementia, mental retardation, active 
malignant tumors, and no sexual activity during the last 6 months. 
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All potential eligible patients were informed about the study and invited to participate 
by the treating physician during a regular outpatient visit between July 2016 and 
January 2018. After written informed consent patients were asked to complete the 
questionnaires during the inclusion visit (test) and two weeks later at home (retest). 
Clinical characteristics of included patients were retrieved from their medical files. 
2.1.2 Reference group
The reference group was invited from one general practitioner’s practice in January 
and February 2017. Exclusion criteria consisted of Dutch language difficulties, neuro-
urological dysfunction, dementia, mental retardation, and no sexual activity during the 
last 6 months. Since patients visiting the general practitioner might have less severe 
health issues, we considered these patients as proper reference group. They provided 
written informed consent and completed the questionnaires once. 
2.2. Questionnaires
The questionnaire set consisted of the MSISQ-15, the EQ visual-analogue scale (EQ-
VAS), Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12), and 
International Index of Erectile Function (IIEF-15). 
• The MSISQ-15 is a self-report measure that evaluates the influence of MS symptoms 
on sexual activity and satisfaction over the preceding 6 months. It is a valid and 
reliable short version of the MSISQ-19 and consists of 15 items. The MSISQ-15 is 
divided in three dimensions to allow focus on the specific domain of sexual concerns; 
primary SD (items 8, 12, 13, 14, 15) secondary SD (items 1, 2, 3, 4, 5) and tertiary SD 
(items 6, 7, 9, 10, 11).  Each item is rated on a five-point Liker scale ranging from 0 
(never) to 5 (always). The total score is the sum of the fifteen items. The maximum 
total score is 75; the higher the score the greater the impact of SD on patients’ lives.5
• The PISQ-12 evaluates sexual function in heterosexual women who suffer from 
urinary incontinence and/or pelvic organ prolapse; it was not specifically designed 
for neuro-urological patients. It is a valid and reliable short-form of the PISQ-31, 
including 12 items.8 The PISQ-12 is recently translated into Dutch and showed good 
reliability and validity.9 Alteration of item 12 during the Dutch PISQ-12 validation 
study resulted in suboptimal answer options. Without item 12 the Dutch version 
was still found to be valid and reliable. We used the Dutch PISQ-12 without item 
12. Responses are graded on a five-point Likert scale, ranging from 0 (always) to 
4 (never). Items 1-4 are reversely scored. The maximum score is 44; higher scores 
indicate better sexual function.9
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• The IIEF-15 is a 15-item self-administered questionnaire for the assessment of male 
sexual function, not specifically for neuro-urological patients. The IIEF-15 addresses 
five relevant domains of male sexual function: erectile function, orgasmic function, 
sexual desire, intercourse satisfaction and overall satisfaction. Linguistic validation 
of the Dutch IIEF-15 was conducted by the MAPI research Institute in Lyon, France. 
Responses are graded on a scale for 0 to 5. The maximum score is 75; higher scores 
indicate better sexual function.10  
• The EQ-VAS is part of the European Quality of Life-5 Dimensions questionnaire.  The 
patient can indicate the health state on the EQ-VAS, from 0 “the worst health you 
can imagine” to 100 “the best health you can imagine”. 
2.3. Linguistic validation
The linguistic validation process of the original MSISQ-15 into the Dutch language 
was performed according to standardized guidelines.11 Three professional translators 
with Dutch as native language separately forward-translated the English MSISQ-15. 
Differences were discussed with the translators, two urologists (BB and JS), and the 
primary investigator (TN). Some minor textual changes were made without changing 
the content, resulting in the final version (see supplementary material), which was then 
backward-translated by a professional translator with English as native language. The 
content validity of the Dutch version was evaluated in face-to-face interviews with 20 
patients.12 Patients were asked to complete the questionnaire. Afterwards, the content 
and wording of the questions were discussed.
2.4. Measurement properties 
The following measurement properties were used to validate the questionnaire:
2.4.1. Content validity 
The content validity examines the extent to which the items of the questionnaire measure 
the concepts of interest in the target population. Researchers subjectively assessed the 
correspondence between the questionnaire items and the clinical symptoms. During 
the linguistic validation, content validity was assessed from interviews with patients.12 
2.4.2. Internal consistency 
The internal consistency is the correlation between the different items in the 
questionnaire and demonstrates if the items measure the same underlying construct. A 
Cronbach’s alpha was calculated for the total score and three domains of the MSISQ-15. 
A Cronbach’s alpha between 0.70 and 0.95 was considered to reflect adequate internal 
consistency.12
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2.4.3. Reproducibility
The reproducibility is the degree to which scores on a questionnaire are corresponding 
in repeated measurements in stable persons. This was determined by reliability and 
agreement. The degree to which patients can be differentiated from each other, despite 
the measurement error, reflects the reliability. The reliability was calculated using the 
intraclass correlation coefficient (ICC) for agreement, where ICC scores over 0.70 are 
acceptable.12,13 The agreement concerns the measurement error, that is, the similarity in 
scores rated on separate occasions. Differences within the limits of agreement (LOA) can 
be interpreted as measurement error. The LOA were calculated as the mean change in 
scores of repeated measurements ±1.96 x standard deviation of the changes.13,14 
2.4.4. Criterion validity 
The extent to which questionnaire scores relate to a gold standard refers to the criterion 
validity.12 For the MSISQ-15 no perfect gold standard exists. In the absence of a gold 
standard the Dutch PISQ-12 and the Dutch IIEF-15 were used for women and men, 
respectively. Pearson’s correlation coefficient was determined (range -1 to 1); when 
values are close to the extremes indicate either a more negative or positive correlation.12 
2.4.5. Construct validity
The construct validity refers to the extent to which hypotheses about the scores of the 
questionnaire relate to other measures. Construct validity is considered adequate when 
at least 75% of the results of the predefined hypotheses are in accordance.12  
The predefined hypotheses were:
1. The reference group will have lower MSISQ-15 scores than the patient group. 
2. Female patients with lower PISQ-12 scores will have higher MSISQ-15 scores. 
3. Male patients with lower IIEF-15 scores will have higher MSISQ-15 scores.
4. Patients who score higher on the EQ-VAS will have lower MSISQ-15 scores.
2.4.6. Floor and ceiling effects
If more than 15% of the respondents would achieve the lowest or highest possible score, 
floor or ceiling effects are considered.12 The floor and ceiling effects were assessed for 
the total and domain scores at baseline in the patient and reference groups. 
2.5. Statistical methods
Based on the guidelines for validation of questionnaires12, we aimed at a sample size 
of 50 MS patients, 50 SCI patients, and 50 control persons. Statistical analysis was 
performed using SPSS version 24.0 (IBM Corp., Armonk, NY). Continuous data are 
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presented as mean and standard deviation. Categorical data are presented as counts 
and percentages. Differences between the patient and reference groups or within the 
patient group, were tested with the Student’s t-tests for continuous variables and chi-
squared tests for categorical variables. Statistical significance was defined as P-value 
<0.05. 
3. RESULTS
A total of 106 patients were included in the study. Three patients were excluded from 
the analysis because they did not return the second questionnaire. One patient did not 
fully complete the questionnaires and was excluded. Of the 102 included patients who 
completed both questionnaires, 49 were female and 53 male. Fifty-three patients had 
MS, of whom 36 (68%) relapsing-remitting MS, 6 (11%) primary progressive MS, 8 (15%) 
secondary progressive MS, and of 3 (6%) the type of MS was unknown. Forty-three 
patients had an SCI and six a cauda equina syndrome. The SCI patients were classified 
by the American Spinal Injury Association (ASIA) impairment scale15 as follows: 21 (49%) 
patients ASIA A, 7 (16%) patients as ASIA B, 4 (9%) patients as ASIA C, 8 (19%) patients 
ASIA D, 1 (2%) patient ASIA E, and in 2 (5%) patients the grade was unknown. The level 
of SCI was cervical in 13 (30%), thoracic in 26 (61%), and lumbar in 4 (9%). The reference 
group consisted of 50 adults, of whom 29 were female and 21 male. Table 1 shows the 
characteristics of the patient and reference groups. 
3.1. Content validity
During the linguistic validation process 12 MS and 8 SCI patients judged the content 
validity to be adequate. The majority confirmed the importance of all questions to 
assess the broad range of problems in sexual function with their neurological condition. 
Further, they found the Dutch version clear, understandable, and easy to complete. No 
adjustments were necessary.
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3.2. Internal consistency
The MSISQ-15 showed a good internal consistency with Cronbach’s alpha’s of >0.8 for 
test and retest in MS patients, SCI patients, and total patient group (Table 2). The internal 
consistencies for the domains were adequate with Cronbach’s alpha’s of >0.7 in the 
total patient group and MS patients. In the SCI patients, the primary domain showed 
a moderate internal consistency with a Cronbach’s alpha of 0.53 (test) and 0.55 (retest). 
The internal consistency for the secondary and tertiary domains was good.  
TABLE 2. Cronbach’s alpha reflects the internal consistency for the MSISQ-15 total and subscale 
scores.
MS
n = 53
SCI
n = 49
Total patient group 
n = 102
Test Re-test Test Re-test Test Re-test
MSISQ-15 total score 0.90 0.91 0.82 0.84 0.87 0.88
MSISQ-15 domains
Primary 0.79 0.78 0.53 0.55 0.70 0.69
Secondary 0.76 0.82 0.79 0.80 0.77 0.81
Tertiary 0.89 0.93 0.89 0.93 0.89 0.93
3.3. Reproducibility
The average test-retest period was 20.3 ± 13.8 days, 30.2 ± 25.7 days, 25.1 ± 20.9 days for 
MS patients, SCI patients, and total patient group, respectively. The ICCs for agreement 
for the total MSISQ-15 and the three domains in MS patients, SCI patients, and total 
patient group were all higher than 0.7, indicating an adequate reliability (Table 3). Table 
3 lists the LOA ranges of the total MSISQ-15 and the domains. 
3.4. Criterion validity
A significant relationship was found between the total score of MSISQ-15 and the total 
score of PISQ-12 in females of the patient group (test: r=-0.682; retest: r=-0.649, Table 
4). In the male study population, the patient group showed a significant relationship 
between the total score of MSISQ-15 and the total score of IIEF-15 (test: r=-0.446; retest: 
r=-0.405, Table 4).
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3.5. Construct validity
All predefined hypotheses were confirmed:
1. The reference group did indeed have lower MSISQ-15 scores than the patient group 
(Table 1).
2. and 3. Female patients with lower PISQ-12 scores and male patients with lower IIEF-15 
indeed had higher MSISQ-15 scores (criterion validity).  
4. In the patient group a significant correlation was found between the MSISQ-15 score 
and the EQ-VAS (Table 4). This confirmed the hypothesis: “patients who score higher on 
the EQ-VAS will have lower MSISQ-15 scores”.
3.6. Floor and ceiling effects
In the patient group, no floor effects were seen for the total score, primary domain, and 
secondary domain (Table 5). Floor effects were seen in the tertiary domain (19% of the 
patients). Ceiling effects were absent in the patient group. 
In the reference group, floor effects were found in all the domains (24-46%). Six (12%) 
reference persons had the lowest possible total score. No ceiling effects were found in 
the reference group. 
TABLE 5. Floor and ceiling effects at baseline for the patient and reference groups
Patients n = 102 References n = 50
Floor Ceiling Floor Ceiling
MSISQ-15 total score 1 (1%) 0 (0%) 6 (12%) 0 (0%)
MSISQ-15 domains
Primary 3 (3%) 0 (0%) 12 (24%) 0 (0%)
Secondary 10 (10%) 0 (0%) 23 (46%) 0 (0%)
Tertiary 19 (19%) 3 (3%) 21 (42%) 0 (0%)
4. DISCUSSION
After linguistic validation of the original English MSISQ-15 into the Dutch language, 
we validated its use for patients with MS and spinal cord disorders such as SCI and 
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cauda equina syndrome. The measurement properties showed this Dutch version of 
the MSISQ-15 to be valid, reliable, and consistent. This enables physicians to assess the 
influence of symptoms of neurological disease on sexual activity and satisfaction in 
patients in clinical practice and in research settings.
The quality of PRO measures for sexual function in neurological patients was assessed 
in a recently published systematic review.3 Strong evidence was found only for the 
MSISQ-15/-19 for patients with MS. PRO measures for patients with SCI showed mostly 
poor to fair quality and re-evaluation of all measurement properties was advised.3 In 
view of this we chose to validate the Dutch MSISQ-15 not only in patients with MS, 
but also in patients with SCI and cauda equina syndrome. In all these three conditions, 
interruption of the spinal cord or the pelvic autonomic nerves interferes with genital 
engorgement, erections, ejaculation, and climax.1,16 Besides the similarity between the 
influence of symptoms on sexual function, the similarity in treatment suggests that the 
instrument might work well in those populations. 
The good internal consistency of the Dutch MSISQ-15 with Cronbach’s alpha’s ranging 
from 0.82 to 0.91 for (re)test and patient (sub)groups (Table 2) is comparable with that 
of the original MSISQ-15 (total Cronbach’s α = 0.92, primary domain α = 0.87, secondary 
domain α = 0.82, tertiary domain α = 0.91).5 The Cronbach’s alpha’s of all subdomains 
were adequate, except for the primary domain in the spinal cord disorder group (0.53-
0.55). The original design of the primary domain focuses on “MS-related-neurologic 
changes” that may directly affect sexual feeling or response. In the spinal cord disorder 
group a moderate correlation of the items in the primary domain was found. This 
could have been caused by the specific well-known problems in SCI patients such as 
dissociation between desire, erection, ejaculation, and orgasm.16 Another explanation 
for the moderate correlation could be the more severe disease-related disability in 
patients with a spinal cord disorder. However, during the face-to-face interviews 
(linguistic validation process) the SCI patients did not mention any irrelevant or missing 
items. Overall, the internal consistency of the total MSISQ-15 score remains good. 
The reproducibility for the Dutch MSISQ-15 in terms of test-retest scores was excellent. 
The mean change between test-retest was ± 0.31 points, demonstrating adequate 
agreement. We found an ICC for agreement of 0.88 for the 15 items of the Dutch 
translation of the MSISQ-15, indicating good reliability. Comparison with other studies 
was not possible, a test-retest was neither performed in the original MSISQ-15 study5 
nor in the MSISQ-19 study4. 
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Patients and references were good distinguishable as shown by the confirmation of 
predefined hypotheses, confirming discriminative ability and therewith good criterion 
validity. Furthermore, confirming its use to specifically deal with sexual problems faced 
by patients with neurological disease.
No ceiling effects were found in patients or references. As expected, floor effects were 
present in all domains in the reference group (24-42%). Still, only 6 (12%) references had 
the lowest possible MSISQ-15 total score. Remarkable is the floor effect of the tertiary 
domain in the patient group (19%). The tertiary domain items measure the psychological 
aspects of SD. Possible explanations for a lowest score are the duration or acceptance 
of living with a neurological disease and having a stable relationship. This could lead to 
a reduced reliability and could have effects on the responsiveness.12 Still the reliability 
was found to be good (ICC tertiary domain 0.85, Table 3).
Analyzing the responsiveness and interpretability of the MSISQ-15 was not possible 
because of the short follow-up. Another limitation of our study was the lack of a golden 
standard. In the absence of a validated Dutch measure of sexual function in neuro-
urological patients, we used the PISQ-12 in women and the IIEF-15 in men. Additionally, 
the IIEF-15 assesses erectile dysfunction over the last month in contrast to the last six 
months of the MSISQ-15. Lastly, treating physicians were asked to recruit all consecutive 
patients meeting the inclusion criteria, but we do not know what proportion actually 
participated and what were the reasons for non-participation.   
One of the strengths of our study was the use of standardized measurement properties 
to evaluate the reliability and validity of the MSISQ-15, proposed by Terwee et al.12 
Furthermore, our study design also allowed testing the MSISQ-15 in patients with spinal 
cord disorders. The results support the usability of the measure in this population, 
except when using the primary domain as subscale on itself. In general, MSISQ-15 
outcomes may support the patient and physician to discuss SD. We recommend the 
Dutch physicians to use this measure in both research and clinical practice to evaluate 
SD in patients with MS and spinal cord disorders. Providing that the result of the primary 
domain in patients with spinal cord disorders should be cautiously handled because of 
the moderate internal consistency. To assess the urogenital function in neuro-urological 
patients we advise to use the MSISQ-15 combined with the SF-Qualiveen. The SF-
Qualiveen is a questionnaire validated in Dutch to evaluate the urinary-specific quality 
of life in MS or SCI patients.17,18
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5. CONCLUSIONS
In conclusion, this Dutch version of MSISQ-15 was tested following well-established 
guidelines on measurement properties and showed good validity and reliability. The 
MSISQ-15 allows us to evaluate SD in patients with MS and spinal cord disorders in both 
research and clinical practice.
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SUPPLEMENTARY MATERIAL: The Dutch version of the MSISQ-15
MSISQ-15: vragenlijst over intimiteit en seksualiteit  
bij multiple sclerose (MS) of een dwarslaesie 
INSTRUCTIES: Deze vragenlijst wordt gebruikt om de impact van multiple sclerosis (MS) of een 
dwarslaesie op intimiteit en seksualiteit beter te kunnen begrijpen. U wordt gevraagd aan te geven hoe 
verschillende klachten van MS of een dwarslaesie  invloed hebben op uw intimiteit en seksualiteit de 
afgelopen 6 maanden.   
De vragen kunt u beantwoorden door één vakje achter de vraag aan te kruisen of aan te vinken. Er zijn 
geen goede of foute antwoorden. Als u twijfelt over uw antwoord, kiest u dan het voor u best passende 
antwoord. 
 
DE AFGELOPEN ZES MAANDEN VORMDEN DE VOLGENDE  KLACHTEN EEN BELEMMERING VOOR MIJN 
SEKSUELE ACTIVITEIT OF TEVREDENHEID: 
(Kruis één vakje per regel aan)                                                                        nooit       bijna       soms       bijna        altijd 
                                                                                                                                               nooit                       altijd 
1.   spierstijfheid of krampen in mijn armen, benen of    
       lichaam 
     
2.   blaas- of plasklachten 
 
     
3.   darmklachten 
 
     
4.   trillen of schudden van mijn handen of lichaam 
 
     
5.   pijn, branderig of ongemakkelijk gevoel in mijn   
      lichaam 
     
6.   het gevoel dat mijn lichaam minder aantrekkelijk    
      is 
     
7.   het gevoel minder mannelijk of vrouwelijk te zijn    
       vanwege MS/dwarslaesie 
     
8.   minder gevoel of gevoelloosheid in mijn  
      geslachtsdelen 
     
9.   angst om seksueel afgewezen te worden vanwege   
      MS/dwarslaesie 
10. bezorgdheid of ik mijn partner seksueel kan    
       bevredigen 
11. minder vertrouwen in mijn seksualiteit vanwege   
       MS/dwarslaesie 
12. gebrek aan seksuele interesse of seksueel  
       verlangen 
13. minder intense of plezierige orgasmen of  
       hoogtepunten 
14. het duurt te lang om een orgasme of hoogtepunt  
      te krijgen 
15. - vagina niet nat of vochtig genoeg (vrouwen)/  
       - problemen om een goede erectie te krijgen of te  
       houden (mannen) 
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ABSTRACT 
Aims: We sought to establish the responsiveness of the Dutch Vancouver Symptom 
Score for Dysfunctional Elimination Syndrome (VSSDES) and Pediatric urinary 
incontinence Quality of life (PinQ) questionnaires. Secondary, we evaluated the outcome 
of urotherapy extended for children with dysfunctional voiding (DV). 
Methods: This cross-sectional multicenter study was done in one tertiary and two 
community hospitals. Children with DV were included, also when refractory to previous 
urotherapeutic treatment. The questionnaires were completed before and after 
urotherapy. The primary outcome measure was the responsiveness of the Dutch VSDESS 
and PinQ. Secondary outcome was the initial success (defined by the International 
Children’s Continence Society) of extended urotherapy.
Results: Between June 2014 and May 2016, 64 children (median age 7 years, IQR 6-10) 
received urotherapy (median 18 weeks, IQR 11-28). In contrast to the VSSDES, the PinQ 
showed good responsiveness. For children and parents, respectively, the area under 
the ROC-curve was 0.79 (P = 0.01) and 0.72 (P = 0.03) for the PinQ and 0.50 (P = 0.98) 
and 0.55 (P = 0.62) for the VSSDES. Fifty children received extended urotherapy, 27 had 
complete, and 14 had partial response. Sixteen children had been refractory to previous 
treatment; four showed complete and six showed partial response. 
Conclusion: The PinQ is able to detect clinically important changes in continence-
specific quality of life after treatment. We support the use of the VSSDES questionnaire 
in addition to the current diagnostics for the diagnosis of DV. Extended urotherapy 
showed to be a successful treatment for children with DV, also for those who had 
received previous unsuccessful treatment.
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1. INTRODUCTION
Lower urinary tract symptoms (LUTS) are a common reason for children to visit the 
pediatrician or pediatric urologist.1-3 Symptoms related to the voiding and storage 
phase of bladder can contribute to numerous functional elimination disorders.3,4 
Dysfunctional voiding (DV) is a common cause of LUTS in neurologically intact children.4 
Voiding symptoms such as straining, hesitancy, dysuria, and storage symptoms such as 
frequency, urgency, or incontinence are suggestive for DV.3-5 Furthermore, DV is often 
associated with recurrent urinary infections, and bowel dysfunction such as constipation 
or fecal incontinence.5,6 The symptoms of DV can have a negative impact on a child’s 
quality of life and self-esteem.1,2,6 The International Children’s Continence Society (ICCS) 
has defined DV as habitual contractions of the urethral sphincter or pelvic floor during 
voiding. The uroflowmetry curve demonstrates a staccato pattern with or without an 
interrupted flow concomitant with activity on EMG.4,5 The exact epidemiology of DV 
is unknown.5 The prevalence of DV in the general population has a wide range: 4.2% - 
46.4%.5,6
Urotherapy and pelvic muscle floor retraining can be a successful treatment in the 
majority of these children.3,6 Urotherapy is a non-standardized conservative based 
treatment option for children with voiding dysfunctions.4,5 According to the ICCS, 
urotherapy includes education about lower urinary tract anatomy and function, as well 
as life-style advices (balanced fluid intake, diet, proper voiding posture without holding 
maneuvers, regular bladder and bowel emptying patterns).4,5 During follow up the child 
will be encouraged to comply with therapy and the LUTS will be monitored by bladder, 
bowel and intake diary.4,5 Urotherapy can be extended with visual biofeedback by two 
approaches: feedback of the uroflow curve and teaching perineal muscle identification 
by EMG electrodes.1,3,5,6 The physical therapist can extend the urotherapy with pelvic 
floor muscle retraining, which implies learning how to relax the pelvic floor during 
voiding.1,3-6
Administering a condition-specific questionnaire can be useful to evaluate LUTS and 
effect of the treatment. Subjective complaints can be translated objectively into a total 
score.4 Two English-language questionnaires were translated into Dutch and proved to 
have good validity and reliability. One is the Pediatric urinary incontinence Quality of 
life score (PinQ), which measures the continence-specific quality of life in children with 
bladder dysfunction.7,8 The other is the Vancouver Symptom Score for Dysfunctional 
Elimination Syndrome (VSSDES), which evaluates the symptoms of patients with DV.9
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In the study presented here we followed children with DV during their treatment. Our 
primary aim of this study was to evaluate the responsiveness of the Dutch-language 
versions of the VSSDES and PinQ. Secondary, we evaluated the results of extended 
urotherapy. 
2. MATERIALS AND METHODS
2.1 Study design and population
The local ethics committee approved this multicenter prospective cross-sectional study 
(MEC-2014-290). Children with the age between 4 and 17 years presenting with DV 
at the pediatric, pediatric urology, or pelvic floor physical therapy outpatient clinics 
at two community hospitals and one tertiary hospital in the Netherlands between 
June 2014 and May 2016 were eligible for inclusion in the study. Children who had a 
previous unsuccessful treatment in a different setting were included as well. Patients 
with a neurogenic disease, anatomic abnormalities of the urinary tract, and previous 
urological surgery were excluded. The diagnosis DV was based on clinical symptoms, 
and a staccato and/or intermittent uroflowmetry with increased activity on pelvic floor 
EMG. After signing informed consent, patients, and parents were asked to fill out the 
questionnaires twice: after inclusion and after finishing urotherapy. 
2.2 Questionnaires
Prior to urotherapy, patients and parents filled out the VSSDES and the PinQ. 
The VSSDES is a 14-item condition-specific measure to evaluate the symptoms of 
bladder and bowel dysfunction. The last question addresses the ease with which the 
questionnaire can be completed, and the response to this question is excluded from 
the total score. Responses are given on a 5-point Likert scale, ranging from zero (no 
complaints) to four (severe symptoms) except for question 3 about voiding frequency 
(5-6 times: score of 0; 3-4 times or 7-8 times: score of 2; 1-2 times or >8: score of 4). All 
items are weighted equally. A total score is obtained by summating the item scores; the 
higher the total score the more severe the symptoms.10 A cutoff score of 11 is established 
for the Dutch version.9
The PinQ is a 20-item questionnaire to evaluate the quality of life of children with 
urinary incontinence. All items are scored on a 5-point Likert scale. A higher total score 
corresponds with a lower quality of life.8 Incompletely filled out questionnaires were 
accepted if no more than two answers were missing. Then the total score is calculated 
by multiplying the number of items in the questionnaire by the mean value of responses 
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to the answered questions. No cutoff score is published for the PinQ. Thibodeau et 
al2 made an assumption to grade the severity of impact on quality of life: mild <20, 
moderate 21-50, and severe >51. 
After urotherapy had finished, patients, and parents again filled out the VSSDES and 
the PinQ and answered an additional question derived from the RAND-36-Item Health 
Survey (RAND 36-HTI): “How is your voiding problem compared to one year ago?” 
(response categories: much better, somewhat better, about the same, somewhat worse, 
much worse).11 
2.3 Outcome measure questionnaires
The primary outcome measure of this study was the responsiveness of the two 
questionnaire’s. A questionnaire’s responsiveness is its ability to detect clinically 
important changes over time in patients when treatment is given. A measure of the 
responsiveness is the area under the receiver operating characteristic (ROC) curve 
(AUC), according to an external criterion. The answer to the question derived from the 
RAND 36-HTI and the initial outcome served as external criteria. The AUC shows the 
ability of a questionnaire to discriminate between improvement and no improvement. 
An AUC of at least 0.7 was considered to reflect adequate responsiveness.12
2.4 Urotherapy
Our secondary objective was to evaluate the outcome of “extended” urotherapy. 
All included children received “standard” urotherapy consisting of initial evaluation, 
education, and management as described by the ICCS.4 Standard urotherapy with visual 
biofeedback by uroflowmetry and EMG electrodes and/or retraining of the pelvic floor 
was defined as “extended” urotherapy. 
In one of the community hospitals only standard urotherapy was given. Children 
visited the pediatrician combined with a trained nurse once or twice. When standard 
urotherapy failed children returned to the outpatient clinic of the pediatrician for 
additional treatment with medication or were referred to a physical therapist. 
Children included in the tertiary hospital and in the other community hospital received 
extended urotherapy given by a trained nurse or physical therapist. Those children had 
approximately 5-7 sessions in 4 months. During this period the children were discussed 
2-3 times with the pediatrician or pediatric urologist. When additional treatment with 
anticholinergics was needed because of persistent urgency with acceptable post void 
residual urine, the pediatrician or pediatric urologist started tolterodine (slow release) 
2 mg 1 daily, or solifenacine 5 mg 1 daily, or oxybutynine 0.4 mg/kg 3 daily for 4-12 
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weeks. The use of anticholinergics was re-evaluated with the pediatrician or pediatric 
urologist during urotherapy. After approximately four months urotherapy was finished. 
When extended urotherapy failed an invasive treatment as botulinum toxin A injections 
into the bladder wall or into the urethral sphincter could be considered. Injections in 
the urethral sphincter were given when an increased activity of pelvic floor muscles or 
external urethral sphincter was seen during voiding on urodynamic study. A total of 100 
IU of botulinum toxin A was injected in equal dose into the external sphincter at the 3, 
9 and 12 o’clock positions under general anesthesia and antibiotic prophylaxis. For boys 
a cystoscope was used. The transurethral approach to the sphincter is more difficult for 
girls, therefore injections were placed paraurethral.13 In cases of persisted symptoms 
of an overactive bladder without post void residual urine botulinum toxin A injections 
(total dose of 70 UI) into the bladder wall were given under general anesthesia and 
antibiotic prophylaxis by cystoscopy.
2.5 Outcome measures extended urotherapy
The outcome of extended urotherapy was defined by the definition of initial success 
proposed by the ICCS: no response (<50% reduction of LUTS), partial response (50 to 99% 
reduction of LUTS), and complete response (100% reduction of LUTS).4 The children who 
received only standard urotherapy were excluded in this evaluation. The initial success 
and symptoms were evaluated after the last visit of urotherapy. The initial success and 
effect on symptoms of an invasive treatment (botulinum toxin A injections) were not 
evaluated. Data such as symptoms, post void residual, urinary frequency, maximum 
voided volume, and fluid intake before urotherapy and at the last visit of urotherapy 
were retrospectively collected. The maximum voided volume was retrieved from the 
voiding chart and refers to the largest volume voided, excluding the first morning 
void. The maximum voided volume was considered small or large if <65% or >150% of 
expected bladder capacity (EBC), respectively.4 The EBC was defined by the formula (30 
x [age in years + 1]mL).4 The maximum level was 390 mL at 12 years.4 
2.6 Statistical analysis
Statistical analyses were performed using SPSS version 21.0 (IBM Corp., Armonk, NY). 
A two-sided P-value <0.05 was considered significant. Descriptive statistics were 
calculated and are presented as median (interquartile range [IQR]), frequency and 
percentiles. To evaluate differences in symptoms and results of the two questionnaires 
between before and after treatment, the paired-samples t-test and the McNemar test 
were used for continuous and categorical variables, respectively. One-way analysis 
of variance (ANOVA) was used for the evaluation of more than two independent 
groups. The answer on the RAND 36-HTI question was dichotomized to “not improved” 
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(including “about the same”, “somewhat worse” and “much worse”) and “improved” 
(including “much better” and “somewhat better”). The AUC was calculated to determine 
the responsiveness.12
3. RESULTS 
The study population consisted of 64 children with dysfunctional voiding and their 
parents. Fifty children received extended urotherapy with or without pelvic floor 
retraining. The fourteen children who received standard urotherapy where only 
included to evaluate the responsiveness of the questionnaires. Patient characteristics 
are displayed in Table 1.
TABLE 1. Patient characteristics of the study population presented as number (%) or median 
(interquartile range)
Study population n = 64
Age, median (IQR) 7 (6-10)
Number of girls, n (%) 35 (55)
Duration of the treatment in weeks, median (IQR) 18 (11-28)
Type of urotherapy, n (%)
Standard urotherapy
Extended urotherapy
14 (22)
50 (78)
Extended urotherapy n = 50
Age, median (IQR) 8 (7-10)
Number of girls, n (%) 28 (56)
Duration of the treatment in weeks, median (IQR) 18 (11-25)
Anticholinergics during urotherapy, n (%) 14 (28)
3.1 Questionnaires
The VSSDES questionnaire was completed before and after urotherapy by 50 (78%) 
children and 49 (77%) parents; the PinQ by 45 (70%) children, and 48 (75%) parents. 
Table 2 presents the mean difference scores (SD). 
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TABLE 2. Total mean score (SD) of the VSSDES or PinQ questionnaire before and after urotherapy 
and the difference between.  
Total score of the questionnaire Before urotherapy After urotherapy Difference P-value
VSSDESb
Child n = 50
Parent n = 49
17.9 ± 6.9
17.9 ± 6.5
11.6 ± 5.9
11.5 ± 6.2
-6.3 ± 6.7
-6.4 ± 6.6
<0.001a
<0.001a
PinQc
Child n = 45
Parent n = 48
23.7 ± 14.8
21.5 ± 11.2
17.0 ± 15.0
17.1 ± 12.9
-6.7 ± 10.9
-4.4 ± 12.0
<0.001a
  0.015a
a Paired t-test
b A higher total score indicates more severe symptoms.
c A higher total score indicates a lower quality-of-life.
The responsiveness of the VSSEDS was measured by the AUC calculated with the RAND-
36-HTI as an external criterion; the AUC was 0.50 (P = 0.98) for children and 0.55 (P = 
0.62) for parents. The AUC for the PinQ was 0.79 (P = 0.01) for the children and 0.72 (P = 
0.03) for the parents (Table 3).
3.2 Outcome of extended urotherapy 
Fifty children received extended urotherapy with or without pelvic floor retraining 
(Table 1). Sixteen children were refractory to previous urotherapeutic treatment and 
received urotherapeutic treatment in a different setting for the second time. Fourteen 
of them had received previous urotherapeutic treatment in combination with pelvic 
floor physical therapy and two had received group urotherapy. The median duration of 
urotherapy was 18 weeks (IQR 11-25 weeks). 
After extended urotherapy symptoms such as daytime and nighttime incontinence, 
urge, dysuria, and abdominal pain all had improved significantly (Table 4). During 
urotherapy anticholinergics were prescribed to fourteen children. After urotherapy, 
64% of the children had stopped the anticholinergics. Before treatment three girls 
experienced urinary tract infections (UTIs) with fever (≥2 in 6 months) and nine girls and 
one boy had UTIs without fever (frequency: 1-3 UTIs in 12 months, five girls unknown). 
During therapy, none of the children experienced UTIs. The mean fluid intake increased 
from 985 mL to 1547 mL (P < 0.001, n = 43). A voiding chart was completed at the 
last visit of urotherapy in 34 children. Nineteen out of 34 children had a maximum 
voided volume <65% or >150% of the EBC before therapy, fourteen children showed 
improvement after treatment. At the last visit of urotherapy 37 children had undergone 
an uroflowmetry, which in 12 (32.4%) of them showed a persistent staccato and/or 
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intermittent flow pattern. In 7 of those 12 children also with increased activity on pelvic 
floor EMG. The mean post void residual of these 37 children decreased from 28.1 mL to 
12.8 mL (P = 0.025).  
TABLE 3. The VSSDES and PinQ scores (SD) and their corresponding RAND-36-HTI response 
reflect the responsiveness. The RAND-36-HTI functions as an external criterion. 
VSSDES Number (%) mean ± SDa
RAND-36-HTI n = 50
Much better/ a little better
Same
Much worse/a little worse 
Area under the ROC curve
P-value
41 (82.0)
7 (14.0)
2 (4.0)
-6.3 ± 7.0
-6.5 ± 5.9
-5.5 ± 2.1
0.50
0.98
Parent RAND-36-HTI n = 49
Much better/ a little better
Same
Much worse/a little worse
Area under the ROC curve
P-value
38 (77.5) 
9 (18.4)
2 (4.1)
-6.8 ± 6.3
-6.8 ± 8.0
2.0 ± 1.4
0.55
0.62
PinQ Number (%) mean ± SDb
RAND-36-HTI n = 45
Much better/ a little better
Same
Much worse/a little worse 
Area under the ROC curve
P-value
37 (82.2)
6 (13.3)
2 (4.5)
-8.3 ± 11.2
-0.9 ± 4.3
5.5 ± 7.8
0.79
0.01
Parent RAND-36-HTI n = 48
Much better/ a little better
Same
Much worse/a little worse
Area under the ROC curve
P-value
37 (77.1)
9 (18.8)
2 (4.1)
-6.7 ± 11.0
1.1 ± 12.4
14.5 ± 5.0
0.72
0.03
a A higher total score indicates more severe symptoms.
b A higher total score indicates a lower quality-of-life.
Based on the definition initial success by the ICCS, the treatment outcome of extended 
urotherapy could be classified as complete response in 27 (54%), partial response in 14 
(28%), and no response in 9 (18%) children (Table 5). There was a significance difference 
in urotherapy outcome between the children refractory to previous urotherapeutic 
treatment and those who received urotherapeutic treatment for the first time, in 
disadvantage of the children refractory to previous urotherapeutic treatment (P = 0.014). 
Overall, nine out of 50 children had no response to extended urotherapy. Three children 
136
Chapter 7
and their parents decided to accept the situation. Six children received botulinum toxin 
A injections in the urethral sphincter (n = 4), or in the bladder wall (n = 1), or in the 
urethral sphincter and bladder wall (n = 1).
TABLE 4. Symptoms before and after urotherapy presented as number (%)
Symptoms n = 50a Before urotherapy n (%) After urotherapy n (%) P-value
Daytime incontinence
- Partial success (50-99%)
- No success (< 50%)
Dry
42 (84.0)
8 (16.0)
23 (46.0)
12 (24.0)
11 (22.0)
27 (54.0)
<0.001b
Nighttime incontinence
- Partial success (50-99%)
- No success (< 50%)
Dry
30 (60.0)
20 (40.0)
16 (32.0)
3 (6.0)
13 (26.0)
34 (68)
<0.001b
Urge (n = 43) 21 (48.8) 6 (14.0) <0.001b
Dysuria 3 (6.0) 0
Abdominal pain 10 (20.0) 2 (4.0) 0.008 b
a Unless stated otherwise.
b McNemar test.
TABLE 5. Initial success following the three ICCS basics principles of treatment outcomes 
presented as number (%).
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Table 5. Initial success following the three ICCS basics principles of treatment outcomes 
presented as number (%). 
 
Extended urotherapy, n = 50
- Complete response 27 (54.0)
- Partial response 14 (28.0)
- No response 9 (18.0)
Refractory to previous treatment, n = 16
- Complete response 4 (25.0)
- Partial response 6 (37.5)
- No response 6 (37.5)
First treatment, n = 34
- Complete response 23 (67.7)
- Partial response 8 (23.5)
- No response 3 (8.8)
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4. DISCUSSION
The evaluation of the responsiveness of the VSSDES and PinQ, and of patient outcomes 
suggest that the PinQ questionnaire can detect clinically important changes over time 
(Table 3) and that symptoms had improved after extended urotherapy (Table 4).
The reliability and validity of the original and Dutch versions of both questionnaires 
were found to be good in earlier studies.7-10 Completing the questionnaires makes 
the symptoms and feelings transparent and negotiable with the health professional 
and family-members. This could lead to increased empathy, support, and treatment 
compliance. Both, Afshar et al and Bower et al, suggest to measure the responsiveness 
of the questionnaires.7,10 As far as we know, this is the first study that reports on the 
responsiveness of the questionnaires. We hypothesized that lower post-treatment 
scores on the PinQ and the VSSDES compared to the baseline scores would reflect 
improvements on quality of life and symptoms. According to the external criterion, the 
RAND-36-HTI question: “How is your voiding problem compared to one year ago?”, the 
AUC was measured. The responsiveness of both the child and parent versions of the 
PinQ proved to be more than adequate, the AUC was both above >0.7. This was not the 
case for the VSSDES. Perhaps the RAND-36-HTI question solely addresses the aspect 
of the voiding dysfunction and does not fully encompass the symptoms. Besides, only 
two parents and children found the voiding dysfunction to be worse now. We noted 
that completing the post-treatment questionnaires was not a priority for the parents 
and children. Resulting in a median interval of 14 weeks (IQR 0-48) between ending 
urotherapy and completing the last questionnaires. 
In this study, the Dutch VSSDES showed to be not useful to detect clinical important 
changes over time in symptoms after therapy. Still, the questionnaire is a reliable and 
valid tool to more objectively and systematically evaluate symptoms of patients with 
DV.9 Our hypothesis for the PinQ could be confirmed. The children and parents who 
answered the RAND-36-HTI question with “much” or “somewhat better” had mean lower 
scores on the PinQ after treatment.
The children in our study showed a good initial success rate after extended urotherapy 
with visual biofeedback by uroflowmetry and EMG electrodes and/or pelvic floor 
retraining. Judged from three ICCS basic principles of treatment outcomes, extended 
urotherapy was successful for 82% (complete response 54%) of the children overall. The 
success of treatment in children who were refractory to previous urotherapy was 63% 
(complete response 25%). Children who did not respond to previous urotherapy may 
be more motivated in new and different setting. It is also possible that the moment 
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and the intensity of attention by the healthcare professional or parent is relevant to 
success. Previous studies have reported success rates of 90-100% of urotherapy with 
the possibility to extend with biofeedback or pelvic floor retraining or medication 
(commonly an antimuscarinic) in children with DV.5,14 Tugtepe et al15 reported on 28 
children with DV refractory to three months of standard urotherapy. All children 
received additional extended urotherapy resulting in 50-100% decrease of LUTS. The 
outcome of the present study is comparable or slightly less favorable than that of these 
previous studies, to which the multicenter design and the inclusion of 16 children 
refractory to a previous treatment may have contributed. Note, however, outcomes 
of urotherapy are hard to compare between studies with different study populations, 
treatment approaches, and definitions of success of DV. In our study, the children have 
received standard urotherapy as defined by the ICCS extended with visual biofeedback 
by uroflowmetry and EMG electrodes and/or retraining of the pelvic floor. If needed an 
additional treatment with anticholinergics was started to treat urge-related symptoms. 
The content of extended urotherapy was similar, despite every child need his or her own 
stepwise approach. The role of pharmacological therapy can be considered as ancillary 
in the management of DV.3,5 A standard protocol for urotherapy following a stepwise 
approach and uniform reporting of outcomes would be helpful in current clinical 
practice and facilitate comparison between studies.  
One of the strengths of this study is the prospective inclusion of all eligible children and 
the use of a standard measure to evaluate the responsiveness.12 Children were recruited 
in different hospital settings and received different types of urotherapy, which makes 
the results of this study more generalizable for current clinical practice. However, the 
different approaches of urotherapy could possibly give some bias on the outcome. 
Limitations include the absence of a control group, the retrospective collection of 
LUTS data and the long interval between finishing urotherapy and completing the last 
questionnaires, which may have confounded the results. 
5. CONCLUSION
In contrast to the VSDESS, the PinQ is a responsiveness questionnaire. The PinQ is able 
to detect clinically important changes over time when treatment is given and can be 
used initially, during follow up and after treatment to evaluate the continence-specific 
quality of life in children with DV. We support the use of the VSSDES questionnaire in 
addition to the current diagnostics (voiding diary and uroflowmetry with pelvic floor 
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EMG) for the diagnosis of DV. Urotherapy with visual biofeedback by uroflowmetry and 
EMG electrodes and/or retraining of the pelvic floor showed to be a successful treatment 
for children with DV, also for those who had received previous unsuccessful treatment. 
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In this general discussion, the main findings of this thesis are presented and placed in 
perspective with the current literature. Furthermore, the future perspectives for clinical 
practice and research are given.
MAIN FINDINGS
Evidence based outcome of surgical treatments of anatomic bladder 
outlet obstruction in the neurogenic population 
The systematic review of chapter 2 an overview of the current literature on the outcome 
of different surgical therapies for the treatment of anatomic bladder outlet obstruction 
in males with neurogenic bladder dysfunction. The types of anatomic bladder outlet 
obstruction discussed are benign prostate obstruction, urethral stricture, and bladder 
neck sclerosis. The most important recommendation for clinical practice is that a 
urodynamic study to determine the exact type of lower urinary tract (LUT) dysfunction 
should not lack in the work-up of bladder outlet obstruction in neuro-urological (NU) 
patients. Identifying the optimal practice was impossible due to limited availability of 
high-quality studies. 
Outcome of bladder outlet procedures in children with neurogenic 
urinary incontinence
In chapter 3 the long-term outcome on continence of bladder outlet procedures, 
such as bladder neck reconstruction and bladder neck sling, in 60 children with mainly 
myelomeningocele as etiology of neurogenic urinary incontinence are discussed. After 
a median follow-up of 10.4 years, continence rate was modest to good (77%, without 
urinary leakage for minimum of 4 hours), although re-intervention was required in 
42% to achieve this result. The re-interventions consisted of redo of the bladder outlet 
procedure, other type of outlet procedure, bulking agents, bladder augmentation and 
bladder neck closure. The definition of urinary continence used in the literature varies 
and makes comparison of outcome with other studies difficult. In view of the young 
age of the patient population, awareness of the outcome on the long term is valuable 
for patient counseling and to create awareness in patients and parents about what to 
expect.
Outcome of adjustable continence balloons in men with stress urinary 
incontinence
The outcome of adjustable continence balloons (ProACT) in the treatment of stress 
urinary incontinence after radical prostatectomy and transurethral resection of the 
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prostate (TURP), respectively in chapter 4 and chapter 5, are evaluated. We evaluated 
results in terms of achieving continence, changes in pads use, complications, re-
interventions and patient-reported estimates of improvement assessed with the Patient 
Global Impression of Improvement (PGI-I) scale. The PGI-I scale is an index that provides 
an overall response to an intervention.1 All procedures, 143 patients post radical 
prostatectomy with a median follow up of 46 (IQR 21-76) months, were performed by 
the same surgeon in Rotterdam in the study of chapter 4. After implantation, daily 
pad usage had decreased significantly from a median of 3.5 (IQR 2.0-5.0) pads per day 
preoperatively to a median of 1.0 (IQR 0.0-2.0) pads per day at 6 months and 0.0 (IQR 0.0-
2.0) pads per day at 1 year. At the end of follow up 30% needed a re-intervention. The 
results of 29 post-TURP patients with a follow-up of 21 (IQR 11-43) months are presented 
in chapter 5. Adjustable continence balloons were implanted by two surgeons, in 
24 patients in Rotterdam and in 5 patients in Rome. The daily pad usage decreased 
significantly from a median of 3.5 (IQR 2.3-5.3), pads per day preoperatively to a median 
of 1.0 (IQR 1.0-1.9) pads per day at 6 months and 1.0 (IQR 0.0-2.5) pads per day at 1 year. 
Twenty-four percent had a re-intervention at the end of follow-up.
Both studies showed a clear beneficial continence outcome in patients with adjustable 
continence balloons in the treatment of stress urinary incontinence post radical 
prostatectomy and post-TURP. On the long term, the majority of the patients reported 
improvement on the PGI-I scale and perceived improvement ≥50% on daily pad use on 
the long term.
Validity of the Dutch version of a patient reported outcome measure for 
sexual function in neuro-urological patients
In chapter 6 the translation and validation process of the Multiple Sclerosis Intimacy and 
Sexuality Questionnaire (MSISQ-15) for the use in Dutch patients with multiple sclerosis 
(MS) and spinal cord injury (SCI) is described. This self-report measure consists of 15 
questions evaluating the influence of MS symptoms on sexual activity and satisfaction 
over the preceding 6 months.2 Standardized guidelines were used to translate the 
questionnaire from English to Dutch.3 Subsequently, a standardized assessment of the 
measurements properties was performed.4 The internal consistency, i.e. the correlations 
between the items in the questionnaire, was adequate for total score and domains. 
The reproducibility was good, as shown from a comparison of the total MSISQ-15 
scores at baseline and 1-2 weeks later. Patients’ MSISQ-15 scores were correlated with 
severity of symptoms of sexual dysfunction measured with reference standards (PISQ-
125 in women and IIEF-156 in men) and confirmed positive rating for criterion validity. 
MSISQ-15 scores in patients were higher than in references indicating good construct 
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validity. This study confirms that the Dutch version of the MSISQ-15 is a reliable and 
valid measure to evaluate symptoms of sexual dysfunction in patients with MS or with 
SCI.
Responsiveness of two patient reported outcome measures and outcome 
of urotherapy in children with dysfunctional voiding
The Dutch version of the Vancouver Symptom Score for Dysfunctional Elimination 
Syndrome (VSSDES) questionnaire can be used to evaluate symptoms of bladder 
and bowel dysfunction.7 The Dutch version of the Pediatric urinary incontinence 
Quality of life (PinQ) questionnaire evaluates the quality of life of children with urinary 
incontinence.8 In chapter 7 the responsiveness, its ability to detect clinically important 
changes over time, of the VSSDES and PinQ questionnaires is tested in 64 children with 
dysfunctional voiding. The responsiveness of the PinQ proved to be good, in contrast 
to the VSSDES. However, the VSSDES questionnaire is still a reliable and valid tool to 
more objectively and systematically evaluate symptoms of patients with dysfunctional 
voiding and therefor a useful tool in addition the current diagnosis (voiding diary and 
uroflowmetry with pelvic floor EMG) for the diagnosis of dysfunctional voiding. The PinQ 
questionnaire can be used at baseline, during follow up and after treatment to evaluate 
the continence-specific quality of life in children with dysfunctional voiding. Besides 
the responsiveness, chapter 7 describes the outcome on LUT symptoms of extended 
urotherapy in 64 children with dysfunctional voiding. Urotherapy is a non-standardized 
conservative treatment for children with voiding dysfunctions, consisting of initial 
evaluation, education, and management. When urotherapy is combined with visual 
biofeedback by uroflowmetry and EMG electrodes and/or retraining of the pelvic floor 
it is defined as extended urotherapy. The majority of children had 50-100% response 
on LUT symptoms after extended urotherapy, also for those who had received previous 
unsuccessful treatment.
THERAPY OUTCOMES WITHIN FUNCTIONAL UROLOGY
Three aspects from clinical practice: patient, physician and evidence
In general, the first step in healthcare is to clarify the patient’s demand of medical 
assistance. Why does a patient approach a physician? What issue is the most bothersome? 
Good patient-physician communication is key to identifying a patient’s needs, 
perceptions and expectations. Besides, communication helps to create an interpersonal 
relationship, and facilitates exchange of medical information and involving the patient 
in making decisions.9 In short, communication is essential to create a bridge between 
patient and physician. 
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Patients with LUT and/or pelvic floor dysfunction may experience symptoms in one 
or more than one of the following domains: urinary, anorectal, sexual dysfunction 
and pelvic organ prolapse. The aim of a treatment is commonly to reduce relevant 
symptoms and improve quality of life. To achieve this, the most optimal practice should 
be identified per individual, preferably in agreement with the patient’s preferences. 
Treatment outcomes studies, systematic reviews and guidelines (often based on 
systematic reviews), are helpful to identify best practice.  
In ‘evidence based medicine’, individual clinical expertise is integrated with the best 
available external clinical evidence to enable decision-making about the care of 
individual patients.10,11 Evidence based medicine focuses on educating physicians in 
understanding and critical appraisal of published literature to optimize clinical care, 
including the science of systematic reviews and the development of clinical practice 
guidelines.10,11 By clinical experience, physicians may obtain the capability to effectively 
harmonize patients’ need and preferences in treatment.10 The best external clinical 
evidence refers to clinically appropriate studies aimed to answer a clinical question. 
Thus, apart from randomized trials and meta-analyses, the answer may come from 
basic science research and also from clinical studies.10 A quality appraisal of the found 
evidence, including the risk of various biases, determines the level of evidence and 
affects the strength of recommendation.11 
Through time, evidence alone has been recognized to have some limitations; it needs 
to be combined with patient values, preferences, and circumstances to provide shared 
decision-making.11 In the process of shared decision-making, the physician shares 
information and supports patients to deliberate and express their preferences.12 This 
may lead to a well-considered decision and tests why a patient would prefer this decision 
above other treatment options. With this intent, conversations between patient and 
physician are an important environment to explore evidence, clinical experience and 
preferences. 
Evidence of effective treatment within function urology 
Systematic reviews on treatment efficacy, such as the one described in chapter 2, aim 
to build evidence by combining outcomes of different studies. Valid comparison of 
outcomes of different studies is often hampered by limitations, like a weak study design 
and different terminologies and parameters of outcome used. A uniform parameter is 
essential to perform meaningful meta-analyses and consistently compare outcome of 
different studies and treatments. Organizations such as the International Consultation 
on Incontinence (ICI) and International Continence Society (ICS) recommend the use 
of subjective and objective measurements in outcome studies involving patients with 
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LUT dysfunction.13,14 Examples of subjective measures are patient reported outcome 
measures (PROMs) obtained by means of questionnaires. Objective measures are, for 
example, voiding diaries, pad test, and urodynamics. Nevertheless, the most appropriate 
outcome parameter is not provided. Two recent reviews presented an overview of 
different outcome measures of cure used in the evaluation of surgical treatments of 
stress urinary incontinence in NU patients15 and non-neurogenic patients16. Both reviews 
found a heterogeneity in subjective (patient reported) and objective (traditional) 
outcome parameters defining cure and were not able to obtain consensus.15,16 
Appropriate outcome measures to define treatment efficacy 
As mentioned above, an important focus of treatment in functional urology is reducing 
symptoms and improving quality of life.17,18 Reaching consensus about the most 
appropriate outcome measures might be complicated by differences in perception 
between physician and patient, and between patients. In other healthcare domains, 
the treatment outcome is more obvious. For example, the outcome in treatment 
of cardiovascular diseases or cancer is often survival. When it comes to urinary 
incontinence, a patient’s perception of successful treatment outcome may range from 
being completely dry to reducing a half of daily pad use. Also, the impact of a certain 
degree of urinary incontinence on quality of life might be different between patients, 
not to mention the physicians‘ perceptions of treatment outcome. This supports and 
encourages to collect PROMs, besides traditional outcomes. 
Furthermore, in the field of functional urology it is important to distinguish NU patients 
from non-NU patients and to distinguish adults from children. Although reducing LUT 
symptoms and improving quality of life is commonly the focus of treatment in these 
populations, factors such as an underlying diseases or patient age may interfere with 
the management and the most suitable outcome measures. To illustrate this, outcome 
measures in children should be adapted to age and understanding capacity. In the 
evaluation of NU patients, extra attention must be paid to preserve upper urinary tract 
and possible effects of the neurological condition on bladder function. 
In the cohort studies on efficacy of adjustable continence balloons (chapters 4 & 5), 
we used the PGI-I as a subjective measure to evaluate patients’ overall response to 
the intervention, besides objective measures such as pad use, re-interventions and 
complications. Urotherapy was evaluated by two PROMs, VSDESS and PinQ, and by data 
on symptoms gathered at outpatient visits, including voiding diary, uroflowmetry and 
post void residual (chapter 7). Bladder outlet procedures in children with neurogenic 
incontinence were retrospectively reviewed based on objective measures retrieved 
from medical files (chapter 3). No PROMs were used in this retrospective study. Overall, 
152
Chapter 8
these studies on treatment efficacy contribute to building evidence. Important to note, 
in all these studies comparison with the literature was challenging due to inconsistent 
use of outcomes. Thus, to improve comparison of treatments within functional urology, 
consensus should be reached how to define the outcome, assuming that heterogeneity 
of the population is taken into account when comparing outcomes. There seems to 
be a role for both a traditional outcome measure (objective) and a PROM (subjective). 
However, until consensus is reached, a clear definition of outcome should be given in 
the study methods. 
PATIENT REPORTED OUTCOME MEASUREMENTS WITHIN 
FUNCTIONAL UROLOGY 
Added value and possible implications of patient reported outcome 
measures 
PROMs have been developed to quantify patients’ perspective of their health 
condition, including the functional status and the impact on symptoms and quality 
of life. These measurable subjective perspectives can be a valuable tool at different 
points during patient care. First, PROMs can be used as diagnostic instrument or as 
baseline measurement to assess a patient’s perception and impact of symptoms on 
one’s daily activities. Second, the disease progression can be monitored with PROMs 
as standardized measures. Lastly, PROMs can be used as an outcome measure in the 
evaluation of a certain treatment - both in clinical practice and in research setting. 
Shared decision-making is a result of patient-centered communication and evidence 
based medicine.19 In evidence based medicine the use of PROMs is well established, 
for example as treatment outcome measure. PROMs may facilitate physician-patient 
communication and promotes shared decision-making.20 When completing PROMs, 
the patient is encouraged to reflect on his or her health condition. This process 
gives the patient the opportunity to gain a deeper understanding on the condition, 
enabling to discuss relevant issues to discuss with the physician.21 Completion could 
lead to clarification of a patient’s own perception and informs the physician about 
the patient’s perspective, which may give insights on the presence and intensity of 
prominently symptoms. Clarification of the most bothersome symptoms experienced 
by an individual patient helps the physician to adequate manage expectations about 
treatment effectiveness. The patient should be able to make an informed decision with 
an assessment of risk and benefit of all treatment options in light of own circumstances. 
This might impact a patient’s treatment choice and improve treatment compliance 
and satisfaction with health care. Beside improving clinical management of individual 
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patients as motive for routine use in clinical practice, comparison of outcomes and 
comparing the provider performances have been driven motives.22 The possible added 
value of PROMs has not gone unnoticed in functional urology. Several international and 
national guidelines have recognized the importance of PROMs and recommend their 
use besides traditional outcome measures.23-26    
Requirements of patient reported outcome measures before 
implementation 
A PROM should not be implemented before its measurement properties have been 
evaluated by a standardized validation process.4 When a PROM is used in a specific 
population it must be confirmed that it has an adequate validity and measures the 
underlying construct in that population. In the Netherlands, several valid PROMs are 
available to assess non-neurogenic patients’ perceptions of the domains of LUT and 
pelvic floor disorders.5,27-30 The use of condition-specific questionnaires is recommended 
in the assessment of NU patients, although these are not yet available in Dutch for each 
domain. The urinary-specific quality of life in NU patients can be measured with the 
Dutch SF-Qualiveen.31,32 Until recently, a Dutch validated PROM to evaluate symptoms of 
sexual dysfunction in NU patients was not available. The Dutch version of the MSISQ-15 
was found reliable and valid to evaluate symptoms of sexual dysfunction in patients 
with MS or with SCI (chapter 6). When using a PROM in the evaluation of treatment 
effectiveness, the PROM must be sensitive to clinical change. This property can be 
established by testing its responsiveness (chapter 7). 
The implementation of valid and reliable PROMs in routine clinical practice faces several 
challenges. Time-consuming collection of information should be minimized by providing 
short and easy to understand PROMs. To achieve high rates of patient participation, 
audience-specific PROMs and innovative approaches are required, particularly 
regarding children, elderly, and sicker patients. Digitally provided PROMs have the 
potential to improve the routine use of PROMs. An additional benefit of digital PROMs 
is the possibility of accurate transfer of data into a patient’s electronic medical chart. 
With regard to the health professionals, defining cut-off scores and minimally important 
change of PROMs helps to increase the ease of interpretation and adapt management if 
necessary. The minimally important change represents the smallest change in score that 
is noticeable to the patient and perceived as important to the patient.33 For example, the 
International Prostate Symptom Score (IPSS), a symptom assessment questionnaire in 
the management of benign prostatic obstruction, categorizes scores as mild, moderate, 
and severe symptoms.34,35 Barry et al36 succeeded to determine the minimally important 
change of the IPSS. Namely, a three-point improvement on the IPSS was the minimum 
change corresponding with slight improvement on symptoms noticed by a patient.36 
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The same study showed correlations between five points improvement on IPSS and 
moderate improvement on symptoms, and between eight points improvement on IPSS 
and marked improvement on symptoms.36 
OPTIMIZATION OF PATIENT CARE IN FUNCTIONAL UROLOGY
Patient care in functional urology might be optimized by building bridges between 
patients, physicians, and researchers. This is seen in the interdependence of evidence 
based medicine and shared decision-making.19 Added value is given to evidence based 
medicine by comparing treatment effectiveness, analyzing treatment efficacy reflected 
by traditional outcome measures and PROMs, and validating PROMs. In view of this 
thesis, Figure 1 presents our contributions to optimize patient care. Figure 1 is based on 
and adapted to a figure of Hoffman et al19, which presents the intersection of evidence 
based medicine and patient-centered communication. 
Shared 
decision-making 
Patient-centered 
communication 
Treatment effectiveness 
 Building evidence by analyzing 
treatment outcomes  
- This thesis: adjustable continence 
balloons, urotherapy, bladder neck 
sling, bladder neck reconstruction 
Systematic review 
 Best available evidence 
- This thesis: Surgical management 
of  anatomic BOO in adults with 
neurogenic bladder dysfunction 
Validation of Dutch PROMs 
 Availability of PROMs  to assess 
the  domains: urinary, anorectal, 
sexual dysfunction, and pelvic organ 
prolapse 
- This thesis: MSISQ, VSDESS, PinQ 
Future 
- Standardizing outcome measures 
- Defining predictors 
- Building a prediction model 
Optimization of 
patient care in 
functional urology 
Evidence based 
medicine 
FIGURE 1. Our contributions to optimize care.
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Outcome predictors in treatments of functional urology 
The possibility to identify the best treatment in an individual in advance would be 
valuable and improve personal-based trade off prior to treatment. Identification of 
variables that predict outcome of an intervention gives insight if a patient will or will not 
respond to a specific treatment and might initiate a different treatment choice in this 
patient. Different predictors should be combined in a multivariate model to accurately 
predict the outcome of treatment. Building a prediction model for functional urology, 
similar to the prostate cancer risk calculator37, is still in its early stages. Outcomes of 
different treatments in functional urology need to be available and outcome measures 
should be standardized. Future research in the field of functional urology should focus 
on identifying these predictors and treatment outcome measures, PROMs might play a 
key role as outcome parameter or as predictor in a model. 
FUTURE PERSPECTIVES
PROMs may identify the domain (urinary, anorectal, sexual dysfunction, and pelvic organ 
prolapse) with the most impact on patient wellbeing and function (diagnostic) and may 
play an important role in informing treatment decisions and as outcome measure. Our 
research group has succeeded in making available validated Dutch PROMs to assess 
the domains of LUT and pelvic floor disorders in non-neurogenic patients. Regarding 
Dutch neurogenic patients, urinary-specific quality of life can be evaluated with the 
SF-Qualiveen and sexual function and satisfaction with the MSISQ-15. A PROM about 
anorectal symptoms is still lacking. Our next step will be the translation and validation 
of the neurogenic bowel dysfunction (NBD) score to measure bowel complaints and 
fecal incontinence in neurogenic patients.38 Furthermore, the ease of use, as well as the 
ease of interpretation and implementation of PROMs in clinical practice can be further 
improved. Additionally, PROMs may give the opportunity to further develop value 
based care i.e., health care driven by health outcomes per euro spent.39
Adequately informing the patient about the expected treatment outcomes is one of 
the essentials in shared decision-making. Besides treatment outcomes in terms of cure, 
possible adverse events or complications or re-interventions should be discussed. Future 
studies with treatment outcomes aim to build evidence within functional urology. 
Intervention studies with long-term follow-up in large cohorts are preferred. Until 
consensus is reached on the most adequate outcome parameter or outcome parameter 
set, we advise the combined use of PROMs and traditional outcome measures.
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In the treatment of male stress urinary incontinence different devices (e.g. artificial 
urinary sphincter, male sling, adjustable continence balloons) are available. High 
quality studies evaluating efficacy are lacking. These studies have a wide variation in 
study design, follow-up, patient population, and biases. Therefore defining the best 
treatment option and drawing meaningful conclusions is difficult.40 A future prospective 
comparative study evaluating the efficacy of artificial urinary sphincter, male sling, and 
adjustable continence balloons in this population would be helpful.  PROMs as study 
endpoint could have an additional value, besides others, like pad count, one hour 
pad test, and complication rates. Suggested validated PROMs assessing the impact of 
urinary incontinence on quality of life pre- and post-operative settings are UDI-6 and 
IIQ-7. Additionally, an overall response of treatment can be provided with the PGI-I. 
The outcomes of these PROMs can be compared between the groups, assuming that 
groups are homogenous and results are stratified based on predictive factors (such 
as neurological diseases and radiation therapy). A study design like this shows the 
combined use of PROMs and traditional outcome measures to evaluate the efficacy of 
an intervention. The next step could be to define preoperative cut-off scores of the UDI-6 
and the IIQ-7, and other predictors, such as patient characteristics or pre-operative pad 
count, to develop a prediction model in order to predict the most effective treatment 
outcome per individual.
Identifying the optimum treatment in an individual has the potential to improve shared 
decision-making. Future research is needed to establish standardized outcome of 
different treatments and identification of variables that predict outcome in functional 
urology. Perhaps PROMs might play a key role as outcome parameter or as predictor 
in a model, as described in the example above. The possibility of optimizing patient 
care in functional urology could be a prediction model. Currently, our research group 
is developing a multivariate model that aimed to predict treatment outcome of 
female urge urinary incontinence based on patient history, patient characteristics and 
investigations.41 
EPILOGUE
In view of improving shared decision-making in functional urology, this thesis aimed 
at adding value to evidence based medicine by comparing treatment effectiveness, 
analyzing treatment efficacy reflected by traditional outcome measures and by 
PROMs, and validating PROMs. PROMs have the potential, in addition to traditional 
outcome measures, to quantify a patient’s perspective of the LUT and/or pelvic floor 
dysfunction. Before implementation of Dutch PROMs in clinical practice, the adequacy 
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of its psychometric measurement properties should have been established. Combining 
evidence based medicine with shared decision-making by building bridges between 
patients, physician, and researcher contributes to optimization of clinical practice. 
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SUMMARY
Functional disorders of the lower urinary tract (LUT), which consists of the urinary 
bladder and its sphincters, and the pelvic floor, are characterized by symptoms in one 
or more than one of the following domains: urinary, anorectal, sexual dysfunction, and 
pelvic organ prolapse. Symptoms of LUT and pelvic floor disorders can have a negative 
impact on the quality of life. Chapter 1, the general introduction of this thesis, describes 
the background and assessment of symptoms of LUT and pelvic floor disorders, and 
outcome measures used in the evaluation of treatment efficacy. Nowadays, various 
patient reported outcome measures (PROMs) are available to capture patients’ 
perspectives of health, disease, and effect of intervention. The aim of this thesis is to 
evaluate effectiveness of conservative and surgical treatment in functional urology, 
reflected by traditional and patient reported outcome measures.
In the first part of this thesis, chapter 2, different surgical therapies for the treatment 
of anatomic bladder outlet obstruction in males with neurogenic bladder dysfunction 
were evaluated in order to identify an effective treatment. This systematic review was 
conducted according to the Cochrane Handbook for Systematic Reviews of Interventions. 
In general, it appears that surgical management of anatomic bladder outlet obstruction 
may result in urinary incontinence. The types of anatomic bladder outlet obstruction 
discussed are benign prostate obstruction, urethral stricture, and bladder neck sclerosis. 
Identified surgical therapies are transurethral resection of the prostate (TURP) in patients 
with Parkinson disease or spinal cord injury (SCI) or cerebrovascular accident, endoscopic 
treatment of urethral stricture by laser ablation or urethrotomy in mainly SCI patients, 
and bladder neck resection in SCI patients. The outcome of TURP may be highly variable, 
from persistent or de novo urinary incontinence, regained normal micturition control, to 
urinary continence. In studies on bladder neck resection and endoscopic urethrotomy 
good results were seen. Laser ablation and cold knife urethrotomy resulted in restarting 
intermittent catheterization or adequate voiding. Due to the limited availability of 
high-quality studies it was impossible to identify the optimal practice. Nonetheless, 
the most important recommendation for clinical practice is that a urodynamic study to 
determine the exact type of LUT dysfunction should not lack in the work-up of bladder 
outlet obstruction in neuro-urological (NU) patients. 
In the second part of this thesis the outcome of different surgical therapies to achieve 
urinary incontinence are described.
Achieving continence in children with urinary incontinence is a challenge, especially 
incontinence secondary to neurogenic sphincteric deficiency. When non-surgical 
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therapy such as anticholinergic medications and intermittent catheterization fails, 
a surgical therapy could be considered. In chapter 3, the long-term outcome on 
continence of bladder outlet procedures, such as bladder neck reconstruction and 
bladder neck sling, in children with neurogenic urinary incontinence are discussed. The 
patient’s needs, gender, and bladder function and the surgeon’s preference has influence 
on the choice of a bladder outlet procedure with or without concomitant surgery such 
as bladder augmentation and continent catheterizable urinary channel. A bladder 
neck reconstruction increases bladder outlet resistance by lengthening and narrowing 
the urethra with tubularization of the trigone. The bladder neck sling procedure was 
based on coaptation, elevation, and narrowing of the urethra by suspension of the 
bladder neck by placing an autologous rectus fascial strip around the bladder neck 
and fixing the ends to the pubic symphysis. In view of the young age of the patient 
population, awareness of the outcome on the long term is important, but scientific 
reports are sparse. In this study, 60 children with mainly myelomeningocele as etiology 
of neurogenic urinary incontinence, underwent a bladder outlet procedure. After a 
median follow-up of 10.4 years, continence rate was modest to good (77%, without 
urinary leakage for minimum of 4 hours), although re-intervention was required in 
42% to achieve this result. The re-interventions consisted of redo of the bladder outlet 
procedure, other type of outlet procedure, bulking agents, bladder augmentation and 
bladder neck closure. Comparison with other studies in the literature is difficult because 
of the different modifications of surgery techniques used, alternated concomitant 
surgery, small number of patients analyzed, varying time of follow-up (the majority 
short term), and different definitions of urinary continence. Those long-term results are 
valuable for patient counseling and to create awareness in patients and parents about 
what to expect. 
In men with non-neurogenic stress urinary incontinence, it is mostly associated with 
prostatectomy, such as incontinence post radical prostatectomy (RP) or incontinence 
post-TURP. The next step after failure of conservative therapy or drug treatment is a 
surgical intervention. Besides male sling and artificial urinary sphincter, a minimally 
invasive option may be chosen, in particular, the adjustable continence balloons 
(ProACTTM). The outcome of adjustable continence balloons in the treatment of stress 
urinary incontinence after RP and TURP, respectively in chapter 4 and chapter 5, are 
evaluated in terms of achieving continence, changes in pads use, complications, re-
interventions and patient-reported estimates of improvement assessed with the Patient 
Global Impression of Improvement (PGI-I) scale. The PGI-I scale is an index that provides 
an overall response to an intervention. 
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In chapter 4 the outcome of 143 patients post-RP with a median follow up of 46 (IQR 
21-76) months are described. Patients with an artificial urinary sphincter or male sling 
in situ and those with a history of adjuvant radiotherapy after RP were excluded. All 
procedures were performed by the same surgeon in Rotterdam. After implantation, 
daily pad usage had decreased significantly from a median of 3.5 (IQR 2.0-5.0) pads per 
day preoperatively to a median of 1.0 (IQR 0.0-2.0) pads per day at 6 months and 0.0 (IQR 
0.0-2.0) pads per day at 1 year. At the end of follow up 30% needed a re-intervention. 
After a median follow up of 56 (IQR 28-79) months, 112 patients had the adjustable 
continence balloons in situ and answered the questionnaire with their daily pad use and 
PGI-I scale. A ≥50% reduction in daily pad use was seen in 64%, the dry rate was 45%, 
and 87% perceived improvement on the PGI-I scale. 
In chapter 5 the results of 29 post-TURP patients with a follow-up of 21 (IQR 11-43) 
months are presented. To our knowledge, this is the first study reporting results of post-
TURP patients separately. The adjustable continence balloons were implanted by two 
surgeons, in 24 patients in Rotterdam and in 5 patients in Rome. The daily pad usage 
decreased significantly from a median of 3.5 (IQR 2.3-5.3), pads per day preoperatively 
to a median of 1.0 (IQR 1.0-1.9) pads per day at 6 months and 1.0 (IQR 0.0-2.5) pads per 
day at 1 year. Twenty-four percent had a re-intervention at the end of follow-up. Twenty-
three patients completed the questionnaire with their daily pad use and PGI-I scale after 
a median follow-up of 28 (IQR 13-63) months. Outcome on continence had improved in 
65%, with a ≥50% reduction in daily pad use, including 26% dry rate. Improvement on 
the PGI-I scale was reported by 96%. 
To summarize both studies, adjustable continence balloons showed a clear beneficial 
continence outcome in patients with stress urinary incontinence. The majority of the 
patients were satisfied and perceived improvement ≥50% on daily pad use on the long 
term. 
In the third part of this thesis the translation and validation of a PROM for sexual function 
in NU patients is described (chapter 6) and the responsiveness of two PROMs to assess 
LUT function in children is studied (chapter 7). 
In the Netherlands, several PROMs to assess patients’ perception of the domains of 
LUT and pelvic floor disorders in non-neurogenic patients are widely available. In the 
assessment of NU patients, the use of condition-specific questionnaires is recommended, 
although these are not yet available in Dutch for each domain. The urinary-specific 
quality of life in NU patients can be measured with the Dutch SF-Qualiveen. A Dutch 
PROM to measure bowel complaints and fecal incontinence in neurogenic patients, such 
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as the neurogenic bowel dysfunction score, is missing. Until recently, a Dutch validated 
PROM to evaluate symptoms of sexual dysfunction in NU patients was not available. 
The Multiple Sclerosis Intimacy and Sexuality Questionnaire (MSISQ-15) demonstrated 
the most adequate measurements properties compared to other PROMS evaluating 
sexual function in neurologic patients. This self-report measure consists of 15 questions 
evaluating the influence of multiple sclerosis (MS) symptoms on sexual activity and 
satisfaction over the preceding 6 months. Although the MSISQ-15 was originally 
developed for MS patients, the similarity between the sexual dysfunction symptoms 
of patients with MS and those with SCI, as well as the similarity in treatment, suggests 
that the instrument might work well in both populations. The objective of our study 
was to provide and validate a Dutch version of the MSISQ-15 for the use in MS and SCI 
patients (chapter 6). The MSISQ-15 was translated from English into Dutch according to 
standardized guidelines. Sexual active patients with MS or SCI were asked to complete 
the MSISQ-15 and PISQ-12 (women) or IIEF-15 (men) at baseline and 1-2 weeks later. 
A reference group without a neurological condition recruited at a general medical 
practice completed the questionnaires once. Afterwards, standardized assessment of 
the measurements properties was performed. The correlations between the items in 
the questionnaire was adequate for total score and domains (internal consistency). The 
reproducibility was good, as shown from a comparison of the total MSISQ-15 scores at 
baseline and 1-2 weeks later. Patients’ MSISQ-15 scores were correlated with severity of 
symptoms of sexual dysfunction measured with reference standards (PISQ-12 in women 
and IIEF-15 in men) and confirmed positive rating for criterion validity. MSISQ-15 scores 
in patients were higher than in references indicating good construct validity. This study 
confirms that the Dutch version of the MSISQ-15 is a reliable and valid measure to 
evaluate symptoms of sexual dysfunction in patients with MS or with SCI.
The responsiveness of a questionnaire is its ability to detect clinically important changes 
over time. So, does the questionnaire measure changes if they have really occurred. 
In the assessment of the LUT function in children two Dutch PROMs are available: 
the Vancouver Symptom Score for Dysfunctional Elimination Syndrome (VSSDES) 
questionnaire and Pediatric urinary incontinence Quality of life (PinQ) questionnaire. 
The VSSDES can be used to evaluate symptoms of bladder and bowel dysfunction. 
The PinQ evaluates the quality of life of children with urinary incontinence. Those two 
Dutch questionnaires showed to be reliable and valid, but the responsiveness was, until 
recently, unknown. The responsiveness of the PinQ proved to be good in children with 
dysfunctional voiding, in contrast to the VSSDES (chapter 7). This confirms the PinQ can 
be used at baseline, during follow up and after treatment to evaluate the continence-
specific quality of life in children with dysfunctional voiding. The VSSDES is still a reliable 
and valid questionnaire to more objectively and systematically evaluate symptoms of 
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patients with dysfunctional voiding and therefor a useful tool in addition the current 
diagnostics (voiding diary and uroflowmetry with pelvic floor EMG) for the diagnosis 
of DV. Besides the responsiveness, chapter 7 describes the outcome on LUT symptoms 
of extended urotherapy in children with dysfunctional voiding. Urotherapy is a non-
standardized conservative treatment for children with voiding dysfunctions, consisting 
of initial evaluation, education, and management. When urotherapy is combined with 
visual biofeedback by uroflowmetry and EMG electrodes and/or retraining of the 
pelvic floor it is defined as extended urotherapy. The majority of children had 50-100% 
response on LUT symptoms after extended urotherapy, also for those who had received 
previous unsuccessful treatment.
In the general discussion, chapter 8, the added value to evidence based medicine by 
comparing treatment effectiveness, analyzing treatment efficacy reflected by traditional 
outcome measures and by PROMs, and validating PROMs is discussed. All chapters 
of this thesis contribute to evidence based medicine. The combination of evidence 
based medicine with shared decision-making contributes to optimization of clinical 
practice. In order to improve comparison of treatments within functional urology, 
consensus should be reached how to define the outcome. A role for both a traditional 
outcome measure (objective) and a PROM (subjective) are suggested. Finally, the future 
perspectives of standardization of outcomes and the possibility of a prediction model 
in functional urology are discussed. 
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SAMENVATTING
De functionele urologie is het gedeelte van de urologie welke zich richt op 
functiestoornissen van de lage urinewegen en de bekkenbodem. Deze functie-
stoornissen kunnen zich presenteren met klachten uit één of meer van de volgende 
domeinen: plasklachten, anorectale klachten, seksuele dysfunctie en prolaps. Deze 
symptomen kunnen een negatieve invloed hebben op de kwaliteit van leven. 
In  hoofdstuk 1, de introductie van dit proefschrift, wordt de achtergrond van deze 
domeinen beschreven. Daarnaast worden verschillende uitkomstmaten om het effect 
van een behandeling binnen de functionele urologie te evalueren toegelicht. Het doel 
van dit proefschrift is het evalueren van de effectiviteit van conservatieve en chirurgische 
behandelingen binnen de functionele urologie. De effectiviteit wordt gereflecteerd 
door traditionele uitkomstmaten en patiënt gerapporteerde uitkomstmaten (PROMs). 
Het geslacht, de leeftijd, en de aanwezigheid van een neurologische aandoening kan 
van invloed zijn op de mate van ernst en hinder van symptomen en op de behandeling 
van een dysfunctie aan de lage urinewegen en/of bekkenbodem. In het eerste gedeelte 
van dit proefschrift, hoofdstuk 2, wordt in een systematische review de effectiviteit van 
verschillende chirurgische behandelingen van een anatomische blaasuitgangsobstructie 
vergeleken in mannen met een neurogene blaas. De chirurgische behandeling van 
een anatomische blaasuitgangsobstructie kan mogelijk leiden tot urine-incontinentie, 
wat een vervelende complicatie is. De anatomische blaasuitgangsobstructies die 
worden besproken zijn: een goedaardige prostaat obstructie, een urethrastrictuur en 
sclerose van de blaashals. De chirurgische behandelingen die werden geïdentificeerd 
zijn een transurethrale resectie van de prostaat (TURP), een blaashalsresectie en een 
endoscopische behandeling van een urethrastrictuur door middel van laser ablatie of 
een urethrotomie. De uitkomsten van een TURP bij mannen met de ziekte van Parkinson, 
een dwarslaesie of een cardiovasculaire aandoening varieerden van persisterende of 
de novo urine-incontinentie tot urine continentie. Goede resultaten werden gezien 
in de studies die de uitkomsten na blaashalsresectie en urethrotomie evalueerden. 
In deze studies werden de resultaten van voornamelijk mannen met een dwarslaesie 
getoond. Zowel laser ablatie als een cold knife urethrotomie resulteerde in adequate 
mictie of de mogelijkheid tot het hervatten van zelfkatheterisatie. Door de gelimiteerde 
beschikbaarheid van goede kwaliteitsstudies was het niet mogelijk de meest optimale 
behandeling te identificeren. Er wordt geadviseerd bij een neuro-urologische patiënt 
een urodynamisch onderzoek te verrichten om de exacte blaasfunctiestoornis te 
identificeren alvorens een blaasuitgangsobstructie te behandelen. Deze systematische 
review geeft een overzicht van de huidige literatuur en benadrukt de noodzaak tot 
verder wetenschappelijk onderzoek binnen deze neurogene patiëntenpopulatie. 
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In deel II van dit proefschrift worden de uitkomsten van verschillende chirurgische 
behandelingen van urine-incontinentie beschreven. 
Het is een uitdaging om bij kinderen met urine-incontinentie continentie te bereiken. 
In het bijzonder wanneer dit secundair is aan neurogene sfincterdeficiëntie. Een 
chirurgische behandeling kan worden overwogen wanneer een niet-chirurgische 
behandeling als anticholinergica of intermitterende katheterisatie faalt. In hoofdstuk 
3 worden de langetermijnresultaten van blaashalschirurgie, zoals blaashalsplastiek en 
fascieslingprocedure, op continentie bij kinderen met neurogene urine-incontinentie 
beschreven. Het doel van blaashalschirurgie is de uitgangsweerstand van de blaas te 
verhogen. Bij een blaashalsplastiek wordt door middel van tubularisatie van een strook 
blaaswand de urethra vernauwd en verlengd. De fascieslingprocedure is gebaseerd 
op elevatie, coaptatie en vernauwing van de urethra door een strook rectusfascie 
rond de blaashals te positioneren. Blaashalschirurgie kan worden gecombineerd met 
een blaasaugmentatie en het aanleggen van een continent katheteriseerbaar stoma. 
Gezien de jonge leeftijd van deze patiëntenpopulatie zijn lange termijn uitkomsten 
belangrijk. In deze studie worden de uitkomsten van blaashalschirurgie bij zestig 
kinderen met voornamelijk myelomenigocele als etiologie van neurogene urine-
incontinentie geëvalueerd. Een periode van minimaal vier uur zonder urine lekkage 
werd gedefinieerd als continentie. Na een follow-up van mediaan 10.4 jaar, was 77% van 
de kinderen droog. Een re-interventie was nodig in 42% van de kinderen. Re-interventies 
die zich voordeden waren het opnieuw uitvoeren van de blaashalschirurgie, een andere 
blaashalsprocedure, bulking agents, blaasaugmentatie en het sluiten van de blaashals. 
Het vergelijken van deze resultaten met de resultaten van andere studies is moeilijk 
vanwege verschillende gebruikte chirurgische technieken, variërende follow-up en 
verschillende definities van continentie. De gepubliceerde langetermijnresultaten zijn 
waardevol bij de bespreking van de verschillende behandelopties met patiënt(e) en zijn/
haar ouders en geven inzicht in de mogelijke verwachtingen van blaashalschirurgie.  
Niet-neurogene urine-incontinentie bij mannen is meestal geassocieerd met een ingreep 
aan de prostaat, bijvoorbeeld urine-incontinentie na een radicale prostatectomie 
of een TURP. Indien een conservatieve en/of medicamenteuze behandeling in deze 
patiëntenpopulatie faalt is de volgende stap een chirurgische interventie. Aanpasbare 
continentietherapie middels ProACTTM-ballonnen is een minimaal invasieve 
behandeloptie naast de male sling en de artificiële urinaire sfincterprothese. De 
aanpasbare continentieballonnen worden percutaan geïmplanteerd, zodat zich aan de 
rechter- en linkerzijde van de urethra één ballon bevindt. Twee titanium ventielen, aan 
elke kant van het scrotum één, staan in verbinding met de periurethrale ballon aan de 
desbetreffende zijde. Na de implantatie kan het volume van de ballonnen poliklinisch 
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worden aangepast om een zo optimaal mogelijk evenwicht tussen continentie en de 
mogelijkheid tot mictie te bereiken. De subcutane ventielen kunnen met een naald via 
het scrotum worden aangeprikt. De uitkomsten van aanpasbare continentieballonnen 
in de behandeling van stress urine-incontinentie na een radicale prostatectomie of een 
TURP worden, respectievelijk, in hoofdstuk 4 en in hoofdstuk 5, geëvalueerd. Er wordt 
gekeken naar de resultaten op gebied van succes, gebruik van incontinentie-inleggers, 
complicaties, re-interventies en patiënt gerapporteerde subjectieve verbetering 
verkregen middels de Patient Global Impresson of Improvement score (PGI-I). De PGI-I 
score is een PROM die inzicht geeft in de mate waarin de behandeling verbetering heeft 
gebracht van de klachten. De patiënt geeft dit aan op een zevenpuntsschaal (‘heel veel 
slechter’ tot en met ‘heel veel beter’). 
De uitkomsten van de aanpasbare continentie ballonnen bij 143 mannen met urine-
incontinentie na een radicale prostatectomie worden in hoofdstuk 4 beschreven. De 
mediane follow-up was 46 (interkwartielafstand (IQR) 21-76) maanden. Mannen met 
in de voorgeschiedenis adjuvante radiotherapie en mannen met een male sling of een 
artificiële urinaire sfincterprothese in situ werden geëxcludeerd. Alle ballon-implantaties 
werden verricht in Rotterdam door één operateur. Het incontinentie-inlegger gebruik 
daalde significant van mediaan 3.5 (IQR 2.0-5.0) inleggers/dag peroperatief naar 
mediaan 1.0 (IQR 0.0-2.0) inleggers/dag zes maanden postoperatief en vervolgens naar 
mediaan 0.0 (IQR 0.0-2.0) inleggers/dag één jaar postoperatief. Aan het einde van de 
follow-up had 30% een re-interventie nodig. Een vragenlijst naar het inlegger gebruik 
en de PGI-I score werd na een mediane follow-up van 56 (IQR 28-79) maanden door 112 
patiënten met de aanpasbare incontinentieballonnen in situ ingevuld. Bij 64% van de 
patiënten werd een halvering of meer op het dagelijks inlegger gebruik gezien, bij 45% 
werd continentie bereikt en 87% gaf verbetering op de PGI-I score aan. 
In hoofdstuk 5 worden de resultaten van aanpasbare continentieballonnen bij 29 
patiënten post-TURP gepresenteerd. De follow-up bedroeg 21 (IQR 11-43) maanden. 
Voor zover bekend, is dit de eerste studie die resultaten van post-TURP-patiënten 
apart evalueert. De aanpasbare continentieballonnen werden door twee verschillende 
operateurs verricht, de implantatie vond bij 24 patiënten in Rotterdam plaats en bij 5 
patiënten in Rome. Het dagelijks gebruik van incontinentie-inleggers daalde significant 
van 3.5 (IQR 2.3-5.3) inleggers/dag preoperatief, naar 1.0 (IQR 1.0-1.9) inleggers/dag 
zes maanden postoperatief en vervolgens naar 1.0 (IQR 0.0-2.5) inleggers/dag één jaar 
postoperatief. Gedurende de follow-up was een re-interventie bij 24% van de patiënten 
nodig. Drieëntwintig patiënten hebben de vragenlijst ingevuld na een mediane follow-
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up van 28 (IQR 13-63) maanden. Verbetering van ≥50% op het dagelijks inlegger 
gebruikt werd gezien bij 65% van de patiënten, inclusief 26% continente patiënten. 
Verbetering op de PGI-I score werd door 96% van de patiënten gerapporteerd. 
Samenvattend, beide studies laten zien dat aanpasbare continentieballonnen een 
positief effect hebben op de continentie bij patiënten met stress urine-incontinentie. 
Op de lange termijn is de meerderheid van de patiënten tevreden en ervaart een 
verbetering van ≥50% op het dagelijks inlegger gebruik.
Deel III van dit proefschrift gaat over patiënt gerapporteerde uitkomstmaten, oftewel 
PROMs. Het vertaalproces en de validatie van een PROM wordt beschreven voor 
gebruik in Nederland (hoofdstuk 6). Daarnaast wordt de responsiviteit getoetst van 
twee PROMs (hoofdstuk 7).
Om de beleving van de niet-neuro-urologische patiënt binnen de verschillende 
domeinen van een functionele stoornis van de lage urinewegen en de bekkenbodem 
te evalueren zijn er verschillende Nederlandstalige PROMs beschikbaar. Bij de 
evaluatie van neuro-urologische patiënten worden conditie-specifieke vragenlijsten 
geadviseerd. Deze conditie-specifieke vragenlijsten zijn nog niet voor ieder domein in 
het Nederlands beschikbaar. In hoofdstuk 6 is de Engelstalig Multiple Sclerosis Intimacy 
and Sexuality Questionnaire (MSISQ-15) vertaald volgens standaard richtlijnen naar 
het Nederlands en zijn de meeteigenschappen geëvalueerd. De MSISQ-15 is een uit 
15 vragen bestaande vragenlijst om symptomen van seksuele dysfunctie in patiënten 
met multiple sclerosis te evalueren. In deze studie werd de Nederlandse MSISQ-15 
gevalideerd bij patiënten met multiple sclerosis of een ruggenmergaandoening 
(dwarslaesie of cauda equina syndroom). Bij inclusie vulden seksueel actieve patiënten 
met multiple sclerosis of een ruggenmergaandoening de Nederlandse MSISQ-15 in en 
als referentiemaat de Nederlandse Pelvic Organ Prolapse/Urinary Incontinence Sexual 
Questionnaire (PISQ-12) door vrouwen of de Nederlandse International Index of Erectile 
Function (IIEF-15) door mannen. Een tot twee weken later werden de vragenlijsten 
nogmaals ingevuld. Een controlegroep zonder neuro-urologische aandoening werd 
verzameld bij een huisartsenpraktijk, zij werden gevraagd de vragenlijst bundel 
eenmalig in te vullen. De testfase toonde een adequate content validiteit, de vragenlijst 
is duidelijk en omvat de problemen omtrent het seksueel functioneren bij een neuro-
urologische aandoening. In de patiëntengroep was de MSISQ-15 score gecorreleerd aan 
de mate van seksueel disfunctioneren gemeten met de PISQ-12 of IIEF-15, wat wees 
op goede criteriumvaliditeit. De MSISQ-15 scores in de patiëntengroep (38.9 ± 11.4) 
waren hoger dan in de controlegroep (21.1 ± 5.4; P < 0.001), dit bevestigd een goede 
constructvaliditeit. De MSISQ-15 toonde goede interne consistentie (Cronbachs alfa 
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>0.8) en reproduceerbaarheid (intraclass correlatie coëfficënt >0.8). Deze studie toont 
aan dat de Nederlandse MSISQ-15 betrouwbaar en valide is om seksuele disfunctie in 
patiënten met MS of een ruggenmergaandoening te evalueren. 
Een andere meeteigenschap van een vragenlijst is de responsiviteit. De responsiviteit 
van een vragenlijst geeft aan of de vragenlijst in staat is over de tijd klinische belangrijke 
veranderingen te detecteren. Er zijn twee Nederlandse gevalideerde vragenlijsten 
beschikbaar om functionele stoornissen van de lage urinewegen en bekkenbodem 
bij kinderen te kunnen evalueren: de Vancouver Symptom Score for Dysfunctional 
Elimination Syndrome (VSSDES) en Pediatric urinary incontinence Quality of life (PinQ). 
De VSSDES kan worden gebruikt om symptomen van dysfunctional voiding te evalueren. 
De PinQ evalueert de kwaliteit van leven bij kinderen met urine-incontinentie. Deze 
Nederlandse versies zijn valide en betrouwbaar. Echter was de responsiviteit van deze 
vragenlijsten, tot de studie in hoofdstuk 7, niet bekend. Deze studie toont aan dat de 
responsiviteit van de PinQ goed is in tegenstelling tot de responsiviteit van de VSSDES. 
Dit bevestigt dat de PinQ kan worden gebruikt in de evaluatie van de continentie-
specifieke kwaliteit van leven bij de eerste presentatie, gedurende follow-up en na 
behandeling van een kind met dysfunctional voiding. Dit geldt niet voor de VSSDES. De 
VSSDES is een betrouwbare en valide vragenlijst om systematisch een objectief beeld 
te krijgen van de symptomen bij kinderen met dysfunctional voiding, zoals in eerder 
onderzoek is aangetoond. Het is een handig instrument naast de huidige diagnostiek 
(plasdagboek en uroflowmetrie met EMG van de bekkenbodem) voor de diagnosestelling 
dysfunctional voiding. Naast de responsiviteit, beschrijft de studie van hoofdstuk 7 de 
uitkomsten van uitgebreide urotherapie bij kinderen met dysfunctional voiding op 
de symptomen van de lage urinewegen. Urotherapie is een niet-gestandaardiseerde 
conservatieve behandeling voor kinderen met plasproblemen. De behandeling bestaat 
uit de initiële evaluatie van symptomen, educatie en management. Uitgebreide 
urotherapie is urotherapie gecombineerd met visuele biofeedback door middel van 
een uroflowmetrie met EMG-elektrodes met of zonder training van de bekkenbodem. 
De meerderheid van de kinderen had na uitgebreide urotherapie een afname van 50% 
tot 100% van de lage urinewegen symptomen, ook wanneer de kinderen een eerdere 
onsuccesvolle behandeling hadden ondergaan. 
Tenslotte, in de algemene discussie van dit proefschrift, hoofdstuk 8, wordt het 
valideren van PROMs en het analyseren van het behandelingseffect weergegeven door 
traditionele en patiënt gerapporteerde uitkomstmaten als toegevoegde waarde aan 
evidence based medicine bediscussieerd. De combinatie van evidence based medicine 
en shared decision-making dragen bij aan de optimalisatie van de klinische praktijk. Om 
behandelingsuitkomsten binnen de functionele urologie beter te kunnen vergelijken 
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is het nodig om consensus te bereiken over hoe de uitkomst zou moeten worden 
gedefinieerd. Er wordt een rol voor zowel een traditionele uitkomstmaat (objectief ) als 
een PROM (subjectief ) gesuggereerd. Als laatst worden de toekomstperspectieven van 
het standaardiseren van uitkomsten en de mogelijkheid tot een voorspelmodel in de 
functionele urologie besproken.

PART V
Appendices
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List of abbreviations
A
LIST OF ABBREVIATIONS 
ASA American Society of Anesthesiologists 
ASIA  American Spinal Injury Association
AUS Artificial Urinary Sphincter 
BNR Bladder Neck Resection (chapter 2)
BNR Bladder Neck Reconstruction (chapter 3)
BNS  Bladder Neck Sling 
BOO Bladder Outlet Obstruction
BOP Bladder Outlet Procedures
BPH Benign Prostate Hyperplasia
CVA Cerebrovascular Accident
DV  Dysfunctional Voiding
EBC Expected Bladder Capacity
EQ-VAS EQ Visual-Analogue Scale
FU Follow-up
IC Intermittent Catheterization 
ICC  Intraclass Correlation Coefficient
ICI International Consultation on Incontinence
ICS International Continence Society
ICCS International Children’s Continence Society
IIEF  International Index of Erectile Function
IPSS  International Prostate Symptom Score 
IPSS QOL   International Prostate Symptom Score Quality of Life item
IQR Interquartile Range
LOA Limits Of Agreement
LUT Lower Urinary Tract 
LUTS Lower Urinary Tract Symptoms
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MMC Myelomeningocele 
MS Multiple Sclerosis
MSISQ Multiple Sclerosis Intimacy and Sexuality Questionnaire
NLUTD   Neurogenic Lower Urinary Tract Dysfunction; 
NR   Not Reported 
NU Neuro-urological 
OR  Odds Ratio
PGI-I   Patient Global Impression of Improvement 
PinQ Pediatric urinary incontinence Quality of life score
PRO Patient Reported Outcome
PROM Patient Reported Outcome Measure
PPI Post Prostatectomy urinary Incontinence
PISQ Prolapse/Urinary Incontinence Sexual Questionnaire
RP   Radical Prostatectomy 
RU Residual Urine
SCI Spinal Cord Injury
SD Sexual Dysfunction
SPC   Suprapubic Catheter 
SUI   Stress Urinary Incontinence 
TUC   Transurethral Catheter 
TURP Transurethral Resection of the Prostate
UI Urinary Incontinence
UTI Urinary Tract Infection
VSSDES  Vancouver Symptom Score for Dysfunctional Elimination Syndrome
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Op deze laatste bladzijdes rest mij iedereen die aan de totstandkoming van dit 
proefschrift heeft bijgedragen te bedanken voor hun steun en medewerking. Wat een 
rijkdom om zoveel talentvolle, gedreven en gezellige mensen om mij heen te mogen 
hebben. Graag wil ik een aantal mensen in het bijzonder bedanken:
Allereerst gaat een speciaal woord van dank uit naar alle patiënten die vrijwillig hebben 
deelgenomen aan de onderzoeken in dit proefschrift. 
Beste professor C.H. Bangma, mijn promotor, hartelijk dank voor uw leerzame 
begeleiding en wijze raad gedurende de afgelopen jaren. Uw betrokkenheid en kritische 
blik hebben de onderzoeken van nuttige inzichten en aanvullingen voorzien. Ook in de 
kliniek heb ik met veel plezier van u mogen leren. Dank voor uw vertrouwen in mij. 
Beste Bertil en Jeroen, mijn copromotoren, bedankt voor de kansen en het vertrouwen 
die jullie mij hebben gegeven. Het is een hele leerzame tijd geweest. Jullie deur stond 
altijd open voor overleg of een kletspraatje. Het lijkt me fantastisch om straks weer in de 
kliniek met jullie te mogen werken.
Bertil, ik heb je leren kennen als een toegewijd arts en slimme onderzoeker. Jouw input 
bij de eerste publicatie was een inspiratie voor alle daaropvolgende manuscripten. Je 
wist mij wetenschappelijk te prikkelen en het beste uit mijzelf naar boven te halen. 
Jeroen, het was heel prettig om samen met jou te sparren over de onderzoeken. Je nam 
de tijd om met een frisse creatieve blik mij weer in de goede richting te wijzen. Bedankt 
voor je betrokkenheid en opbeurende woorden wanneer nodig. Jouw telefoontje van 
afgelopen september is natuurlijk één van de hoogtepunten die ik niet snel zal vergeten! 
Graag wil ik prof. dr. G.M. Ribbers, prof. dr. L.M.O. de Kort en prof. dr. R.Q. Hintzen hartelijke 
danken voor de inhoudelijke beoordeling van mijn proefschrift en de bereidheid om 
zitting te nemen in de promotiecommissie. Ook de grote commissie, prof. dr. F.J. Feitz, 
prof. dr. K. Everaert, prof. dr. M.J. Roobol-Bouts en dr. H.W. Elzevier, wil ik hartelijk danken 
voor de tijd en interesse in dit proefschrift en voor de aanwezigheid op deze bijzondere 
dag.
Elaine, Lisette en Sarah, bedankt voor het opzetten van de functionele onderzoekslijn. 
Lisette, jouw enthousiasme werkte aanstekelijk al voordat ik mocht starten aan dit 
promotietraject. Bedankt voor je betrokkenheid en de prettige samenwerking aan twee 
publicaties. Tess en Sophie veel plezier met het voortzetten van de lijn!
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Ilse, mijn partner in crime, de afgelopen jaren begonnen we en eindigden we de dag 
samen op de fiets (of soms tandem). Wat hebben we elkaar goed leren kennen en weten 
te motiveren. We hebben niet alleen ontzettend hard gewerkt in onze bekkenbodem-
hoek, maar ook veel gelachen en liters (grove maling) koffie gedronken. Bedankt voor 
de fantastische tijd, ik hoop nog heel lang met je te mogen samenwerken, jenga-torens 
te bouwen en mooie momenten te beleven. 
Het promotietraject begon voor mij in combinatie met de baan als arts-assistent 
kinderurologie. Joop, Katja en Fred bedankt voor deze leerzame tijd en voor jullie 
ondersteuning op zowel klinisch als op wetenschappelijk vlak. 
Alle andere coauteurs, Jan Groen, Enrico Finazzi-Agrò, Marjan van Ledden-Klok, Jacintha 
Verhallen-Dantuma, Tebbe Sluis en Marit Yska, dankjewel voor jullie expertise en 
bijdrage aan verschillende artikelen in dit proefschrift. 
Beste Ko, bedankt voor het taalkundig verbeteren van al mijn artikelen. Een reactie liet 
nooit op zich wachten. Je hebt me enorm geholpen, hartelijk dank.
Poli-assistenten van de polikliniek Kinderurologie in het Sophia, medewerkers van de 
polikliniek Revalidatiegeneeskunde in Rijndam en medewerkers van huisartsenpraktijk 
Blaak, allemaal hartelijk dank voor jullie hulp bij het mogelijk maken van de 
vragenlijstvalidatie studies. In het bijzonder wil ik Dorine Spijkerman, Thao Nguyen, 
Puck Oude Elferink, Nynke van der Linden, Astrid en Roelie bedanken voor hun inzet. 
Verena, bedankt voor jouw hulp bij de aanvragen voor de METC.
Brigitte en Nancy, natuurlijk wil ik jullie bedanken voor alle praktische hulp, maar vooral 
voor het vele lachen, de leuke verhalen en de steun. Ondanks dat bijna alle hoofdstukken 
data bevatten die via jullie postvak zijn binnen gekomen, heb ik toch voor een andere 
kaft gekozen. Het was een feestje om samen tot de laatste enveloppen af te tellen! 
Geen dag gaat voorbij zonder lunch, dank aan “de lunch groep” voor de gezellige 
lunches op de 17de en later 15de verdieping van het Na gebouw. 
Alle arts-onderzoekers, arts-assistenten en urologen met wie ik de afgelopen jaren in 
het Erasmus MC heb gewerkt wil ik bedanken voor de prettige samenwerking, interesse 
in mijn onderzoek en bovenal de gezellige sfeer in de kliniek en de tuin, tijdens 
onderwijs- en refereeravonden en op congressen en borrels. Ik kijk ernaar uit om na de 
vooropleiding terug te keren!
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Raya, bedankt voor de ontzettend leerzame en gezellige tijd in Suriname. De Surinaamse 
gastvrijheid is ongekend. Ik kom zeker terug.  
Tom, bedankt voor jouw Rotterdamse “touch” aan dit proefschrift. 
Lieve vrienden en vriendinnen, in 2007 verhuisde ik naar Rotterdam en inmiddels zijn 
er vele vriendschappen ontstaan: JC Giraffe, de “B’s” en boys ;) , de Kralingsche eetclub, 
studiematen en de meiden van de hockey. Bedankt voor jullie interesse in mijn verhalen 
over mijn onderzoek en bovenal voor alle gezellige, vrolijke en intieme momenten van 
de afgelopen jaren. Ik hoop dat er nog veel van dit soort momenten zullen volgen!
Lieve Mijke, bedankt voor jouw doortastendheid en tomeloze enthousiasme om iedere 
keer te vragen en te luisteren naar mijn sores. Koffietjes drinken, lunchen, bordspellen 
spelen, borrelen, dineren, servies gooien… Na een gesprek met jou is er geen vuiltje 
meer aan de lucht. En jouw tijd is inderdaad ook gekomen ;)
Lieve Suzan, de wetenschap bracht ons vriendschap. Wat begon als een avontuur in China, 
is nu vriendschap voor het leven. Jouw positieve instelling en doorzettingsvermogen is 
indrukwekkend. Dank voor al je afleiding en steun de afgelopen jaren. Fijn dat jij mijn 
paranimf wilt zijn!   
Lieve (schoon)familie, dank voor jullie gezelligheid, interesse en medeleven in mijn 
studie en werk. Marjoke en Pieter, bedankt voor de gezellige koffiebezoeken op locatie 
en jullie support.  
Lieve Robert en Maikel, broer(tje)s, door jullie weet ik dat mijn werk in ieder geval in 
Amsterdam en hoog in de lucht of aan de andere kant van de wereld gelezen wordt. Ik 
ben trots op jullie. Maikel, hoe jij je droom achterna bent gevlogen en er vol voor bent 
gegaan, neem ik graag als voorbeeld aan. Robert, ik ben trots op jouw gedrevenheid en 
de manier waarop jij jezelf blijft ontwikkelen. Jullie zijn geweldige broers!
Lieve papa en mama, dankzij jullie ben ik waar ik nu ben. Jullie hebben ons opgevoed 
met geweldig veel steun, liefde en vertrouwen. We hebben door jullie geleerd bij ons 
zelf te blijven, dromen te realiseren door hard te werken en het uiterste uit ons zelf te 
halen. Wat ben ik jullie dankbaar!
Dan tot slot, lieve Bou, jouw onvoorwaardelijke steun en liefde is oprecht en kent geen 
grenzen. Bedankt dat je altijd voor me klaar staat en me af en toe een duwtje in de rug 
of een schop onder mijn kont geeft. Ontzettend trots ben ik dat jij aan mijn zijde staat, 
ook als paranimf. Samen kunnen we alles aan. Ik verheug me op al het moois wat ons 
te wachten staat! 
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Name PhD student Toscane Claudia Noordhoff
Erasmus MC department Urology 
PhD period April 2016 – June 2019
Promotor Prof. dr. C.H. Bangma
Supervisors dr. B.F.M. Blok, dr. J.R. Scheepe
1. PhD training Year ECTS
General courses
Research Integrity 2016 0.3
BROK (‘Basiscursus Regelgeving Klinisch Onderzoek’) 2016 1.5
Basic Introduction Course on SPSS 2016 1.0
Endnote Course 2016 0.3
Biomedical English Writing 2017 2.0
Specific courses
Summer Academy TIAS-MBE, August 2016, Tilburg, The Netherlands 2016 3.0
Seminars and workshops
Department Journal Club 2016-2018 3.0
Department educational program ‘refereeravond’ 2016-2018 1.0
Department educational program ‘onderwijsuur’ 2016-2018 1.0
Presentations
Oral presentation at the Sophia Research Day, Rotterdam, The Netherlands 2017 0.7
Poster presentation at the ICS meeting, Florence, Italy 2017 0.7
Oral presentation at the NVU, Nieuwegein, The Netherlands 2017 0.7
Oral presentation at the ICS meeting, Philadelphia, United States 2018 0.7
Oral presentation at the Erasmus MC ‘refereeravond’, Rotterdam, The Netherlands 2018 0.7
Oral presentation at the NVU, Nieuwegein, The Netherlands 2018 0.7
(Inter)national conferences
32nd Annual EAU congress, London, United Kingdom 2017 1.0
NVU voorjaarsvergadering, Den Bosch, The Netherlands 2017 0.3
ICS meeting, Florence, Italy 2017 1.0
NVU Najaarsvergadering, Nieuwgein, The Netherlands 2017 0.3
33rd Annual EAU congress, Copenhagen, Denmark 2018 1.0
NVU voorjaarsvergadering, Nijmegen, The Netherlands 2018 0.3
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1. PhD training Year ECTS
ICS meeting, Philadelphia, United States 2018 1.0
NVU Najaarsvergadering, Nieuwegein, The Netherlands 2018 0.3
Others
Trial coordinator Artisan overactive bladder study (rechargeable neuromodulator) 2018 1.0
Organising committee Sophia Research Day 2018, Rotterdam, The Netherlands 2017-2018 3.0
2. Teaching Year ECTS
Lecturing
Workshop ‘PROMs in urology’ at Multidisciplinary Symposium 
about Multiple Sclerosis, Nieuwegein, The Netherlands
2017 1.0
The course ‘Urogenital trauma’ 2017, 2018 1.0
The course ‘Physical examination of men’ 2018 1.0
Other
Supervising interns at the paediatric urology clinic 2016 1.0
Coach of 4 bachelor medicine students 2017-2019 2.0
Total 32.5
Awards
Best in category prize ‘paediatrics’
Oral presentation: Twenty-five years’ experience in bladder outlet procedures in children 
with neurogenic urinary incontinence. ICS meeting 2018, Philadelphia, United States 
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